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ABSTRACT 
African Potato (Hypoxis hemerocallidea), (AP) is an African traditional medicine (TM) that 
is commonly used for various nutritional/medicinal purposes and also by people infected with 
the human immuno deficiency virus HIV and AIDS patients as an immune booster. The use 
of AP has also been recommended by the former Minister of Health of South Africa for use 
by HIV positive people.  The main phytochemical component of AP is a norlignan glucoside, 
hypoxoside, and other relatively minor components have also been reported. A recent in vitro 
study reported the effects of AP extracts, hypoxoside and rooperol (the metabolite of 
hypoxoside) on human metabolic enzymes such as the cytochrome P450 (CYP450) group of 
enzymes and also on the transporter protein, p-glycoprotein (P-gp). This research focussed on 
investigating the clinical significance of those in vitro effects on the pharmacokinetics of 
efavirenz (EFV) in humans. EFV was chosen as the substrate drug because it is in first-line 
regimen of treatment of HIV/AIDS in South Africa, and also has been reported to be a 
substrate for the specific CYP isozymes, 3A4 and 2B6, in common with APs metabolic 
involvement with 3A4.  
 
A high performance liquid chromatography method with ultra-violet detection (HPLC-UV) 
for the quantitative determination of EFV in plasma was developed and successfully 
validated according to international standards with good reproducibility, accuracy, recovery, 
linear response and requisite sensitivity. The preparation of the plasma samples for analysis 
was effected by using a simple and rapid precipitation method, and the mobile phase 
consisted of readily available solvents. EFV in plasma samples was found to be stable under 
the relevant storage conditions studied. The oral dose of AP, administered as a freshly 
prepared traditional decoction, was standardised based on the hypoxoside content, and the 
quality of all the AP decoctions was analysed immediately prior to administration, using a 
validated HPLC-UV method.  
 
A single dose, two-phase sequential study was conducted over a period of 31 days in 10 
healthy volunteers. The clinical study was approved by the Rhodes University Ethical 
Standards Committee, and all the participants agreed to the conditions of the study by giving 
their informed consent. On day 1 of the study, human subjects were administered a 600 mg 
EFV tablet and blood samples were collected before dosing and at various intervals over a 
period of 48 hr post dosing. From day 16, a traditionally prepared AP decoction was 
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administered daily at a standardized dose of 15 mg/kg/day per subject until day 30.  On day 
29, volunteers were administered a single 600 mg dose of EFV as was done on day 1. Plasma 
samples were harvested immediately after blood sample collection and frozen at -80 ºC until 
assayed. Geometric mean ratios of relevant pharmacokinetic parameters, Cmax (maximum 
plasma concentration achieved following dosing) and AUC0-48 (area under the curve of a plot 
of drug plasma concentrations versus time representing the extent of absorption) of EFV 
before and after co-administration of 14 successive daily doses of AP were compared and 
evaluated to determine whether an interaction had occurred. All subjects completed the study 
and the geometric mean ratios of Cmax and AUC0-48 were 97.30 and 102.82 with 
corresponding 90% confidence intervals (CIs) of 78.81-120.14% and 89.04-118.80%, 
respectively. Whereas the acceptance criteria for the ratios of the AUCs fell within the preset 
90% CIs indicating no interaction, the Cmax ratios fell outside the limits. Although the 
protocol was developed in accordance with the United States of America Food & Drug 
Administration’s Guidance for Drug Interactions, a priori stating that both criteria need to 
fall within the acceptance limits to indicate no interaction, an argument is presented to waive 
the Cmax requirement for the declaration of an interaction.  As a result, the pharmacokinetic 
data generated during this study indicated that the effect of AP on the pharmacokinetics of 
EFV is not clinically significant. Hence, co-administration of AP is unlikely to affect the 
clinical use of EFV.  
 
In summary the objectives of this project were: 
1. To develop and validate a suitable HPLC-UV method for the quantitative 
determination of EFV in plasma. 
2. To perform a mini-validation of the determination of hypoxoside for use as a marker 
in the quality control and standardisation of AP decoctions. 
3. To conduct a clinical interaction study in order to determine whether AP affects the 
pharmacokinetics of EFV following concurrent administration. 
4. To apply the validated HPLC-UV method to determine plasma concentrations of EFV 
in plasma of human subjects. 
5. To use appropriate statistical methods and treatments such as a non-compartmental 
pharmacokinetic analysis to determine the occurrence of an interaction. 
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CHAPTER 1 
HUMAN IMMUNODEFICIENCY VIRUS (HIV)  
INFECTION AND TREATMENT 
1 HIV INFECTION  
 
HIV is a retrovirus, which was first isolated in 1983 [1]. Infection with this virus can lead to 
the disease state, a syndrome called Acquired Immunodeficiency Syndrome (AIDS). In 2003 
AIDS was declared a pandemic by the World Health Organisation (WHO).  It is now the 
number one killer in the developing world [2].  
 
1.1 Viral Taxonomy  
 
There are two types of HIV, namely HIV-1 and HIV-2. The former is most common and is 
the organism responsible for the majority of infections worldwide. Progression to the disease 
state is much slower in HIV-1 infection compared to HIV-2. HIV-2 is rare and has only been 
isolated from people living in West Africa [3]. 
 
The HIV-1 is divided into groups M, N and O, but group classification is rarely used except 
in virology studies (Figure 1.1). Group M is further divided into subtypes A to J, where the 
most virulent of these is subtype C, which is characterised by rapid progression to the disease 
state. Subtype C is common in sub-Saharan region [4]. 
 
 
Figure 1.1. An illustration of HIV classification. 
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1.2 Viral Morphology  
 
Virions, which are viral particles, consist of an external (surface) structure, on which is an 
envelope and an internal structure (Figure 1.2). The viral membrane on the envelope is lipid 
soluble and its surface is composed of envelope proteins gp-41 and gp-120 that are encoded 
by the env gene, and are highly glycosylated. Gp-41 is embedded in the membrane of the 
HIV particle, whereas gp-120 sits on the outside of the viral membrane. Gp-120 which has 
high affinity for the CD4 antigen, interacts with this antigen on the T-helper lymphocytes or 
macrophages. This interaction results in a conformational change on the gp-120, thereby 
exposing the sites that interact with the chemokine receptors (CCR5 or CXCR4). This 
uncovers the fusion protein, gp-41, resulting in another morphological change. The gp-41 
then penetrates the membrane of the host hell.  
 
The internal structure of the virus (viral core) is composed of a genome which consists of a 
diploid RNA, structural proteins and other proteins, and is separated from the external 
structure by protein coat material. The protein coat material is encoded by the gag gene. 
Internal proteins are encoded by the pol gene and the associated enzymes participate in 
integration and replication. These enzymes are reverse transcriptase (RT), protease and 
integrase. The RT enzyme has very little proof reading capacity (correction), therefore, errors 
can be incorporated into the proviral DNA during replication. Cells that are attacked by the 
virus are CD4 T4-helper cells (CD4+ T cells), Natural Killer cells, CD8 Killer T cells (CD8+ 
T cells), macrophages and dendritic cells. HIV continues to replicate in semen, forming a 
reservoir [5, 6].  
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Figure 1.2. Life cycle of HIV in humans [7]. 
 
1.3 Pathophysiology of HIV Infection  
 
1.3.1 Acute Infection  
 
After infection with HIV some people will be asymptomatic, while others experience a flu-
like illness characterised by fever, general malaise and sore throat within two to four weeks 
of infection. These symptoms usually last for about one to two weeks. Cells that are infected 
by HIV initially are the macrophages in semen or vaginal secretions. The macrophages then 
shed the viruses which bind to the dendritic cells. Immature dendritic cells develop into 
mature effector cells upon activation by microorganisms, and move to the draining lymph 
nodes where they stimulate inexperienced CD T helper cells. After the initial infection there 
is a decrease in CD4+ T cells and a rise in CD8+ T cells. The virus titres rise sharply, 
resulting in viraemia, which quickly returns to normal.  Mucosal CD4+ T cells are lost during 
the early acute infection stage while others are lost later during chronic infection. The body 
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also responds by producing antibodies that are specific to the virus. This can take up to six 
months and this period is called the “window period” [8]. 
 
1.3.2 Chronic Latent Stage  
 
The second stage of the infection is characterised by an immune response from cytotoxic B 
and T lymphocytes. In order to counteract the rapidly-replicating virus, the cell-mediated 
response increases. At this stage, the virus has a half-life of between 5 and 6 hr. Infected cells 
are destroyed either by the body’s immune system or by the virus.  Some infected T4 cells 
can live longer and revert back to a resting memory stage. They will not express any viral 
antigens, and the genome inside can be reactivated by an antigen. These are known as 
memory cells and can survive for many years [8]. 
 
Viral particle numbers are then reduced by the strong immune response, resulting in latency. 
However, the virus continues to replicate in the lymph nodes. The viral particle count is used 
to measure the burden of infection. 
 
1.3.3 AIDS 
 
After the latency period which can last from 1 to 15 years, the immune system begins to fail 
to control the infection. The number of CD4+ T cells and dendritic cells diminish and the 
CD4+ T cells are used as markers of the stage of the infection. Loss of control over the virus 
results in immunosuppression which makes the body susceptible to infections by 
opportunistic bacteria, fungi, protozoa and viruses. At this stage, the virus replicates 
uncontrollably, and as there is no proofreading by the host DNA, hence mutations occur. 
These mutations can lead to treatment failures. This stage of the combination of HIV 
infection and AIDS is usually abbreviated as HIV/AIDS.  
 
1.4 Epidemiology 
 
It has been estimated that there are approximately 33 million people living with HIV in the 
world [2] (Figure 2.3). The majority (62.5%) of these infections are in Sub-Saharan Africa. In 
South Africa this percentage is estimated at 18.8% of the adult (15-49 years of age) 
  
 
5 
 
population, which means 5 300 000 people are infected with HIV. The number of people in 
South Africa who needed treatment in 2005 was 790 000 but only ~ 207 000 (23%) received 
therapy. The burden of disease (BOD) of AIDS in Africa has been estimated to be four times 
higher than in developed countries [9]. Most of the countries which have a high BOD because 
of HIV infection are middle- to low- income countries, and, therefore, the BOD can have 
negative effects on the economy of such countries [10].  
 
 
Figure 1.3. Global Prevalence of HIV infections in 2007 [2]. 
 
1.5 Treatment of HIV/AIDS 
 
During the early 1990s, antiretroviral (ARV) drug treatments for HIV infection were 
introduced and more recently, various treatments involving new ARVs and combination 
therapy have been successfully used. Nonetheless, the efficacy of some ARVs has been 
reduced by mutations of the virus, leading to resistance. Due to these mutations, combination 
therapy, referred to as Highly Active Antiretroviral Therapy (HAART) is employed to reduce 
the viral load and increase the number of CD4+ T cells. Currently, national and international 
guidelines on HIV/AIDS treatment have been developed and, in addition, traditional 
medicines are also being used in the treatment and/or management of HIV/AIDS symptoms 
[10, 11]. 
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1.5.1 Orthodox Medicines 
 
The aim of HIV/AIDS treatment is to reduce HIV related illnesses (opportunistic infections), 
increase patient CD4+ T cell count and suppress viral replication to undetectable viral levels.  
There are six classes of ARVs, namely: nucleoside analogues/nucleotide reverse transcriptase 
inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease 
inhibitors (PIs), fusion inhibitors, chemokine receptor antagonists and integrase inhibitors 
(Table 1).  The modes of action of the different classes of ARVs are:  
 
• NRTI nucleoside analogues are triphosphorylated within the target cell prior to acting 
on the reverse transcriptase (RT), and some undergo further modification e.g. 
didanosine is converted to its active moiety 2’,3’- dideoxyadenosine-5’-triphosphate. 
They function by inhibition of synthesis of DNA by RT, the viral enzyme that copies 
viral RNA into DNA of a newly infected cell.  
• NRTI nucleotide analogues require only two additional phosphorylations to become 
active inhibitors of the RT because they are already monophosphorylated and the 
mode of action is the same as for the NRTI nucleoside analogues.  
• NNRTIs bind to the RT enzyme causing conformational changes in the enzyme 
structure, resulting in inhibition of the enzyme.  
• PIs bind to the enzyme protease, preventing cleavage of the gag and gag-pol 
polyproteins, thereby halting release of mature virus particles.  
• Fusion inhibitors bind to the HIV envelope protein gp-41 which is involved in viral 
entry and prevents entry into the target cell. By binding to gp-41, fusion inhibitors 
interfere with conformational changes of the envelope required for fusion with the 
target cell.  
• Chemokine co-receptor antagonists bind to the co-receptors (either CCR5 or CXCR4) 
on the surface cell of the CD4+ T-cell preventing entry to the target cell. In contrast 
with other ARVs which act on the viral enzymes, chemokine co-receptors antagonists 
act on the proteins of the target cell.  
• Integrase inhibitors bind to a viral enzyme integrase and interfere with incorporation 
of the reverse-transcribed HIV DNA into the chromosomes of the target cell.  
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Table 1.1. Antiretroviral drug classes. 
Class Name of drug 
Nucleoside Reverse Transcriptors Abacavir 
 
Emtricitabine 
 
Lamivudine 
 
Stavudine 
 
Zalcitabine 
 
Zidovudine 
Nucleotide Reverse Transcriptors Tenofovir 
Non-nucleoside Reverse Transcriptors Delarivine 
 
Efavirenz 
 
Nevirapine 
Protease inhibitors Amprenavir 
 
Atazanavir 
 
Indinavir 
 
Lopinavir 
 
Nelfinavir 
 
Ritonavir 
 
Saquinavir 
Fusion Inhibitors Efuvirtide 
Chemokine Receptor Antagonists Maraviroc 
Integrase inhibitors Raltegravir 
 
 
The prognosis of patients with HIV infection has been greatly improved by HAART.  Viral 
suppression depends, amongst other factors, on the pharmacokinetics of the medicines and on 
adherence to treatment. The latter is influenced by side-effects, pill-burden, availability of 
treatment and stigmatisation [12]. Any negative effect on the pharmacokinetics of ARVs, e.g. 
drug-drug interactions and herb-drug interactions, may affect the outcome of treatment, hence 
it is important to ensure that the pharmacokinetics of these medicines is not altered. 
Therefore, clinicians and pharmacists have to be aware of possible interactions in order to 
prevent negative effects of such interactions on HAART.  
 
1.5.2 Traditional Medicines 
 
The use of Traditional medicines (TMs) has been on the increase over the past few years. 
More recently, there has been a dramatic increase, as evidenced by the increased 
commercialisation and marketing of TM products. WHO defines TMs as those medicines 
used in the practice of traditional medicine [13]. The WHO definition of ‘traditional 
medicine’ is: “health practices, approaches, knowledge and beliefs incorporating plant, 
animal and mineral based medicines, spiritual therapies, manual techniques and exercises, 
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applied singularly or in combination, to treat, diagnose and prevent illnesses or maintain well 
being.” [14]. This definition is very broad because of the need to ensure that it includes all 
types of traditional medicine, practised in the world.  WHO has established some definitions 
[15] for the terminology used in traditional medicine and these are: 
 
• Complementary/Alternative medicine (CAM) – broad set of healthcare practices that 
are not part of, and not integrated into, the specific country’s dominant healthcare 
system. Medicines used in this context are often referred to as CAMs. 
• Herbal medicines – herbs, herbal material, herbal preparations, and finished herbal 
products that contain, as active ingredients, parts of plants, or other plant materials or 
combinations of the above 
• Herbs – crude plant material such as leaves, flowers, fruit, stems, wood, bark, roots, 
rhizomes, or other plant parts, which may be whole, fragmented or powdered. 
 
In recent years, the use of TMs has increased dramatically, and the market for these 
medicines is estimated at $60 billion worldwide [13]. Use of TMs varies from country to 
country, and is summarised below: 
 
 In China, TMs (more appropriately known as traditional Chinese medicines or TCMs) 
have a separate pharmacopeia and comprise 30-50% of the total medicinal 
consumption. 
 In Europe, North America and other developed region, over 50% of the population 
have used CAMs at least once. 
 In Germany, 90% of the population have used a natural therapy at some point in their 
life. 
 In the United Kingdom, annual spending on CAMs is $230 million and these 
medicines and their properties and uses, have been incorporated as a subject in the 
curricula of some pharmacy degree programmes. 
 In Ghana, Mali, Nigeria and Zambia, the first-line therapy for 60% of children with 
high fever caused by malaria is the use of herbal medicines at home. 
 In the Unites States, 158 million of the adult populace have used a natural remedy at 
some stage in their life. Between 1995 and 2000, the number of doctors who had 
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undergone special training in alternate or natural remedy medicine had nearly 
doubled. 
 In South Africa, 75% of people with HIV/AIDS, otherwise known as People Living 
with AIDS (PLWA), use TM/CAM. 
One of the reasons for the increase in the use of TMs is the belief that these products are free 
from side-effects, compared to orthodox medicines, especially for the management/treatment 
of chronic diseases.  
 
Recently, African countries have agreed to include these medicines in the mainstream 
healthcare system [16]. As a result of the lack of mainstream healthcare facilities, people 
frequently visit traditional healers instead. WHO reported that 25% of modern medicines are 
made from plants which were first used traditionally [13]. Published clinical research on TMs 
is currently very limited. Despite the lack of scientific evidence of efficacy, quality and 
safety, the use of TMs to meet primary healthcare needs is high in Africa and also in Latin 
America where it is; estimated at 80% of the population [13].   
 
There are many factors that influence the use of TMs/CAMs, and research on the use of TMs 
is increasing. In a study conducted in Ghana, it was found that culture, religion, finance and 
economics, education, advice of family members  and introduction of Western systems 
(educational, medical and cultural) have all influenced the choice of healthcare system used 
[17]. Based on the findings from this study, the authors concluded that both traditional and 
modern medicines play a fundamental part of Ghanaian culture and that there is a need to 
integrate the two in order to provide a comprehensive healthcare system which best serves the 
interest of the population. In Mozambique, a study of medicinal plants used in the treatment 
of common ailments, such as diarrhoea, malaria, respiratory complaints and sexually 
transmitted diseases, showed that 46 different plant species were used [18], indicating a wide 
use of plants, medicinally. 
 
In South Africa, the use of TMs is widespread [19] and one of the reasons for the use of TM 
is low medical doctor-to-patient ratio, which is estimated at 50: 50000, while that of 
traditional doctors is 50: 400; thus patients have far greater access to traditional doctors. 
Other reasons include economic, cultural and social. In the Eastern Cape region of South 
Africa, which has a population of 6.3 million (15% of South African population), it has been 
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reported that TMs are used to enhance personal well-being, as well as to treat diseases [20]. 
This region has a large low-socio-economic-standing population in several rural areas, and 
this suggests that the majority of this population use traditional methods of healthcare [21]. 
The traditional healthcare industry in South Africa is estimated at R500 million per annum 
[22], and in the Eastern Cape, a large proportion of the population relies to some extent on 
the generation of income from such natural resources [23]. Use of TMs in this region has 
increased by 54% with Hypoxis hemerocallidea (African Potato) being the most popular plant 
[24], due in part to the increase of HIV/AIDS prevalence. South Africa also plays an 
important role in the increase of research on TMs [25].  
 
Assessment of quality of TMs is one of the critical initial steps that must be undertaken 
before assessing safety and efficacy. Information derived from plant/product quality will, to 
some extent, provide information about the safety and efficacy of the product. In China, a 
pharmacopeia on TMs has been developed and has been used for many years. In Germany, 
there are monographs of CAMs used in that country [26]. Development of monographs for 
TMs/CAMs is more challenging than that for orthodox medicines because TMs/CAMs 
usually contain more than one constituent, resulting in a highly complex multi-component 
matrix.  The quality of some South African plant products and their constituents have been 
established and published in the literature [27, 28], and the work done by Nair et al [27] is 
considered important since commercialisation of TMs and associated products is rapidly 
increasing, and this work has shed valuable information on the quality of commercially 
available African Potato products. 
 
Research on TMs conducted in South Africa includes both in vitro and in vivo studies. These 
studies have evaluated efficacy, safety and/or quality [29]. Recognition of the need to 
integrate TMs into the mainstream healthcare system began in the early 1990s, following the 
democratic election of a new government in South Africa (i.e., the post-apartheid era).  
During this recent period, researchers have evaluated the healthcare situation, (both past and 
current systems) and have proposed different models for integration [30].  These and other 
proposals culminated in workshops and communication between healthcare practitioners and 
traditional healers. The South African government had already taken steps to include 
traditional healers into the mainstream healthcare system before the heads of state of the 
Southern African Development Community (SADC) signed and ratified the SADC Protocol 
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on Health [31]. Cooperation between traditional healers and healthcare professionals has 
resulted in traditional healers providing HIV/AIDS education, as well as demonstrations of 
condom use [32]. 
  
1.5.2.1  Policies Regarding TMs  
 
A WHO TMs Strategy [33] outlines the need for member states to integrate TMs into 
mainstream healthcare systems. The focus areas of this strategy are policy, safety, efficacy, 
quality, access and rational use. Governments are urged to: 
• Devise national policy and regulation for the proper use of TMs and their assimilation 
into national healthcare systems.  
• Institute regulatory mechanisms to control the safety and quality of TM products and 
of TM practice. 
• Create understanding about safe and effective TM therapies among the public and 
consumers. 
• Cultivate and conserve medicinal plants to guarantee their sustainable use. 
An office has been established at the WHO headquarters in Geneva, Switzerland, to 
coordinate activities related to TMs with collaborating TM centres around the world, which 
are dedicated to the various TM strategies. The Geneva office, in consultation with member 
states, has produced a number of documents to assist these member states in achieving the 
objectives of the main strategy.  
 
Research on plant material to treat HIV/AIDS has increased [34]. However, none of the plant 
substances or even semi-synthetic plant-derived molecules have yet been formally approved 
by regulators for marketing. In recent years, TMs have been discussed at the World Health 
Assembly and resolutions have been reached which will help member states of the WHO to 
meet the objectives of the main strategy [35]. In addition, the Joint United Nations 
programme on HIV/AIDS (UNAIDS) has been involved in activities to incorporate TMs into 
mainstream healthcare.  In a meeting sponsored by UNAIDS, a task force was appointed for 
the East and Southern Africa regions whose objective was to build a research programme for 
safe and effective local treatments of HIV/AIDS [32]. Participants of this meeting included 
traditional healers, and most countries represented at that meeting reported some initiatives 
by their countries which involved traditional healers. 
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In the SADC region, a SADC Protocol on Health [36] is now used by member states to guide 
their health policies. In order to meet some of the objectives listed in this protocol, the 
member states have agreed to cooperate and assist one another with: 
• Research and documentation on TMs and their use.  
• The establishment of a regional databank of TMs, medicinal plants and procedures, in 
order to ensure their protection, consistent with regimens related to intellectual 
property rights governing genetic resources, plant varieties and plant technology. 
This demonstrates the commitment of member states to TM use and increased research. Some 
SADC member states have also begun to regulate TMs, though not to the same extent as 
orthodox medicines, since the complexity of TMs amongst other reasons require a different 
system of regulation, amongst other reasons. Regarding TMs and HIV/AIDS, meetings have 
been held amongst SADC Ministers of Health during which the role of traditional and 
indigenous therapies has been discussed [37].  Attendants of one such meeting included, 
SADC ministry delegates, and ministers, delegates from United Nations Children’s Fund 
(UNICEF) and UNAIDS, traditional healers, alternative/complimentary therapists and 
affected individuals (PLWA). 
 
1.6 HIV/AIDS and TMs  
 
1.6.1 Background  
 
Use of TMs/CAMs among people PLWA is high as with all chronic disorders [11, 32, 38, 
39]. The reasons for high usage are wide ranging and differ between developed and 
developing countries. They include cultural, economic, and social factors, as well as 
perceived efficacy and perceived safety. Until recently, ARVs were not readily available to 
most patients who needed them, especially those living in rural areas. These patients, 
therefore, tended to use TMs/CAMs to manage symptoms. Cost of ARVs was identified as 
one of the barriers to accessing such life-saving medicines and provision of free ARVs to 
patients in resource-poor settings was found to be associated with a significant probability of 
viral suppression [40]. A WHO 3 by 5 initiative, which is aimed at ensuring that 3 million 
people who needed ARVs should be on HAART by 2005, was initiated in 2003 to increase 
access to HAART [41]. As a result of this initiative and commitments by governments and 
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non-governmental organisation (NGOs), there are now significantly more people on HAART 
in Africa (Figure 1.4). Reduction in prices of ARVs [42] as a result of the World Trade 
Organisation agreement on Trade-Related Aspects of Intellectual Property rights (TRIPS) has 
also increased accessibility of HAART to PLWA in developing countries, especially in sub-
Saharan Africa.   
 
Figure 1.4. Trend of availability of ARVs in sub-Saharan Africa [2]. 
 
Despite improved access to, and ample evidence of the efficacy of HAART, there are still 
PLWA who prefer TMs [43, 44]. Some patients stop ART and use TMs because of severe 
side-effects, among other reasons [45]. This situation has been further fuelled by reports in all 
media about powerful immunostimulant properties being claimed for some TMs which give 
false hope to PLWA. These reports also present TMs as devoid of side-effects making them 
more attractive to PLWA. The use of TMs may affect adherence to HAART which is critical 
to suppression of viral replication.  The perceived lack of side-effects of TMs is worsened by 
irresponsible marketing methods of these products by the product owners, who provide naive 
members of the public with erroneous and misleading information. Furthermore, this 
marketing occurs with little or no intervention by the medicines regulatory authorities, since 
regulation of TMs/CAMs is weak, if not absent in most countries [46].  
 
Among PLWA on HAART, there are some who combine this treatment with TMs [38, 47, 
48]. A multi-centre study conducted in Botswana, Lesotho, South Africa and Swaziland 
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involving 683 volunteers identified healthcare strategies used by PLWA to manage 
HIV/AIDS symptoms [11]. Volunteers were given a structured questionnaire and asked to 
describe three to six symptoms that they had experienced and also provide information about 
their management of the symptoms. Most of the patients reported orthodox medicines as their 
preferred choice followed by TMs/CAMs. The use of TMs and ARVs simultaneously can 
lead to interactions [49], hence there is an urgent need to conduct drug-TM interaction 
studies. Information regarding such interactions must be available to patients so that they are 
made aware of the quality, safety and efficacy of the medicines they are taking. In the case of 
orthodox medicines, this information is given to patients in the form of a Patient Information 
Leaflet. In the case of TMs, this information is very limited and is usually unavailable, hence 
therapy may be critically compromised by a lack of information. This has been confirmed in 
a Canadian study which demonstrated how HIV/AIDs patients were unable to access safety 
and knowledge of drug interactions related to CAMs [50]. 
  
There are many substances which are derived from plant materials which have been claimed 
to possess some antiretroviral activities. These products have been purported to inhibit HIV 
replication in nearly all stages of the virus life-cycle [34]. Substances were extracted by 
various solvents prior to assessing their activity against replication. Pre-clinical and clinical 
research on the activity of plant material against viral replication is on-going, and some in 
vitro studies are summarised Table 1.2.  
 
Table 1.2. Antiretroviral properties of some plant extracts. 
Name of plant Part of plant Substance extracted Enzyme inhibited Reference 
Sutherlandia frutescens flowers None stated RT [51] 
leaves None stated RT 
Lobostemon trigonus flowers None stated RT 
Eucalyptus globoidea buds Globoidnan A Integrase [52] 
Rosa rugosa roots Rosamultin Protease [53] 
Peltophorum africanum roots No extraction RT and integrase [54] 
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1.6.2 Safety of TMs 
 
Users of TMs tend not to report any side-effects they may experience from these medicines, 
since such associations are considered not probable in view of their long historical use. Most 
of these patients do not disclose to the healthcare providers their use of a TM unless specific 
questions regarding these are asked. This makes data collection on TMs more challenging, 
compared to orthodox medicines. One of the hindrances of communication about TMs is that 
they are not yet integrated into the main healthcare system and have been shunned upon in 
the past, hence users tend to be secretive about their use [55]. Research on the safety of the 
products has increased in the past years, and in recognition of the lack of guidelines on 
research on TMs, WHO Western Pacific region, has published Research Guidelines for 
Evaluating the Safety and Efficacy of Herbal Medicines [56]. These guidelines assist 
researchers to cover all aspects of the product, including related species when evaluating 
safety and efficacy of TMs.  
 
Unstructured regulation of TM/CAMs across the world also makes it difficult for safety 
profiles to be established [57]. Pharmacovigilance does not exist for TMs products in many 
countries [58], and this is because of lack of, or weak legislation. Various ways of 
establishing the safety of TMs which includes traditional use, chemical data, undertaking 
pharmacological and toxicological studies, intervention trials, epidemiological studies, 
patient case records and post-marketing surveillance have been reported [57]. It is important 
to note that data from post-marketing surveillance can be obtained only if the product is 
registered and as previously mentioned, most countries do not issue marketing authorisation 
for TMs so information from this source is limited. Some information on the safety of TMs, 
which are widely used in developed countries, however, is available in the literature. 
 
In a review of potential health risks and medicinal interactions, Magee [59] listed uses, side-
effects and potential drug interactions between a number of TMs and orthodox medicines. 
From this review, it can be seen that there are some known side-effects and adverse reactions 
of TMs. A pattern of fatal cases from TMs were reported by Stewart et al [60] who showed 
that 43% of  poisoning cases were associated with plant materials, and within this category, 
62% of these were used as a traditional remedy. 
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1.7 Drug-TM Interactions 
 
Drug-TM interactions occur when a TM and an orthodox medicine influence the effects of 
each other. This may cause a change in pharmacodynamic and/or pharmacokinetic 
parameters which may affect efficacy or safety of either the orthodox medicine or the TM.  
Efficacy may be reduced or increased and adverse events may increase. One of the challenges 
with TMs is that they often contain more than one active ingredient which makes it difficult 
to assess or predict a specific interaction. Whereas drug interactions are usually studied 
during the initial development phase of orthodox medicines, this is not usually done in the 
case of TMs because there is generally no development phase similar to that of orthodox 
medicines except, perhaps, that of development pharmaceutics if a pharmaceutical dosage 
form is required. Therefore, little information is available on drug-TM interactions.   
 
1.7.1 Pharmacodynamic Interactions 
 
A pharmacodynamic interaction occurs when a drug affects the pharmacodynamic response 
of another drug. These types of interactions generally either increase or decrease the actual 
response to the drug treatment. Pharmacodynamic interactions between ARVs and TMs have 
not been as well studied as pharmacokinetic interactions [61].  
 
1.7.2 Pharmacokinetic Interactions 
 
Pharmacokinetic interactions occur when a drug or TM affects absorption, distribution, 
metabolism or excretion of another drug or TM. These types of interactions are difficult to 
predict but can be evaluated using in vitro and/or in vivo studies. The most extensively 
studied interactions are metabolic interactions involving the cytochrome P450 enzyme system 
and absorption interactions involving the transporter protein p-glycoprotein (P-gp). The 
results from in vitro studies give an indication of which enzymes or transporter proteins will 
be affected by the TM or orthodox medicine.  
 
Data from in vitro studies can serve as a possible predictor of drug interactions. The 
prediction of drug interactions has been a topic of discussion among scientists for many years 
and proposals to improve existing methods have been suggested [62]. Unfortunately, the 
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prediction of drug interactions from in vitro studies may not always give an accurate measure 
of the clinical significance of an interaction [63, 64].  Hence, it must be emphasized that 
whereas in vitro data can be particularly valuable in developing strategies to study in vivo 
drug interactions, confirmation of the absence or presence of drug interactions should be by 
appropriate in vivo investigations.  Clinical studies thus still remain the most important source 
of information on the effects of drug-TM interactions [65] on bioavailability. Some studies on 
drug-TM interactions are listed in Table 1.3. 
 
1.7.2.1 Cytochrome P450 Enzyme System 
 
The cytochrome P450 (CYP450) enzyme system is a superfamily of haemoproteins that 
transform endogenous and exogenous substances in some living organisms e.g. bacteria, 
fungi, plants and animals. The name P450 comes from the fact that these enzymes have a 
spectroscopic absorption peak at or near 450 nm when bound, and reduced by carbon 
monoxide. In humans, CYP450 enzymes are involved in metabolism of exogenous substances 
including medicines, alcohols, organic solvents, chemicals and environmental pollutants. 
Endogenous physiological compounds such as bile acids, steroids and fatty acids undergo 
some oxidative, peroxidative and reductive metabolism through the CYP450 enzymes [66]. 
These enzymes are divided into families and subfamilies, CYP450 proteins from all sources 
having more than 40% in amino acids are placed in the same family and are designated an 
Arabic numeral. Each subfamily consists of enzymes in which the amino acid sequence is 
more than 55% homology, and this is identified by a capital letter.  Individual enzymes are 
denoted by an Arabic numeral, and the corresponding gene which expresses the individual 
enzyme is denoted by the same number in italics. In humans, 14 families and 20 subfamilies 
have been reported. Genetic polymorphism of some of these enzymes exists resulting in two 
groups of metabolisers, namely: poor or slow metabolisers, and extensive or rapid 
metabolisers. The slow metabolisers possess a homozygous autosomal recessive allele, while 
the other group possess heterozygous or homozygous dominant allele.  
 
Table 1.3. Clinical studies of interactions between TMs/CAMs and orthodox medicines and effects on bioavailability. 
Name of 
TM/CAM 
Interacting drug Sample size Study Design Results Adverse effects Reference 
St. Johns Wort 
(Hypericum 
perforatum) 
Norethindrone 
and 
ethinyl estradiol 
16 healthy female 
volunteers 
Non-randomised single-
blind, sequential 
AUC ↓13-15% 
Cl/F ↓25% 
Breakthrough 
bleeding during 
the St. Johns 
Wort phase 
[67] 
Nevirapine 5 (HIV positive men, 
control 176 used 
population 
pharmacokinetics) 
Case study Clearance ↓35% none [68] 
Imatinib mesylate 10 healthy volunteers 
( 7 male) 
Open-label, complete cross-
over, fixed sequence 
AUC ↓32% 
Cmax ↓29% 
none [69] 
Quazepam 13 healthy male 
volunteers 
Randomised, double-blind, 
cross-over 
AUC ↓55 ng h ml-1  
Cmax  ↓8.7 ng/ml 
none [70] 
Tacrolimus 10 healthy volunteers 
(8 male and 2 female) 
Two-phase, cross-over AUC↓34% none [71] 
Theophylline 12 healthy volunteers Randomised, open-labelled, 
cross-over 
No significant difference none [72] 
Milk Thistle 
(Silybum 
marianium) 
Indinavir 16 (8 in each group, 2 
from the control 
group excluded) 
Randomised parallel AUC ↑ 21.9% mild [73] 
Indinavir 10 Open label AUC ↓ 9%, 
trough concentrations ↓  25% 
mild [74] 
 Indinavir 10 (7 men) Sequential crossover Not conclusive because sample 
size was small, study was not 
powered for bioequivalence 
none [75] 
Garlic Saquinavir 9 healthy volunteers Two-treatment, 3 period, 
single sequence, longitudinal 
AUC ↓ 51% 
Cmax ↓ 54% 
none [76] 
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Metabolism of endogenous and exogenous compounds involves biotransformation into 
hydrophilic or polar compounds to enhance elimination. Biotransformation reactions are 
classified into phase 1 and 2 reactions. Phase 1 reactions include oxidation, reduction and 
hydrolysis, while Phase 2 reactions links either a parent drug or a product of phase 1 
metabolism to an endogenous substrate. Reactions of phase 2 biotransformation include 
acetylation, conjugation with amino acids, glucuronidation, glutathione conjugation, 
methylation and sulphation.  Orthodox medicines, including TMs may be substrates of more 
than one enzyme. Studies have shown that these enzymes are widely distributed in the body 
but concentrated in the liver.  CYP 3A4 is found in the mucosa of the small intestine and 
other enzymes are present in the duodenum [77]. Some CYP450 enzymes are found in the 
brain and adipose tissue.  
 
Interactions involving CYP450 enzymes generally are of two types: induction or inhibition. 
Inhibition reduces metabolism, while induction increases metabolism. Usually, substrates of 
CYP450 enzymes are potential inhibitors of those enzymes but there are cases where an 
inhibitor may not be a substrate of the inhibited enzyme. Inhibition is an immediate 
phenomenon that becomes evident as soon as the inhibitor comes into contact with the 
enzyme. The extent of inhibition depends on the concentration of the inhibitor at the site of 
the enzyme relative to the intrinsic potency of the inhibitor [78].  
 
There are two categories of inhibition: direct and irreversible. Direct inhibition can occur in a 
competitive, non-competitive, uncompetitive or mixed (competitive and non-competitive) 
manner, and the process usually begins with the first dose of the inhibitor. Irreversible 
inhibition involves metabolism-dependant inhibition where metabolism of another drug is 
completely blocked. A rare interaction which is a variation of the irreversible inhibition is 
called metabolism dependent “reversible” inhibition. In this case a drug is metabolised and 
the metabolite is a more potent inhibitor than the parent drug [78].  
 
Induction of the CYP enzymes requires prior exposure to a chemical inducer of the 
hepatocyte’s CYP-synthesis mechanism. This results in up-regulation of the production of 
one or more CYP enzymes. Unlike inhibition, induction has a slow onset and consequently a 
slow recovery to baseline when the inducer is removed. The magnitude of induction depends 
on both the concentration of the inducer and on the duration of the exposure [78].   
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1.7.2.2 P-glycoprotein 
 
P-gp is a transport protein which was initially implicated in multi-drug resistance in 
neoplastic tissues of Chinese hamster cells [79]. It is encoded by the multi-drug resistance-1 
(MDR1) gene.  P-gp is a dimer comprising of 1280 amino acids with 2 adenosine 5´-
triphosphate (ATP) binding domains and is classified as a member of the ATP-binding 
cassette superfamily of transport proteins. These transporters are known as ATP-binding 
cassette (ABC) transporters. P-gp has a wide range of substrates both structurally and 
pharmacologically. In general, the substrates are large molecules and are lipohilic and 
cationic at physiological pH.  P-gp transports drugs across from epithelial cells into the 
intestinal lumen (Figure 1.5), and is located on the apical membrane of these cells; therefore, 
it can affect absorption of drugs. Any change in the expression of the MDR1 gene which 
would affect the activity of P-gp may alter the pharmacokinetics of P-gp substrates.  
 
 
 
Figure 1.5. Diagrammatic representation of p-glycoprotein-mediated drug efflux [80]. 
 
P-gp is involved in drug absorption as well as in drug disposition. This transporter is also 
found in the liver where it transports substrates from hepatocytes into the canalicular space, 
kidney, leucocytes and the blood brain barrier. The role of P-gp in the kidney is to eliminate 
xenobiotics from the blood into the urine and to some extent, limit re-absorption of these 
substrates into tubular cells.  
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It has been reported that P-gp shares some substrates and inhibitors with CYP3A4, and have 
been found to have common tissue distribution [81]. Substances which are substrates of both 
P-gp and CYP3A4 may be absorbed into the epithelial cells, metabolised in the cells and also 
be excreted into the intestinal lumen [82], creating a cyclic effect. Therefore, transporter 
affinity of a drug or TM needs to be considered in conjunction with the impact of 
metabolising enzymes such as CYP450 isoenzymes [83].   
 
Induction of P-gp has also been studied in cell lines, animals and humans. Rifampicin is a 
potent inducer of P-gp activity. In a study on healthy human volunteers, orally-administered 
rifampicin reduced the Cmax and AUC of digoxin, but there was no effect on intravenous 
administration [84].  Duodenal biopsies revealed that rifampicin increased intestinal P-gp 
content 3.5 fold. Some TM/CAM extracts have been found to modulate P-gp activity which 
could lead to drug-TM interactions (Table 1.4).  
 
Table 1.4. Interactions of TM/CAM and orthodox medicines involving P-gp.  
Name of Herb Interacting 
Drug 
Study design Sample size Results Reference 
Milk Thistle 
(Silybum 
marianium) 
Digoxin Randomised, 
open-label, 
four-way 
cross-over 
16 healthy 
volunteers (8 
female) 
No significant 
change in AUC and 
Cmax 
[85] 
Black Cohosh Digoxin No significant 
change in AUC and 
Cmax 
St. Johns Wort cyclosporine - 1 organ transplant 
patient 
Rejection of 
transplant 
[86] 
 
1.7.3 In vitro Studies: Effect of Hypoxis hemerocallidea on the CYP Enzymes and the 
Protein Transporter P-glycoprotein  
 
Assessment of the inhibition of CYP3A4, 3A5 and CYP19 by AP extracts, hypoxoside, 
rooperol, AP formulations and other compounds was done by Nair [87].  The AP was dried 
by different methods and prepared in the same manner (boiled in water). The results showed 
very high inhibition of CYP3A4 and 3A5 at greater than 98% inhibition by rooperol. 
Inhibition by hypoxoside was less than half that of rooperol while inhibition by AP extracts 
(traditionally prepared) was about 21.0, 40.0 and 45.0 for CYP3A4, 3A5 and CYP19, 
respectively. These were very important findings, since most people use AP sold by 
traditional healers. 
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Effects of the same samples mentioned above on P-gp were examined using ritonavir as the 
positive control. The method used to investigate the functional activity of P-gp in CaCo-2 
cells was based on measuring rhodamine 123 (Rh123) retention/efflux in the presence of P-
gp modulators. The Rh123 is a cationic fluorescent dye taken up by cells and actively 
pumped out of the cells by P-gp. In the presence of P-gp inhibitors, the ability of CaCo-2 
cells to efflux Rh123, is decreased resulting in intracellular accumulation of Rh123. Results 
of this assay showed induction rather than inhibition by the AP extracts, hypoxoside and 
rooperol [88]. The highest induction was seen with hypoxoside even though it had a minimal 
effect on the inhibition of CYP enzymes. As mentioned previously, in vitro data can provide 
useful information to alert researchers to the possibility that drug interactions may occur 
when various medicines are used concurrently. In vitro data, therefore, serve as a signal that 
drug interactions may occur but it is again re-emphasized that such in vitro results must be 
confirmed by carrying out appropriate in vivo investigations.    
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CHAPTER 2 
EFAVIRENZ AS AN ANTIRETROVIRAL AGENT 
2 EFAVIRENZ  
 
2.1 Introduction 
 
Efavirenz (EFV) is an HIV-1 reverse transcriptase inhibitor (NNRTI) approved in many 
countries for use in combination with other antiretrovirals for the treatment of HIV-1 
infection. In the WHO Anatomic and Therapeutic Classification (ATC), EFV is classified as 
a systemic antiretroviral, and has been coded J05A G03.  The scientific name of EFV is (4S)-
6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one. 
Synonyms of EFV are: 5B706; DMP-266; Efavirentsi; Efavirenzum; L-743 and L743726. 
The molecular formula of EFV is C14H9ClF3NO2, and its molecular weight is 315.7. EFV 
structure is shown in Figure 2.1. 
 
Figure 2.1. Chemical structure of EFV. 
 
2.2 Synthesis 
 
EFV was discovered by Merck Research Laboratories company, West Pont, PA, USA, which 
provided the first report on its reverse transcriptase inhibitor properties in 1995 [89].  
 
 
2.3 Purity 
 
Sources of EFV impurities are generally solvents and intermediate products from the route of 
synthesis. The International Pharmacopeia [90] lists the possible impurities, and states that 
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the purity of EFV should be within 97% to 103% of C14H9ClF3NO2 calculated with reference 
to the dried substance 
 
2.4 Physicochemical Properties of EFV 
 
2.4.1 Solubility 
 
EFV is practically insoluble in water but soluble in methanol. It is a non-hygroscopic 
lipophilic material. The aqueous solubility of EFV is 9.2 µg/ml (pH 8.7) at 25°C, and it 
increases as the pH increases above pH 9 [91]. The increase in solubility at higher pH is 
because of the loss of the proton on the amine of the carbamate moiety.  
 
2.4.2 Ultraviolet (UV) Absorption 
 
The UV spectrum of a solution of EFV exhibits one maximum absorption at λ=247 nm [90]. 
A UV spectrum of EFV in acetonitrile: 0.1 M formic acid: methanol (52:43:5 %v/v) is shown 
in Figure 2.2. 
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Figure 2.2. UV spectrum of EFV. 
 
2.4.3 Description 
 
It is a white to slightly pink powder [90].  
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2.4.4 Melting Point and pKa  
 
The melting point of EFV is 137 ± 1.4 °C, and its pKa is 10.2 at 25°C. At 60 °C, the pKa of 
EFV was determined from non-linear regression analysis as 9.1 [91], and this is consistent 
with the effect on increased temperature on the ionisation of the proton donor. 
 
2.4.5 Polymorphism 
 
EFV exhibits polymorphism and there are four polymorphs, I, II, III and IV, which have been 
identified [92]. In another patent three polymorphs were identified [93]. The three 
polymorphs of EFV were identified using both Differential Scanning Calorimetry (DSC) and 
X-ray Diffraction. Form III is the most stable of the forms and is used to make compressed 
tablets. 
 
2.4.6 Stereochemistry 
 
Stereoisomerism exists when a molecule or chemical entity has at least one asymmetric 
carbon, known as a chiral centre. EFV has two enantiomers, the R (inactive) and S (active) 
enantiomers [89]. The R enantiomer has no activity on the reverse transcriptase enzyme. 
 
 
2.5 Stability 
 
The aqueous stability of EFV was evaluated as a function of pH and buffer species by Maurin 
et al [91]. The following buffers were used: acetate, borate, citrate, hydrochloric acid, 
phosphate, sodium hydroxide and the pH range from 1.0 to 12.8. The solution stability was 
assessed at a temperature of 60 °C. Degradation of EFV was rapid at a pH range 9.2 to 12.8 
and it followed first-order kinetics. The carbamate hydrolysis pathway has been proposed as 
the predominant reaction throughout the pH range studied. There may have been two 
kinetically indistinguishable mechanisms of hydrolysis (Figure 2.3). The two pathways are 
consistent with classical methods of carbamate hydrolysis.  
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Figure 2.3. Mechanism of hydrolysis of EFV [91]. 
 
2.6 Pharmacological Activity of EFV 
 
2.6.1 Mode of Action 
 
EFV is a member of the NNRTI group of ARVs which are of diverse molecular structure 
even though they act on the same site. NNRTIs, unlike NRTI, do not have to undergo 
phosphorylation prior to binding at the RT polymerase substrate site. NNRTIs bind to a 
specific site called non-nucleoside reverse transcriptase inhibitor binding pocket (NNBP). 
The NNBP is located between the sheets of the “palm” and the base of the “thumb” 
subdomains, near the anticipated DNA binding site on the p66, Figure 2.4. It has been 
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reported that the NNBP is located at a distance of 10Å (1 nm) from the polymerase substrate 
site on the HIV-1 RT [94]. The HIV-1 RT is a heterodimer, consisting of two polypeptides of 
sizes 66kDa and 51kDa, these are referred to as p66 and p51. These two polypeptides contain 
the same amino acids, although the p51 polypeptide does not appear to have any active sites. 
A recent study by Tacheddjian et al [95] found that EFV enhances formation of homodimers 
p66/p66 and p51/p51, as well as binding to p51. This might be one of the reasons why EFV is 
highly potent against HIV-1 RT. 
 
 
Figure 2.4. Diagram of the HIV-1 RT heterodimer in the complex with an NNRTI [96].  
 
Two domains of the HIV-1 RT are DNA polymerase and ribonuclease H (RNaseH). These 
domains are located in the p66 polypeptide. Four subdomains on each of the polypeptides 
exist, and are denoted as “fingers, thumb, palm and connection”, see Figure 2.4. The 
subdomains consist of different amino acid residues: finger (1-85 and 118-155), palm (86-
117 and 156-237), thumb (238-318) and connection (319-426) [94]. There is a large cleft 
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formed in the p66 which accommodates the template/primer substrate, in this case an 
NNRTI. These amino acid residues can be hydrophobic or hydrophilic in nature, but most are 
hydrophobic such as those on the NNBP.  On binding to the NNBP, the NNRTI interacts with 
the amino acid residues to form hydrogen bonds, and π-π interactions are also involved 
(Try181, Tyr188, Phe 227, Trp 229 and Tyr 318 have aromatic side chains).  The amino acid 
residues mould the inner cleft such that the NNBP is almost closed. Flexibility is needed in 
order for NNRTIs to bind to the NNBP, and this has been confirmed by Ragno et al [97] in 
cross-docking of RT and NNRTI complexes studies.  
 
NNRTIs have at least one aromatic ring which is capable of participating in π-π interactions 
with the amino acid residues. They also have groups which are capable of donating and/or 
accepting electrons to form hydrogen bonds, e.g. NH-C=O or NH-C=S, and are hydrocarbon 
rich, hence bind well at the hydrophobic NNBP. Once bound to the NNBP, NNRTIs induce 
conformational changes to the orientation of the amino acid side-chains. This directly affects 
the global hinge-bending mechanism that controls p66 fingers and thumbs subdomains. 
Conformational changes do not directly affect the mobility of each subdomain. The NNRTI 
binding thus slows down the rate of reaction, which is catalysed by HIV-1 RT (rate limiting 
step), hence replication of HIV is greatly reduced. 
 
Studies have shown that NNRTIs bind to NNBP without affecting polymerase site, thus 
inhibiting the HIV-1RT uncompetitively. This was confirmed by simultaneous binding of the 
natural deoxynucleaic triphosphate (dNTP) to the polymerase site, and NNRTI binding to the 
NNBP on the HIV-1 RT [98].  Therefore, NNRTIs are currently used in combination with 
NRTIs. At the molecular level, it has been shown that NNRTIs inhibit the removal of 
nucleoside analogues from the DNA terminus by HIV-1 RT, which is mediated by 
physiological concentrations of ATP [99]. EFV was found to be the most potent NNRTI, 
even on the mutations of K103N, Y181C and K103N/Y181C.  
 
Interactions of EFV and NNBP are strongest at the Lys101 [100] with interaction energy of -
11.29 kcal/mol (the overall energy was -22.75 kcal/mol). Thus, the strongest interaction was 
with Lys101. Binding energy of EFV was lower than that of Nevirapine (NVP), which could 
be the other reason for EFV being more potent than NVP. Binding energy is a measure of 
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flexibility of the molecules.  Studies on deformation energy have shown that flexibility is an 
important aspect of effective binding to NNBP. 
 
EFV is not active against human DNA polymerases α, β and γ, Escherichia coli RNA 
polymerase and HIV-2 RT polymerase with IC50 (50% inhibitory concentration) >300 µM 
[89]. It is highly effective against the wild-type HIV-1 RT virus with IC50 Ki (inhibitory 
constant) greater than 2.93 nM.    
 
2.7 Mutations at the NNBP 
 
The RT has an inherent high replication error rate, which is estimated at about 10-4 
replications. Like other RNA-dependent polymerases, RT lacks proofreading mechanisms, 
hence the high error rate. The life-cycle of HIV can be completed in 24 hr (up to 1010-1011). 
These mutations can occur prior to administration of ARVs or during administration of 
ARVs. Mutations occur on the amino acid residues on the NNBP such that the binding of the 
inhibitors is affected.  
 
Major mutations at NNBP are K103N, V106A, V179D, Y181C, A98G, K101E, V108I, 
G190AIS, P225H, M3230L and E138K. These mutations affect the conformation of NNBP, 
hence reducing the strength of binding of the inhibitors to the site. The most common 
mutation which is resistant to EFV is K103N. Low level resistance of EFV has been 
associated with P225H and Y181C. Compared to older NNRTIs, EFV is less affected by 
mutations at the NNBP. This could be because EFV forms strong hydrogen bonds with the 
Lys101 residue in the palm, and is more flexible than older NNRTIs [101, 102].  
 
2.7.1 Types of Mutations 
 
Mutations can involve base substitution or base frame shift of the amino acid residues in or 
near the NNBP.  These substitutions are initiated by the template-primer slippage because 
they occur at the 3´ or 5´ end of the protein. Single substitution of one amino acid is the most 
common mutation, e.g., K103N. There are mutations where two or more amino acid 
molecules are substituted, but the frequencies of these are fewer [103]. 
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2.7.2 Factors Affecting Mutations 
 
EFV has a long plasma half-life such that when the treatment regimen dosing is interrupted 
(either by treatment holiday or poor adherence), the virus is exposed to single therapy of EFV 
which can result in mutations. Patients with CYP2B6 516TT genotype are more prone to 
mutations if triple therapy is stopped simultaneously, because then, EFV plasma half-life is 
prolonged in these patients [104, 105]. The presence of high level of mutations which are 
resistant to drugs have been found to increase the rate of mutations of the wild-type viruses 
[103]. Poor adherence results in varying plasma concentrations of drugs, and consequently, 
increased mutations [106]. 
 
2.8 Hyper-susceptibility to EFV 
 
Hyper-susceptibility is defined as exhibition of significant increase in susceptibility of the 
virus to ARVs. In some cases where patients were previously treated with NRTIs and were 
NNRTI-naïve, it was found that 34% were hyper-susceptible to EFV [107]. Replication 
assays revealed that the hyper-susceptibility was associated with H208Y/T215Y and 
V118I/H208Y/T215Y mutations. These are double and triple mutations. There was no hyper-
susceptibility for the single mutations.  
 
2.9 Pharmacokinetics of EFV 
 
The pharmacokinetics of EFV has been studied in rats, monkeys [108] and humans [109]. In 
rats and monkeys, EFV exhibited nonlinear pharmacokinetics within the relatively high range 
of dosing used, which was aggravated by delayed gastric-emptying in these species and 
saturable metabolic processes [108]. In humans, the delay in gastric emptying is not 
significant because the dosing is once daily, hence the amount of drug in the body remains 
within the linear range.  
 
2.9.1 Absorption 
 
EFV is well absorbed after the oral administration to humans. Only less than 1% of an oral 
dose is excreted in urine and faeces. Peak plasma concentrations are reached within 5 hr of 
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dosing and the drug’s pharmacokinetics is linear with plasma concentrations increasing with 
increasing dose.  
 
2.9.2  Effect on P-glycoprotein 
 
The effect of EFV on P-gp activity has been assessed on different cells and yielded different 
results. In canine kidney cell lines, EFV was found to inhibit multi-drug resistance proteins 
[110], while it was found to induce P-gp in peripheral blood mononuclear cells isolated from 
healthy volunteers [111].  In an in vitro study on Caco-2 cells undertaken by Stӧrmer et al 
[112], EFV was found to be a weak inducer of P-gp, and,  therefore, less likely to affect drug 
efflux. The effect of EFV on P-gp activity on immortalised rat brain cell line has been found 
not to be significant, and EFV uptake through the blood-brain barrier of adult male Wistar 
rats was not affected by P-gp inhibitors [113]. In another study by Berruet et al [114], EFV 
was found not to be an inducer or inhibitor in rats. Mouly et al [115] assessed the effect of 
EFV on intestinal P-gp, and found that the effect of EFV on P-gp was not detectable, hence 
no clear conclusion was reached. Thus, the effect of EFV on P-gp is still not well established. 
 
2.9.3 Distribution 
 
Lipophilicity of EFV renders it highly distributed in the body. EFV has been found in various 
sites and cells in the body such as the microglia, semen, lymphocytes and peripheral blood 
mono-nuclear cells. In a population pharmacokinetic meta-analysis involving 334 healthy 
human volunteers from phase 1 clinical studies, the apparent volume of distribution (Vd/F) 
after a single and multiple doses were 151 L and 190 L, respectively [116]. In another 
population pharmacokinetic study involving 235 HIV positive patients from a cohort of 
patients on EFV based regimens, Vd/F was found to be 252 ± 14% [117]. From these two 
studies, it can be concluded that EFV is widely distributed in the body. Almond et al [118] 
found that the ratio of intracellular EFV AUC0-24 to unbound EFV AUC0-24 was over 200, 
which showed that there is more unbound EFV in the intracellular spaces than in plasma. In a 
study where 11 patients on EFV were assessed for penetration of EFV into the CSF, EFV was 
not detectable but this method does not state the lower limit of quantitation (LLOQ), of the 
LC/MS method [119]. EFV has a high affinity for adipose tissues in humans [120] due to its 
lipohilicity. 
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2.9.4 Metabolism and Elimination 
 
EFV is a substrate of the cytochrome P450 (CYP450) enzyme family, in particular CYP2B6 
and CYP3A4. Metabolism of EFV has been studied in cynomologous monkeys, guinea-pigs, 
hamsters, humans and rats, and EFV was found to be extensively metabolised in all these 
species [109]. There are some differences and similarities in the metabolism between species. 
In humans, metabolites were mainly found in urine, while plasma samples showed mostly 
unchanged EFV. Seven metabolites were found in human urine (Figure 2.5) [109], and six 
were found in plasma.  Oxidative hydroxylation at three positions in the EFV molecule is the 
main mechanism of metabolism. These metabolites then undergo phase II conjugation, and 
this is where there are significant differences between species. In humans the preferential 
route is conjugation with glucuronic acid at C8, whereas in rats, it was sulphuric acid.  The 
main metabolites are the glucuronide conjugates of 8-hydroxyefavirenz and 7-
hydroxyefavirenz after multiple dosing, while the N-glucuronide conjugate of EFV was the 
major metabolite after single dosing. The structures of these metabolites were confirmed by 
mass spectroscopy (MS) and nuclear magnetic resonance (NMR).  
 
In one in vitro study using human liver microsomes (HLMs), CYP2B6 was determined as the 
main enzyme involved in the metabolism of EFV [121].  Primary metabolites of EFV were 
found to be 8-hydroxyefavirenz (main) and 7-hydroxyefavirenz (minor), and 8,14-
dihydroxyefavirenz (secondary) in the in vitro study. The formation of 8,14-
dihydroxyefavirenz showed a longer lag-time relative to formation of 8-hydroxyefavirenz. It 
was confirmed that the formation of 8,14-dihydroxyefavirenz followed a step-wise 
hydroxylation of  EFV, with 8-hydroxyefavirenz as an intermediate. Metabolites of EFV 
were evaluated for antiretroviral activity, and it was found that none of them exhibited any 
antiretroviral activity [122]. 
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Figure 2.5. Proposed metabolic pathway for EFV in humans [109].  
 
The clearance of EFV is higher in Caucasians than in Blacks and Asians [123]. This 
phenomenon can be caused by variability in the gene expressing CYP2B6.   Prevalence of 
homozygous CYP2B6 */*6 allele among West Africans and African-Americans were found 
to be higher than Caucasians, Asians and Hispanics [124]. Ståhle et al [125] found high intra- 
and inter-patient variability in plasma EFV concentrations, with inter patient variability 
reaching 84%. It was suggested that the high variability could be caused by polymorphism 
exhibited by CYP2B6. Patients with the homozygous CYP2B6 */*6 allele have been found to 
have higher plasma concentrations than those with heterozygous *6, or those without the *6 
allele [126, 127]. Patients with the homozygous recessive allele are at higher risk of 
developing adverse events from high EFV plasma concentrations. There is thus a higher 
probability that patients with the homozygous CYP2B6 */*6 allele will experience more 
prolonged EFV plasma exposure following discontinuation of therapy [104]. This could lead 
to the undesirable situation of EFV monotherapy on discontinuation of the ARV regimen. 
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Therefore, it is important that patients do not discontinue therapy or take holidays from 
therapy unless a proper plan has been made by clinicians. 
 
The elimination half-life of EFV after single and multiple oral doses is 55-76 hr and 40-55 hr, 
respectively, the latter being because EFV induces its own metabolism. EFV can induce or 
inhibit CYP3A4, thereby affecting plasma concentrations of CYP3A4 substrates [115]. 
Conjugated oxidative metabolites are excreted in bile and in urine [109]. Only less than 1% is 
excreted unchanged in urine and faeces. 
 
2.10 Drug Interactions of EFV 
 
2.10.1 EFV as a Substrate of CYP3A4 
 
Since EFV is a substrate of CYP3A4 and CYP2B6, inhibitors and inducers of these enzyme 
systems may affect EFV plasma levels. The following drugs and herbs/plants/TMs have been 
shown to affect metabolism of EFV, however the mechanisms of inhibition or induction were 
not stated: 
• Rifampicin increases metabolism of EFV, resulting in a reduction in AUC (22%), 
and Cmin (25%) in healthy individuals. The recommendation is that the dose of 
EFV may be increased to 800 mg daily in patients on rifampicin except for low 
body weight patients [128]. 
• Carbamazepine increases metabolism of EFV, resulting in a reduction in AUC, 
Cmax and Cmin, with mean ratios and 90% CI being 0.64 (0.60-0.68), 0.79 (0.74-
0.85) and 0.53 (0.47-0.59), respectively. The mean ratios and the 90% CI of these 
parameters were outside the 0.8 to 1.25 bioequivalence limits [129]. 
• Voriconazole increased the steady-state mean AUC0-24 and Cmax of efavirenz by 
43% and 37%, respectively [130].  
• Nevirapine decreases EFV AUC (22%), Cmax (17%) and Cmin (36%) on co-
administration. Due to higher risk of side effects and no improvement in efficacy 
over either NNRTI alone, this combination is not recommended [131]. 
• St. Johns Wort can induce metabolism of EFV by induction of metabolising 
enzymes and/or transporter proteins which could lead to reduced plasma levels of 
EFV. This induction effect may persist for at lease 2 weeks after cessation of 
treatment with St. Johns Wort [132]. 
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2.10.2 Induction of CYP3A4 
 
EFV induces CYP3A4, and has been associated with clinically significant drug interactions 
(Table 2.1). Using the Erythromycin Breath Test (ERMT), hepatic CYP 3A4 activity was 
significantly increased by EFV compared to placebo in healthy human volunteers [115].  
Induction occurred on day 11 of dosing with 200 mg EFV, and on day 4 after dosing with 
400 mg EFV.  Dissipation of induction occurred 21 days after the last dose of 400 mg EFV, 
and this is due to the long half-life of EFV. Induction of CYP3A4 was found to be both time- 
and dose-dependent. EFV’s induction is less than that of rifampicin which induces CYP3A4 
by 125% compared to 55% of EFV. 
    
Table 2.1. Pharmacokinetic interactions of EFV resulting from induction of CYP450 enzymes. 
Drug Pharmacokinetic 
Parameters 
Isoenzyme 
Induced and 
mechanism 
Clinical 
Significance 
Recommendation Reference 
Buprenorphine AUC ↓50% CYP3A4 
N-dealkylation 
Yes Close monitoring, 
dose alteration 
[133] 
Methadone AUC ↓52% 
Cmax ↓45% 
CYP3A4 
NS* 
Yes Close monitoring, 
dose alteration 
[134] 
Rifabutin AUC ↓38% 
Cmax ↓32% 
Cmin ↓45% 
CYP3A4 
Oxidation  
Yes Close monitoring, 
dose alteration 
[135] 
Carbamazepine AUC ↓27% 
Cmax ↓20% 
Cmin ↓35% 
 
CYP3A4 
NS 
Yes Carbamazepine 
plasma levels 
should be 
monitored, if 
necessary 
alternative 
anticonvulsants 
should be used 
[129] 
Bupropion AUC ↓55% 
Cmax ↓34% 
AUC of active 
metabolite un 
changed 
CYP2B6 
Hydroxylation  
Possibly Close monitoring, 
dose alteration if 
necessary 
[136, 137] 
Ketoconazole AUC ↓72% 
Cmax ↓44% 
Cltot↑201% 
CYP3A4 
Oxidation  
Yes Alternative 
treatment to 
considered 
[138] 
Voriconazole AUC ↓55% 
Cmax ↓36% 
NS Yes Dose of 
voriconazole should 
be adjusted 
[139] 
AUC ↓80% 
Cmax ↓66% 
NS  Co-administration 
contraindicated 
[130] 
Simvastatin AUC ↓58% 
 
NS Yes Monitor cholesterol 
levels and adjust 
dose if necessary 
[140] 
Atorvastatin AUC ↓34% NS 
Pravastatin AUC ↓40% NS 
*NS- not stated 
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Clinical studies have been conducted to asses the effect of EFV on the pharmacokinetics on 
different drugs metabolised via CYP3A4 and 2B6 isoenzymes. Interactions between EFV and 
some Protease Inhibitors (PIs) e.g., indinavir, lopinavir, azatanavir, have been confirmed in 
clinical studies, and results showed reduction in plasma levels of the PIs.  These interactions 
have to be monitored clinically to avoid adverse events. 
 
2.10.3 Inhibition of CYP3A4 
 
EFV competitively inhibits CYP3A4 isoenzyme activity which results in clinically significant 
interactions. This competitive inhibition could result in increased plasma concentrations of 
the interacting drugs. Co-administration of EFV with astemizole and cisapride are 
contraindicated because of the possibility of occurrence of life-threatening cardiac 
arrhythmias, however the mechanism of inhibition was not reported [132].  
 
2.11 Efficacy 
 
A study conducted on HIV positive patients in South Africa revealed that EFV, in 
combination with didanosine and lamuvidine, reduced plasma viral load and increased mean 
T cell count within 10 days of commencing therapy [141]. Undetectable viral levels were 
reached by some patients and the time to reach undetectable levels in those patients who had 
low (<150 cells/µl) cell count was significantly lower.  In treatment-naïve patients, reduction 
of viral load up to 2.4 log10 copies/ml has been observed on EFV-based triple regimen [142]. 
This reduction was evident as early as 3 months post-initiation of treatment. After 9 months 
of treatment, the highest increase of T cells was observed. Patients in an AIDS Clinical Trials 
Group (ACTG) A5095 study which was randomised, double blinded and placebo controlled, 
were assessed for virological and immunological response following a three or four ARV 
treatment regimen [143]. Treatments involved 3NRTIs; 2NRTIs and EFV; 3NRTIs and EFV. 
The 3NRTIs treatment arm was discontinued early, due to inferior results. Viral suppression 
was achieved from week 16 through 3 years on the EFV-based treatment arm, as well as in 
the other two arms. 
 
The efficacy of EFV was compared to that of nevirapine as a secondary objective in a single 
centre, observational, prospective, comparative cohort study among 100 study participants 
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who were treatment naive [144]. After 48 weeks of treatment, 79% of patients on the EFV 
arm had achieved viral suppression, compared to 74% NVP. Thus, there were no significant 
differences between the two NNRTIs. 
 
2.12 Clinical Uses 
 
Clinically, EFV is effective against HIV replication and positive results were assessed both 
by virological and immunological responses [145-147]. Surrogate markers for efficacy of 
EFV used in some of these studies are lack of, or delayed development of, AIDS defining 
illnesses. In treatment-naïve patients, the rate of viral suppression can also be used as a 
measure of efficacy. There are no data to show efficacy of EFV alone, because clinical 
studies would be inappropriate and unethical, since ARVs should not be given as single 
therapy. This is due to failure of treatment of single therapy; hence efficacy of EFV has been 
shown in combination with other ARVs. 
 
2.13 Side-effects 
 
Dermatological and neuropsychiatric side-effects are the main adverse events following 
treatment with EFV. Rare but potentially serious skin rashes have been reported during use of 
EFV, including Stevenson-Johnson syndrome.  The most common (greater than 10%) but not 
life-threatening are psychiatric symptoms (dizziness, depression, insomnia, anxiety), pain and  
skin rashes are very common with a median onset of 8 days [148]; increase in High Density 
Lipids (HDL) and total cholesterol; diarrhoea and nausea.  It has been reported that the 
psychiatric symptoms resolved after changing therapy from EFV to nevirapine in a 
retrospective analysis study [149]. Less common side-effects are headache, impairment of 
concentration, somnolescence, abnormal dreams, fatigue, severe depression, hallucinations, 
nervousness, pruritis, vomiting, dyspepsia, abdominal pain and anorexia. These symptoms 
can persist even after three months of therapy [150].  In one patient who took an overdose of 
EFV, the CNS symptoms subsided when EFV treatment was stopped [151]. In a study 
conducted on Japanese patients who were on EFV-based HAART, it was found that the most 
common side-effect was abnormal dreams, and one of the patients reported loss of libido 
[152].  
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CHAPTER 3 
AFRICAN POTATO (Hypoxis hemerocallidea): DRUG INTERACTIONS 
 
3 AFRICAN POTATO 
 
3.1 Geographical Distribution  
 
Hypoxis is a genus of the hypoxidaceae family which is widely distributed around the world, 
with reports of existence in various countries including America [153, 154], New Zealand 
[155], South Africa [156], Malawi [157], Madagascar, Mauritius [158], Mozambique [159], 
Zimbabwe and other Central Africa countries [160]. 
 
3.2 Taxonomy 
 
There has been various efforts undertaken by botanists to describe species of Hypoxis, and 
the more recent revision is reported by Singh [156].  In this taxonomic revision, 30 species of 
Hypoxis in Africa are reported, and of these, 21 are endemic to southern Africa. This diverse 
genus lacks distinct diagnostic characteristics which have been reported to be difficult in 
describing the species taxonomically. However, the nomenclature presently is based on leaf 
characters, leaf venation, floral characters, inflorescence and their use [156]. Singh [156] 
reduced this large number of species to nine synonymic names for the species where most of 
the species are grouped under one of names are shown below: 
• Hypoxis angustifolia var buchananii 
• Hypoxis argenta var sericea 
• Hypoxis colchicifolia 
• Hypoxis floccosa 
• Hypoxis hemerocallidea 
• Hypoxis longifolia 
• Hypoxis obtusa 
• Hypoxis ridigula 
• Hypoxis ridigula var pilosissima 
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The most abundant species in the Eastern Cape region of South Africa is Hypoxis 
hemerocallidea. It was first described by Fisch, C. A. Mey and Ave´-Lall in 1842 as Hypoxis 
rooperi, and has now been included as a synonym for Hypoxis hemerocallidea by the 
taxonomists. These plants exhibit some variations in leaf dimensions, numbers of bright 
yellow flowers, and dimensions of pedicels. Young plants have 2 flowers on long or short 
pedicels, while in older plants, the number of flowers varies from 4 to 12, with variable 
length of firm pedicels (Figure 3.1). 
 
 
Figure 3.1. Photograph of a young Hypoxis hemerocallidea plant [161]. 
 
The plant has an underground bulb called a “corm”, and this corm is vital to the resistance of 
the plant to cold winters. The corm is brown in colour, and has adventitious roots. When cut 
open, the inside of the corm is bright yellow, and turns dark-brown within a few minutes. The 
sizes of the corm vary according to the age of the plant, one-year-old corms can weigh up to 
200 g, and the older ones are even larger (800 g). Due to the resemblance of the corm to a 
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potato, this plant has also become commonly known as “African Potato”. It is also called the 
African “yellow” star flower, because of its bright yellow flowers. 
 
3.3 Uses 
 
Ethanobotany suggests that Hypoxis plants, especially their corms are used by traditional 
healers in Africa for years. Some of the uses reported in literature have been listed in Table 
3.1. Both the corms and the leaves of Hypoxis hemerocallidea have been used for the 
treatment of various diseases.  
 
Table 3.1. Traditional uses of Hypoxis hemerocallidea. 
Reported Use Part of plant Preparation Area Reference 
Diabetes Corms Fresh corms, 
boiled and 
taken orally 
Eastern Cape, 
South Africa 
[162] 
Prostate 
hypertrophy 
NS* NS* Maputo, 
Mozambique 
[18] 
Urinary or 
venereal 
diseases 
NS* NS* KwaZulu Natal, 
South Africa 
[163] 
Cancer Corms Pulverised 
corms are 
boiled and 
taken orally 
Eastern Cape, 
Southern Africa [164] 
Wound 
management 
Leaves 
 
 
corms 
Dry powder 
sprinkled on 
wounds 
Fresh or dried 
material 
extracted and 
used as wash 
Eastern Cape, 
South Africa 
[165] 
HIV/AIDS 
management 
NS* NS* Johannesburg, 
South Africa 
[47] 
*NS – not stated 
 
3.4 Chemical Constituents 
 
The main compounds reported are known as norlignans with a Ph-C5-Ph or Ph-C3 (C2)-Ph 
skeleton [159]. It has been suggested that these norlignans are derived from cinnamic acid 
and cynnamyl alcohol and linked β-γ´ and α-β´. The chemical structures of norlignans are 
based on the linkage positions between two units [166]. The linkages in the compounds from 
the hypoxidaceae species are C7-C8´ linkages. It is not surprising to find similar constituents 
of hypoxis genus in other hypoxidaceae like Curculigo recurvata in Italy [167]. 
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Reports on isolation of compounds from Hypoxis dates back to 1982 when Marini-Bettolo et 
al [159] extracted the corm of Hypoxis obtusa from Mozambique using methanol. An 
uncommon structure which they named hypoxoside was found to be the major constituent of 
the corm, with yields of 3.7%. In 1983, Drewes et al [168] extracted hypoxoside from 
Hypoxis rooperi and other species, including H. accuminata, H. nitida, H. obtusa, H. rigidula 
and H. latifolia. Yields of 3.5 and 4.5% hypoxoside were reported in extracts from H. 
hemerocallidea. The concentration of hypoxoside is reported to vary from corm to corm. 
 
3.4.1 Hypoxoside  
 
3.4.1.1 Chemical Name 
 
The chemical name of hypoxoside is (e)-1,5-bis-(4´β-D-glupyranosyloxy-3´-hydroxyphenyl)-
pent-4-en-1-yne. 
 
3.4.1.2 Structure  
 
The structure of hypoxoside (Figure 3.2) was confirmed by Marini-Bettolo et al 1981; 1985; 
Drewes 1984, Nair 2007, and Laporta 2007 [27, 168-170] by spectroscopic methods.  
 
 
 
 Hypoxoside Obtuside A Obtuside B 
R β-D-glucose β-D-glucose H 
R1 β-D-glucose H β-D-glucose 
 
Figure 3.2. Structures of hypoxoside, obtuside A and obtuside B. 
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3.4.1.3 Physicochemical Properties 
 
The melting point of hypoxoside is 149-151°C, and it is very soluble in both methanol and 
water [169]. When dissolved in methanol, it exhibits three maxima in UV spectra at 212, 258 
and 298 nm. 
 
3.4.2 Obtuside A and B 
 
Obtuside A and B (Figure 3.2) were isolated from H. obtusa by Marini-Bettolo et al in 1982 
[169], at the same time when they isolated hypoxoside.  
 
3.4.3 Nyasoside 
 
Nyasoside, (Figure 3.3) was extracted from Hypoxis nyasica plant collected from Malawi 
using methanol, and yielded 3.0%, which was less than the yield of hypoxoside (5.0%) from 
the same plant [171]. Like hypoxoside, nyasoside is a di-glucoside which on hydrolysis with 
β-glucosidase yielded D-glucose and an oily aglucone called nyasol. 
 
 
 
 
nyasoside nyasol nyaside mononyasine A mononyasine B 
R1 β-D-glucose H β-D-glucose H β-D-glucose 
R2 β-D-glucose H Ap►6-Glucose β-D-glucose H 
 
Figure 3.3. Chemical structure of nyasoside, nyaside, nyasol, mononyasine A and mononyasine B. 
 
3.4.4 Nyaside 
 
This compound was isolated at the same time as nyasoside [171] (Figure 3.3). 
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3.4.5 Mononyasine A and B 
 
Mononyasine is a glucoside which was first identified by Messana et al [172] after extraction 
from Hypoxis nyasica. The plant was collected from Malawi and a sample was kept in the 
University of La Sapienza Botanical Gardens. Two of these glucosides were found in the 
extract, and the structure was elucidated by electron impact mass spectrum. The two 
compounds were named mononyasine A and mononyasine B (Figure 3.3). These two 
structures were solved by 13C nuclear magnetic resonance (NMR) spectroscopy. On 
hydrolysis with β-glucosidase, both compounds yielded glucose and an oily aglucone called 
nyasol. 
 
3.4.6 Obtusaside 
 
Obtusaside is a phenolic glycoside (Figure 3.4) which was extracted using methanol from 
Hypoxis obtusa by Msonthi et al [157]. The plant was collected from Malawi and identified 
as Hypoxis obtusa. The structure was elucidated by both 1H and 13C NMR. Enzymatic 
hydrolysis with β-glucosidase yielded a 2,5-dihydroxybenzyl alcohol.  
 
where, R1 and R2 are hydrogen atoms 
 
Figure 3.4. Chemical structure of Obtusaside. 
 
3.4.7 Nyasol 
 
Nyasol (Figure 3.4) was isolated and identified by Mass and NMR spectroscopic methods by 
Sibanda et al [173]. This compound, along with hypoxoside, nyasoside, nyaside, 
mononyasine A and mononyaside B, was extracted by methanol from a plant harvested in 
Zimbabwe. The plant was identified as Hypoxis angustifolia.  
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3.4.8 Sterols and Sterolins 
 
Some sterols and sterolins have been identified, and in some cases, quantified in the extracts 
of Hypoxis. In 1975, a patent was registered with the British patents office, on the extraction 
of sterols and sterolins from plant material, in particular Hypoxis [174]. These were identified 
as β-sitosterol and β-sitosterol glucoside. Four years later, another patent was registered by 
Pegel et al [175] in America, on methods of extraction of these sterols and sterolins from 
Hypoxis plants. In both cases, the amount of sterols and sterolins recovered were claimed to 
be high, while another study reported far much lower amounts [176].   
 
3.5 Pharmacological Activity of AP 
 
3.5.1 Immunomodulation Properties 
 
Bouic et al [177] reported on in vitro effects of β-sitosterol (BSS) and β-sitosterol glucoside 
(BSSG) on human peripheral lymphocyte proliferation. Lymphocyte proliferative responses 
are believed to have restorative properties in the immune system, as demonstrated in studies 
conducted by Salen et al [178]. For the in vitro proliferative assay, both the mononuclear 
cells and T-cells were used. Enhanced proliferation was seen on T-cells which had BSS and 
BSSG only, and not on the mononuclear cells. It was concluded that these results showed that 
BSS and BSSG are capable of enhancing T-cell proliferative responses. 
 
3.5.2 Antioxidant Activity 
 
The antioxidant activity of Hypoxis rooperi extract and its main compounds, hypoxoside and 
the metabolite of hypoxoside, rooperol, were assessed by Laporta et al [170]. Both 
hypoxoside and rooperol showed antioxidant activities which increased with increasing 
concentrations of the compounds. However it is reported that rooperol exhibited higher 
antioxidant activity than hypoxoside [170]. 
 
Free radical scavenging activity using, 1,1-dipheny-2-prcryl hydroxyl (DPPH) assay, of 
aqueous AP extract, hypoxoside and rooperol, were evaluated by Nair et al [87]. Aqueous 
extracts of AP showed high levels of activity that increased with increasing concentration. 
Rooperol showed high free radical scavenging activity compared to the reference compound; 
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quercetin, but hypoxoside did not exhibit similar activity. In the same study, the antioxidant 
activity was assessed using Ferric Reducing Activity Plasma (FRAP), and rooperol exhibited 
high antioxidant activity, while hypoxoside did not exhibit any activity. It was suggested that 
the slight antioxidant activity of AP aqueous extract could be due to other compounds, and 
not to hypoxoside. Methanolic and aqueous extracts of Hypoxis hemerocallidea were found 
to possess free radical scavenging activity which was comparable to that of vitamin C, which 
was the control [179]. This study assessed antioxidant properties, using free radical 
scavenging method, while the former employed FRAP, lipid peroxidation assay, superoxide 
anion oxidation assay, as well as free radical scavenging method. Therefore, the antioxidant 
property report by Nair et al [87] provides a comprehensive assessment of potential 
antioxidant activity, since each test provides a different insight on potential antioxidant 
activity. 
 
3.5.3 Anti-inflammatory Properties 
 
It is reported that hypoxoside and Hypoxis rooperi did not inhibit activity of COX-1 and 
COX-2 enzymes in vitro, but rooperol noticeably inhibited both these enzymes [180]. 
Methanolic extracts of Hypoxis hemerocallidea were assessed for prostaglandin-synthesis 
inhibition, and found to inhibit synthesis of prostaglandins. In 2006, Steenkamp et al [179] 
assessed the anti-inflammatory activity of Hypoxis extracts, and indomethacin was used as a 
control and reported that ethanolic extracts exhibited higher inhibitory effects than aqueous 
extracts. 
 
In experimental models of rat oedema, aqueous Hypoxis extract was evaluated for anti 
inflammatory activity and compared to diclofenac [181]. The model was rat hind paw 
oedema, which was induced by injection of intra-plantar injection of fresh egg albumin. This 
pholgistic agent resulted in acute inflammation of the paw, and an aqueous extract of Hypoxis 
hemerocallidea is reported to have produced significant reduction in inflammation [181]. 
 
3.5.4 Antinociceptive Properties 
 
Thermal and chemical tests were used to assess antinociceptive properties of aqueous 
Hypoxis hemerocallidea extracts in mice [181]. The thermal pain was induced by placing the 
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mice in a beaker which was heated by a hot plate, and the pain stimulus (jumping out of 
beaker) was assessed. There was a significant increase in the time taken to respond to pain in 
mice dosed with extract compared to control group. However, this was less than the response 
from the morphine group. Based on this result, it is reported that the AP aqueous extract may 
have centrally- and peripherally-mediated analgesic properties [181]. Chemical pain was 
induced by intra-peritonially administering 0.2 ml of 3% acetic acid solution to the mice. The 
mice were divided into three groups: control, AP aqueous extract, and diclofenac. AP 
aqueous extract significantly relieved pain more than the control, but was less than 
diclofenac. These investigations concluded that an AP aqueous extract exhibited analgesic 
properties. 
 
3.5.5 Antidiabetic/Hypoglycaemic Effects 
 
The hypoglycaemic effects of methanolic extracts of Hypoxis hemerocallidea were evaluated 
in male Wistar rats weighing 250-300 g [182]. The doses of AP extract were 100-800 mg/kg 
orally and were compared to placebo and standard treatments of glibenclamide (5 mg/kg) 
administered orally and insulin 5 µU/kg subcutaneously. The AP extracts produced 
significant reduction in blood glucose concentration. In another study, Ojewole et al [181] 
compared the hypoglycaemic effects AP aqueous extracts to control and chlorpropamide (a 
first generation sulphonylurea). The AP aqueous extract was found to significantly reduce 
blood glucose levels. However, the mechanism of this hypoglycaemic effect is not reported. 
 
3.5.6 Anticonvulsant Activity 
 
Plant species traditionally used in the treatment of epilepsy and convulsions were selected 
and assessed for binding to GABAA – benzodiazepine receptor complex. Hypoxis 
hemerocallidea, Hypoxis angustifolia and Hypoxis colchicifolia species were some of the 
species and extracts which were prepared with both ethanol and water [183]. All the hypoxis 
leaves and corms showed dose-dependent anti-convulsant activity.  
 
3.5.7 Antibacterial Activity 
 
One of the traditional uses of AP is the treatment of wounds where both leaves and the corm 
have been used [165]. The antibacterial properties of Hypoxis hemerocallidea leaves and 
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corm were assessed by Katerere et al [184] after extraction with acetone and methanol. The 
important nocosomial organisms tested were Staphylococcus aureus, Pseudomonas 
aeruginosa, Escherichia coli and Enterococcus faecalis. The dried corm extract was the most 
effective against S. aureus. The antibacterial activity of ethanolic and aqueous extracts of 
Hypoxis hemerocallidea against Escherichia coli were assessed and found to inhibit growth 
of the organism but this inhibition was reportedly less than the inhibition induced by 
ciprofloxacin [179].  
 
Laporta et al [180] reported on antibacterial activity of Hypoxis rooperi extract, hypoxoside 
and rooperol against Staphaylococcus aureus and Escherichia coli. The antibacterial effect 
observed was comparatively less than that of neomycin which was used a reference. It was 
also reported that the gram-positive strain S. aureus was the most sensitive bacteria. 
 
Inhibition of motility and multiplication of bacteria by agglutinins of lectins in some plants 
were assessed. Lectins are non-enzymatic proteins which bind to mono- and oligosaccharides 
reversibly with high selectivity. Hypoxis hemerocallidea reportedly produced some 
agglutinins which resulted in precipitation and inhibition of the growth of S. aureus and 
Bacillus subtilis [185].  
 
3.6 Pharmacokinetics 
 
The pharmacokinetics of hypoxoside and rooperol were studied in humans [186] and 
mammals (baboons) [187]. It is reported that there were differences in the profiles of the 
metabolites between species. 
 
3.6.1 Absorption 
 
It is reported that hypoxoside is not absorbed into the circulatory system, but is converted to 
its aglycone, rooperol (Figure 3.5) by β-glucosidase, due to enzymatic hydrolysis after oral 
administration [186]. The presence of biotransformation products were analysed in serum, 
faeces and urine of an adult male volunteer after administration with 1 g of hypoxoside. 
Analysis of faeces 6 hr post dosing showed the presence of rooperol, while after 24 hr, no 
rooperol was found in urine.  Therefore, it was concluded that some of the rooperol was 
absorbed from the colon, and some was eliminated in the faeces. It was suggested that the 
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formation and absorption of rooperol were zero-order saturable processes [188]. The 
bioavailability of rooperol has not yet been established. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Metabolism of hypoxoside.  
 
3.6.2 Metabolism and Elimination 
 
Rooperol undergoes extensive first-pass metabolism such that no rooperol can be detected in 
the serum after administration of hypoxoside. Three metabolites of rooperol were isolated 
from serum samples of man after oral administration with hypoxoside [186]. These 
metabolites were rooperol-disulphate, rooperol-diglucuronide and rooperol 
monoglucuronide-monosulphate mixture, the latter being the major one [186].  Structures of 
these metabolites were confirmed after selective enzyme hydrolysis with arylsulfatase and/or 
β-glucuronidase. The end products of the hydrolysis were rooperol, dehydroxyrooperol and 
bis-dehydroxyrooperol. The metabolites have long half-lives, 50 hr for the major one, and 30 
hr for the other two, respectively [188] and are eliminated in the urine whereas rooperol is 
eliminated via faeces.  
 
 
3.7 Clinical Studies 
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Extracts of Hypoxis hemerocallidea have been used in various clinical studies to determine 
efficacy based on purported content of sterols and sterolins. Berges et al [189] conducted a 
randomised, placebo-controlled, double-blind clinical trial of β-sitosterol in patients with 
benign prostatic hyperplasia. The 200 patients with symptomatic begnin prostatic hyperplasia 
received 20 mg β-sitosterol or placebo daily for six months. The assessment was based on 
modified Boyarsky scores, which were compared before and after treatment (primary 
outcome), and the secondary outcomes included urine volume, residual urine volume, and 
prostatic size. The authors report that after six months there was significant improvement of 
modified Boyarsky scores in the β-sitosterol-treated group. Residual urinary volume was 
decreased in the β-sitosterol group, compared to the placebo group. The mechanism of action 
of β-sitosterol in the treatment of BPH is, however, not yet known. 
 
The effect of a plant sterol/sterolin mixture on cytokine secretion of cells from HIV-positive 
patients’ peripheral blood was evaluated [190]. The study was conducted on three groups of 
volunteers, healthy donors, HIV-positive individuals not on ART, and HIV-positive 
individuals on a sterol/sterolin mixture (Moducare® which is claimed to contain 20 mg sterol 
and 0.2 mg sterolin). Volunteers were administered sterol/sterolin mixture dosage form for a 
period of six months. It is reported that this study showed that more INF-γ (which is 
produced by T cells) was expressed in patients who were treated with the sterol/sterolin 
mixture when compared to the other groups. Therefore, the authors concluded that these 
results could translate into a stabilisation of CD4+ T cell numbers in vivo, hence slow or no 
progression of the disease. The blinding of the study, was however, not reported, and 
statistical acceptance criterion for a clinically significant difference was not stated a priori.  
 
An open-labelled study on HIV-infected patients was conducted over a six-year period [191]. 
This resulted in follow-up data from only 123 patients over a period of 39 months. Plasma 
viral loads and T cell counts were used as measures of efficacy. After 39 months, there was 
no significant change on T cells of patients whose cell at baseline was 200-500/µl. Patients 
whose T cell count was greater than 500/µl showed significant changes in viral load, but 
there was no significant change in the T cell count. It was concluded that this sterol/sterolin 
mixture could be beneficial for those individuals who are diagnosed shortly after infection.  
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3.8 Safety of Hypoxis hemerocallidea 
 
A lethal dose (LD50) in mice was found to be 1948 ± 57 mg/kg of aqueous AP extract after 
oral administration [181]. Assessment for signs of toxicity was continued for up to 48 hr, and 
log-doe response plots were constructed to determine the median lethal dose (LD50). Lower 
doses (≤ 1600 mg/kg) of aqueous AP extracts were found to be safe, while relatively higher 
doses were toxic and/or lethal to the mice. In another study, mice were given 2000 mg/kg 
(45% hypoxoside) of standardised hypoxis extract and there was absence of toxicity on 
assessment two weeks post-dosing [170].  
 
The safety of AP on neonatal rats was assessed by Erlwanger and Cooper [192].  Suckling 
rats of 10 days of age were divided into four groups, according to the randomisation 
schedule. The groups received high dose ethanol extracts, low dose ethanol extracts, high 
dose aqueous and low dose aqueous extracts. The visceral organs, proximal and distal half of 
the small intestine were examined microscopically for intestinal morphology. It was found 
that suckling rats on the low dose alcoholic extract had reduced weight of the pancreas, 
compared to the control, and the group on low dose aqueous extract. The reduction in 
pancreatic weight did not have an effect on the weight of the neonates, and similar 
phenomenon was not observed at high doses. Therefore, it was suggested that the reduction in 
pancreatic weight may not be of biological significance.  
 
A phase I clinical trial was conducted involving 24 cancer patients at Karl Bremer Hospital, 
Bellville, South Africa [193], where the toxicity of hypoxoside, which was administered in 
the form of a hypoxis plant extract, was assessed. The patients were dosed with 1200 - 3200 
mg standardised hypoxis plant extract (50-55% hypoxoside content) per day, in three divided 
doses. It was concluded that the biochemical and haematological tests revealed no obvious 
toxic effects from the administered hypoxoside.  
 
3.9 In vitro Drug Interaction Studies 
 
The effects of Hypoxis hemerocallidea on CYP3A4, pregnane X receptor (PXR) and P-gp 
were examined using a microsome-based in-vitro fluorometric microtitre assay. Inhibitory 
capacities of commercially-available preparations and aqueous extracts of hypoxis were 
examined. Significant inhibition of CYP3A4 by the hypoxis preparations and extract were 
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shown at an initial concentration of 100 mg/ml [194]. There was significant activation of 
PXR on exposure to hypoxis, while moderate activity was shown on the P-gp. These results 
identified potential for clinically significant interactions. Other in vitro drug interaction 
studies have previously been discussed in Chapter 1. 
   
3.10 Registered Patents 
 
Several patents concerning Hypoxis rooperi, hypoxoside and rooperol have been registered in 
the United States and Europe following studies on rooperol, hypoxoside, sterols and sterolins 
mixture, and their analogues in the treatment of HIV infection and other diseases [195, 196]. 
The patents include methods of extraction and preparation of derivatives [174,197]. A patent 
registered under the title “method of treating viral infections” was registered by Liebenberg 
[198], which relates to corms of the family of hypoxidaceae in preparation of medicament to 
treat viral infection by reducing the rate of decrease of T lymphocytes. 
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CHAPTER 4 
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) 
METHODS FOR AFRICAN POTATO AND EFAVIRENZ 
 
4 INTRODUCTION  
 
4.1 Background 
 
High Performance Liquid Chromatography (HPLC) is used routinely in pharmaceutical 
analysis. Following injection of a sample onto an HPLC column packed with a stationary 
phase, the components in the mobile phase (MP) migrate through a chromatographic column 
at different rates, depending on their relative affinities for the two phases. Affinity for either 
mobile or stationary phase depends on various factors such as the adsorption, size and charge 
of the components amongst others [199]. Compared to gas chromatography, HPLC does not 
require compounds to be volatile, therefore, it can be used for a wide variety of compounds.  
 
The extent of separation of compounds in HPLC is defined by resolution (Rs), and there are 
other parameters used to determine system functionality. These parameters include column 
efficiency (N), capacity factor (k), and tailing factor [200]. 
 
4.1.1 Resolution 
 
Resolution can be varied by changing the chromatographic experimental conditions, and is 
influenced by selectivity, column efficiency and retention [201]. Resolution is a measure of 
separation between two adjacent peaks, and for adequate separation, the value of Rs should 
not be less than two [202]. The following equation is used to calculate resolution: 
 
  √  
	

	  

   Equation 4.1 
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4.1.2 Column Efficiency 
 
Column efficiency is the ability of a column to produce sharp and narrow peaks with good 
resolution, and is measured in number of theoretical plates (N). This is based on the theory 
that assumes that the column is composed of a series of discrete theoretical plates, and that 
the migration of a solvent and solute is a stepwise transfer from each plate to the next. It is 
also assumed that at each plate, equilibrium of the sample occurs between the MP and the 
stationary phase. The efficiency of a chromatographic column is said to improve with the 
number of equilibrations, or increase in the number of plates. Therefore, the number of plates 
(N) is a measure of column efficiency. Another theory exists for the column plate number as 
a function of all experimental conditions where plate number is a function of plate height and 
column length (Equation 4.2). The height equivalent of a theoretical plate (H) varies with the 
velocity of the MP as it passes through the column.  
 
        Equation 4.2 
where,  
N = Number of theoretical plates 
L = Length of column packing (cm) 
H = Height equivalent of theoretical plates 
The theory was limited in describing other effects on column efficiency, and it was, therefore, 
replaced by the kinetic or rate theory which is capable of accounting for these variables. 
Nevertheless, N and H are still used in description of column efficiency. Column efficiency 
can be defined in terms of peak asymmetry and retention time (Equation 4.3 and 4.4) 
 
     Equation 4.3 
    Equation 4.4 
where,  
tR = Retention time of solute 
W = Width of peak at base 
Wh/2 = Peak width at half-height  
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A good column has an efficiency of not less than 2000 [200]. Figure 4.1 shows 
chromatographic separation of two compounds and peak measurements used to calculate 
system functionality parameters. 
 
 
Figure 4.1. Chromatographic separation of two compounds [202].  
 
4.1.3 Capacity Factor 
 
The capacity factor or retention factor is the measure of compound retention on the column. It 
describes where the solute peak of interests elutes relative to the solvent or void volume, and 
is defined by Equation 4.5 and while column dead time is defined by equation 4.6.  
 
 
     Equation 4.5 
where, 
tR = Retention time of solute 
t0 = Column dead time 
 
Equation 4.6 
where, 
Vm = Column dead volume 
F = Flow rate 
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4.1.4 Selectivity 
Selectivity or separation factor is a measure of separation of two solutes, and is defined as: 
 
       Equation 4.7 
where,  
k´B = capacity factor for the strongly retained solute 
k´A = capacity factor for the rapidly eluting solute 
The selectivity factor, α, is always greater than 1, and there are two main ways to improve 
resolution, illustrated in Figure 4.2. The first way is by increasing the sharpness of the peak 
whilst maintaining the peak centre constant, and the second way is by increasing the distance 
between the zone centres of the two peaks.   
 
 
Figure 4.2. Illustration of increasing efficiency and increasing selectivity [202]. 
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4.1.5 Tailing Factor 
 
Ideally peaks should be Gaussian in shape, but in reality, that generally does not occur. 
Hence, peak shapes are characterised by tailing or asymmetry, and this is measured by the 
tailing factor or asymmetry factor.  This parameter is important in method development 
because peaks with poor symmetry can result in poor resolution of peaks, imprecise 
quantification, undetected minor peaks co-eluting under the tail and poor retention 
reproducibility. 
 
4.2 Application of HPLC  
 
The procedure of liquid chromatography (LC) is widely known as High Performance Liquid 
Chromatography (HPLC) because in 1960s, columns packed with smaller particle sizes were 
developed, requiring sophisticated chromatographic equipment compared to their 
predecessors in order to result in the requisite high separation performance. Advantages of 
HPLC include the use of small sample size, lack of destruction of sample, high selectivity 
and wide accessibility/availability. Several different mechanisms of sample retention by the 
stationary phase in LC are possible (Table 4.1) [199]. The MP is generally a liquid, whereas 
the stationary phase varies. The various LC modes cover the separation of a wide range of 
analytes. 
 
Table 4.1. Different liquid chromatographic modes. 
LC Method Stationary phase Type of equilibrium Analytes 
Liquid-liquid or partition Liquid adsorbed on a solid Partition between immiscible 
liquids 
MW< 10 000, 
polar, non-ionic 
Liquid-bonded phase Organic species bonded to a 
solid phase 
Partition between  liquid and 
bonded surface 
MW< 10 000, 
polar, non-ionic 
Liquid-solid Solid particles Adsorption MW < 10 000, non 
polar 
Ion exchange Ion exchange resin  Ion exchange  
Size 
exclusion 
Gel 
filtration 
Liquid in polymer particles 
and the particles are 
hydrophilic  
Partition/ sieving MW> 10 000, 
Polar or ionic 
compounds 
Gel 
permeation 
Liquid in polymer particles 
and the particles are 
hydrophobic 
MW> 10 000, non-
polar 
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Liquid bonded phase chromatography is the most widely-used because of its stability. The 
bonded phase columns have a limited sample capacity, therefore, small sample sizes have to 
be used to avoid column overload. There are two types of liquid bonded phase 
chromatography namely, normal phase and reversed phase. In normal phase chromatography, 
the stationary phase is polar and the MP is relatively non-polar, and is usually used to 
separate polar compounds. The retention times of polar compounds will be longer on normal 
phase chromatography. The most commonly-used type is reversed phase HPLC, where the 
stationary phase is non-polar relative to the MP performed using bonded octyl (C8) or 
octyldecyl group (C18) silane packings. The bonded phase packings are prepared by reaction 
of an organochlorosilane with a hydroxyl group of the silanol moiety. The 
organochlorosilanes often have a straight-chain octyl (C8) or octyldecyl group (C18).  
 
4.3 Quantitative Analysis of Hypoxoside in African Potato Decoctions  
  
4.3.1 Introduction 
 
Reversed (RP) phase HPLC is a much-used analytical technique for the separation of 
chemical compounds in TM/CAM plant materials, as well as in pharmaceutical dosage forms. 
As previously mentioned, this method is versatile and not influenced by the volatility or 
stability of the analyte, hence, it can be used to separate various classes of analytes including 
TMs/CAMs [203]. The versatility of HPLC has enabled the use of a variety of detectors 
which include ultraviolet-visible (UV-VIS), mass spectroscopy (MS), evaporative light 
scattering detection (ELSD), fluorescence, electrochemical and even nuclear magnetic 
resonance (NMR). HPLC is used for the comprehensive qualitative analysis (fingerprinting) 
of TMs/CAMs, and used to compare profiles because of its ability to provide useful content 
information [204, 205]. Compounds with strong chromophores that absorb light in the 
wavelength region of about 200 to 800 nm are usually monitored using UV-VIS detection. 
Recent advances in technology have yielded a photodiode array (PDA) detector which is an 
extremely useful multi-wavelength detection technique.  PDA detectors (also known as diode 
array detectors or DAD) can determine purity of each peak as well identify peaks with the aid 
of PDA spectral libraries. These features are very important in the analysis of TMs/CAMs, 
which usually contain many compounds, some of which may be present in only very small 
amounts. Compounds with differing electroactivity which may cause characteristic 
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voltametric responses can be selectively measured using electrochemical detection (ECD). 
Moreover, compounds that lack the necessary chromophores leading to poor UV-VIS can be 
detected by a refractive index (RI), or evaporative light scattering detector (ELSD) [206] as 
well as ECD. 
 
Recent advances in mass spectrometric (MS) instrumentation have led to the incorporation of 
liquid chromatography coupled with mass spectroscopy (LC-MS-MS) for use in routine 
analysis [207]. This method allows for the identification and confirmation of the mass  of 
compounds which can be of complex and diverse structures present in plant materials, and 
thus provides a powerful and useful application for both qualitative and  quantitative analysis.  
 
There is a dearth of information in the published literature describing the methods for the 
quantitative analysis of hypoxoside. A RP-HPLC method for the determination of hypoxoside 
distribution in three different Hypoxis species was reported by Vinesi et al in 1990 [208], 
however, no validation data and related information were provided.   
 
 In 1992, Betto et al [209] reported a RP-HPLC method using an acidic (pH 3.0) eluent to 
separate and determine some known norlignan glucosides isolated from Hypoxidaceae 
species. A gradient method was used, but here again, no validation data to support its 
application was provided, despite the claim that the method could be used for TMs and 
analysis of pharmaceutical preparations. Kruger et al [186] reported an HPLC method which 
was purported to be a quantitative analytical method for the analysis of hypoxoside and its 
metabolites in human plasma, urine and faeces. The MP consisted of guanidinine 
hydrochloride and ammonium sulphate for the sorption enrichment of xenobiotics in 
biological fluids. Validation and quantitative data of this method were also not reported, 
despite its application for the analysis of biological fluids from human subjects who had 
taken part in a clinical study. This method was also applied to extracts of H. rooperi and H. 
latifolia for the identification of hypoxoside. 
 
A validated RP-HPLC method used for the quantitative determination of hypoxoside in plant 
extracts including traditionally-prepared decoctions and in pharmaceutical dosage forms, has 
recently been reported by Nair et al [27]. The method used a binary mobile phase, detection 
was by PDA detector, and the method was characterised by high accuracy and precision. 
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Therefore, this method was adopted for the analysis of traditionally-prepared decoctions of 
AP. Since this method was routinely used in our laboratory, a mini-validation comprising 
repeatability of the calibration plots by another analyst, was carried out.  
 
4.3.2 Equipment and Reagents  
 
The HPLC system consisted of a Waters Alliance system, model 2690, equipped with a 
pump, an autosampler, an online degasser, and a model 2995 PDA UV detector (Waters, 
Milford, MA, USA). Samples were centrifuged using an IEC HN-SII® Centrifuge 
(Damon/IEC Division, Needham Hts, Massachusetts, USA), and the hypoxoside standard 
(87.9%) was qualified for use and provided by a colleague, Dr. Patnala. 
 
4.3.3 Chromatographic Conditions  
  
Separation was achieved on a Phenomenex® Luna C18 (2) (5 µm, 150 mm × 4.6 mm i.d) 
column at 23 ± 2 °C, using acetonitrile: water (85:15 v/v) as the mobile phase. The flow rate 
of the mobile phase was 1 ml/min, 10 µl samples were injected, and hypoxoside elution was 
monitored by UV detection at λ = 260 nm. The internal standard used was sulphamerazine 
(SMZ). 
 
4.3.4 Methods 
 
The absorption spectrum of hypoxoside was determined by HPLC coupled with a DAD [27] . 
The purity of the standard provided was also assessed using the HPLC-DAD method, and the 
structure was confirmed using LCMS. Calibration plots were prepared using a range of 
calibration standards consisting of 5, 10, 20, 40 and 80 µg/ml.  
 
4.3.5 Results and Discussion 
 
The hypoxoside standard was readily soluble in methanol and water. The UV spectrum is 
depicted in Figure 4.3 below, and corresponds to the UV scan of hypoxoside previously 
reported [27, 186]. 
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Figure 4.3. UV absorption spectrum of hypoxoside. 
 
The calibration plots of hypoxoside were all linear using un-weighted regression analysis 
(Table 4.2). 
 
Table 4.2. Linearity 
DAY Y -intercept Gradient of calibration 
curve 
Correlation coefficient 
1 -0.021 0.031 0.999 
2 -0.045 0.034 0.999 
 
A typical chromatogram showing the separation of hypoxoside and the internal standard 
(SMZ) is shown in Figure 4.4.  
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Figure 4.4. Chromatogram of calibration standard of hypoxoside with SMZ. 
 
4.3.6 Conclusions  
 
The data from the peak purity of hypoxoside using HPLC-UV confirmed the absence of UV 
absorbing impurities. The hypoxoside standard was thus sufficiently pure (87.9%) and was 
acceptable for use as an analytical reference for quantitative analysis.  
 
4.4 DEVELOPMENT AND VALIDATION OF A HPLC METHOD FOR THE 
DETERMINATION OF EFAVIRENZ IN HUMAN PLASMA 
 
4.4.1 Introduction  
 
A bioanalytical method is essential for the evaluation and interpretation of pharmacokinetic 
data following administration of medicines to humans. There are three main analytical phases 
involved; viz, method development, method validation and successful application of the 
method. These stages are all critical for the development of an accurate, precise and 
reproducible method, which has the necessary selectivity and sensitivity to measure the 
relevant drug in biological fluids.  
 
SMZ 
Hypoxoside 
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4.4.2 Review of Published Methods 
 
EFV has been analysed in biological fluids and tissues using various methods which have 
been published in the scientific literature. Most analytical methods for the determination of 
EFV have involved HPLC, using Ultra Violet (UV) detection (Table 4.3) as well as other 
detection methods, such as mass spectroscopy [210] and fluorescence detection [211].  
Capillary electrophoresis [212] has also been used.  In some of those methods, EFV was 
determined simultaneously with other antiretrovirals.  
 
Table 4.3 summarizes the various HPLC - UV methods which are associated with high 
recoveries of EFV from plasma and adequate Lower Limit of Quantification (LLOQ) (~ 100 
ng/ml) for use in pharmacokinetic studies. Sample volumes ranged from 200 - 900 µl plasma, 
whereas a smaller sample size of 100 µl was used by Kappelhoff et al [213]. Several of these 
methods use liquid-liquid extraction, or solid phase extraction, to extract EFV from plasma 
whereas a protein precipitation method followed by a dilution step with distilled water has 
also been used [213]. The main objective of this work was, therefore, to develop a rapid, 
accurate, precise, selective, sensitive and cost-effective bioanalytical method for the 
determination of EFV in human plasma. 
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Table 4.3. Review of the analytical methods used for the determination of EFV in human plasma. 
Stationary phase Analyte Mobile phase Extraction 
procedure 
Recover
y (%) 
LLOQ 
(µg/ml) 
Lower QC 
and 
precision at 
lower QC 
(%) 
Injection 
volume  
(µl) 
Flow rate 
(ml/min) 
Internal 
standard 
Regression 
analysis 
Reference 
C18 Symmetry® 
(250 mm × 4.6  mm 
ID, 5 µm) 
EFV and 
others 
Gradient condition 0.01 
M KH2PO4 and 
Acetonitrile 
SPE 113.9 0.1 0.625 (8.3) 20 1.0 NR Unweighted [214] 
Symmetry® shield 
RP8 (100 mm × 3.0 
mm ID, 5 µm) 
EFV and 
other ARVs 
Acetonitrile : 50 
mmol/L Formic acid ( 
40:60) 
LL 96 0.1 0.3 (5.1) 80 0.75 then 
increased to 
1.6 
NR Weighted 
1/(concentration)2 
[215] 
Nova Pak® C18 
(100 mm × 8 mm 
ID, 4 µm) 
EFV and 
other ARVs 
Acetonitrile: methanol: 
tetramethylammonium 
perchlorate 
LL 81 to 97 0.047 0.94 (7.7) 25 1.5 NR NR [216] 
C 18 , (150 mm × 
4.6 mm ID, 5 µm) 
EFV alone 10 mM Phosphate 
buffer : acetonitrile 
(55:45) 
LL 95 to 
106 
0.0625 0.25 (6.8) 20 2.4 nefazodone NR [217] 
Luna® Phenomenex 
(250 mm × 4.6  mm 
ID, 5 µm) 
EFV and 
rifampicin 
Sodium phosphate 
buffer: acetonitrile: 
methanol (40:45:15) 
initially then gradient 
LL 98 0.05  50 1.0 NR NR [218] 
Zorbax® Extend 
C18 (150 mm × 2.1  
mm ID, 5 µm) 
EFV and 
nevirapine 
25 mM triethylamine in 
water: acetonitrile 
(65:35) 
P 85.0 to 
95.8 
0.1 0.250(5.6) 25 0.2 carbamazepine Weighted, 
1/(concentration)2 
[213] 
Zorbax® C18 (75 
mm × 4.6   mm ID, 
3.5 µm) 
EFV alone Acetonitrile: phosphate 
buffer pH 3.5 (50:50) 
LL >78  0.2 (8.6)  0.8 nelfinavir Weighted, 
1/(concentration) 
[219] 
Supelcosil® LC8 
(150 mm × 4.6 mm 
ID, 3 µm) 
EFV alone Acetonitrile: 50 mM 
potassium phosphate 
with triethylamine 
added to 1%, pH 
adjusted to 5.75 with 
orthophosphoric acid 
(55:45) 
 
SPE 102 to 
109 
0.1 0.2 (8.6) 80 1.0 L-737,345 Weighted, 
1/(concentration) 
[220] 
XTerra® RP 18 
(150 mm × 2.1  mm 
ID, 5 µm) 
EFV alone Acetonitrile: 67 mM 
potassium dihydrogen 
phosphate, adjusted to 
pH 7.4 with sodium 
hydroxide 32% (50:50) 
LL 96. 2 0.025 0.2 (6.9) 100 0.2 A86093 unweighted [221] 
  
 
64 
 
Stationary phase Analyte Mobile phase Extraction 
procedure 
Recover
y (%) 
LLOQ 
(µg/ml) 
Lower QC 
and 
precision at 
lower QC 
(%) 
Injection 
volume  
(µl) 
Flow rate 
(ml/min) 
Internal 
standard 
Regression 
analysis 
Reference 
Zorbax®  C18 (150 
mm × 2.1  mm ID, 
3.5 µm) 
EFV and 
other ARVs 
A. 50 mM phosphate 
monobasic: methanol 
(85:15) 
B. A: acetonitrile: 
methanol (25:60:15), 
gradient 
SPE >90 0.025 0.12 (2.1) 80 0.9 then 1.1 midazolam weighted [222] 
C18 Symmetry® 
(250 mm × 4.6  mm 
ID, 5 µm) 
EFV and 
other ARVs 
A. Acetonitrile: 0.025 
M 
tetramethylammonium 
perchlorate in 0.2% 
aqueous trifluoroacetic 
acid  (T) (55:45) 
B. methanol: T   
(55:45), gradient 
LL 80 NR 0.5 50 0.9 NR unweighted [223] 
Discovery® C8 
(250 mm × 4.6  mm 
ID, 5 µm) 
EFV and 
other ARVs 
A. 25 mM potassium 
phosphate buffer pH 3.1 
B. Acetonitrile 
C. methanol (gradient) 
LL 90.7 0.05 0.204 (6.3) NR 1.5 NR Weighted, 
1/(concentration)2 
[224] 
Abbreviations: 
LL- Liquid-liquid; SPE – Soli phase extraction; P- precipitation; NR- not reported.
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4.4.3 Methods 
 
4.4.3.1 HPLC Method Development 
 
The main objectives in the development of a suitable bioanalytical method for the analysis of 
EFV in plasma includes the following: 
• separation of  EFV from matrix components 
•  resolution of EFV peak from other peaks 
•  accurate and precise determination of the amount of EFV in human plasma 
•  successful analysis of study samples within a short period of time. 
Based on these objectives, a suitable HPLC method was developed by evaluating and 
optimising the chromatogram functionality parameters that influence successful outcomes 
following application of the method.  
 
4.4.3.2 Reagents and Chemicals 
 
EFV was obtained as a donation from Aspen Pharmacare (Port Elizabeth, South Africa) and 
diclofenac sodium from the Biopharmaceutics Research Institute (BRI), Rhodes University. 
HPLC grade acetonitrile and methanol were purchased from Romil Ltd., Cambridge, United 
Kingdom and formic acid (99.9%) was sourced from Associated Chemical Enterprises Pty, 
Ltd Johannesburg, South Africa. Water was purified by reverse osmosis and filtration through 
a Milli-Q purification system (Millipore, Milford, MA, USA). Human plasma with potassium 
edentate (K-EDTA) as an anticoagulant was obtained from the South African National Blood 
Services, Eastern Cape Headquarters (Port Elizabeth, South Africa) and was stored at -10 ± 
2°C. 
 
4.4.3.3 Equipment and instrumentation. 
 
The HPLC system consisted of a Waters Alliance system, model 2690, equipped with a 
pump, an autosampler, an online degasser, and a model 2995 PDA UV detector (Waters, 
Milford, MA, USA). Chromatographic separation was achieved on a reversed phase  HPLC 
column and guard column (Phenomenex Luna® C18 (2) ,5 µm, 150 X 2.0 mm i.d. and 
Phenomenex Luna® C18 guard column, 4 mm × 3.0 mm i.d. obtained from Phenomenex, 
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Macclesfield, UK). An Epperndorf® model 5415 centrifuge was used (Epperndorf Geräteban 
Netheler & Hinz GmbH, Hamburg, Germany) and the nitrogen evaporator (N-EVAP® 
Analytical Evaporator, Organomation Associates Inc., Massachusetts, USA) was used to 
evaporate samples to dryness. Vortexing was accomplished using a Lab Dancer vortexer 
(IKA® Laboratory Equipment, Straufen, Germany). 
 
4.4.3.4 Column Selection 
 
The choice of HPLC column must take into account the molecular structure and 
chromatographic behaviour of the analyte, amongst others. EFV is a weakly basic molecule 
(pKa = 10.2), soluble in methanol and is hydrophobic. In RP- HPLC, EFV will preferentially 
partition from the MP onto the stationary phase, resulting in increased retention times. The 
bonded phase of the stationary phase in RP-HPLC affects the retention time of the analyte, 
with C18 columns giving slightly longer retention times. These columns are generally stable 
even at low pH, thereby increasing column life-time.  Since the aim of this study was to 
develop a rapid analytical method with run time less than ten minutes, a C18 column was 
chosen and the composition of the MP was developed and optimised accordingly.  
 
A reversed phase Luna C18 (2) (Phenomenex®, Macclesfield, Cheshire, England) was 
identified for use for the analysis of EFV in human plasma, and consisted of a  5 µm particle 
size with a pore diameter of 100 Å, internal diameter of 2.0 mm and column length was 150 
mm. This particular column packing and geometry allows for fast diffusion of the analyte in 
and out of the stationary phase, thereby yielding high efficiency [201]. A Phenomenex Luna® 
guard column (4 mm × 3.0 mm i.d) was used to protect the column. 
 
4.4.3.5 Choice of Internal Standard 
 
Use of an internal standard was deemed necessary to compensate for possible variability due 
to sample manipulation and extraction where errors can thereby be minimised.  An internal 
standard (IS) is a different chemical compound from that of the analyte. The IS must be well 
resolved from the analyte and mimic the analyte behaviour during pre-treatment. Ideally, an 
IS should be structurally similar to the analyte. Therefore, in the case of EFV where 
structurally similar compounds are not readily available, other compounds were assessed for 
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suitability. Since EFV is a weakly basic compound, basic compounds were evaluated for 
suitability. The basic drugs which were readily available namely, acyclovir, carbamazepine, 
diazepam and Propranolol, were assessed for suitability as IS. All of these drugs were eluted 
within 2.5 min, and would likely not be separated from interfering substances present in 
plasma, and close to the void volume of the column. Hence, none of the drugs were 
considered to be suitable as an IS. Hence, some acidic drugs were tried such as diclofenac 
sodium (DIC Na), flurbiprofen (FLU), ibuprofen and ketoprofen, and the corresponding 
retention times are shown in Table 4.4. 
 
Table 4.4. Acidic compounds investigated.  
Drug Retention time 
(min) 
diclofenac sodium 6.8 
flurbiprofen 6.4 
ibuprofen 7.6 
ketoprofen 4.0 
 
The retention time for ketoprofen was too short, whereas all the other compounds eluted later 
(> 6 min), and were considered as possible candidates for use as an IS. Flurbiprofen (FLU) 
was initially chosen as the preferred IS because it has a maximum UV absorbance (λmax) at 
247 nm [90], which is similar to the λmax of EFV. The initial method development was done 
using FLU, but subsequently when extraction procedures for EFV from plasma were 
investigated, interference between FLU and compounds in plasma precluded the use of FLU 
as IS. DICNa was subsequently chosen as the IS, although its λmax was at 275 nm. However, 
this proved advantageous since no interference from plasma components were seen at 275 
nm. In order to monitor EFV at its λmax of 247 nm, the use of a PDA detector was used 
whereby both EFV and the IS could be simultaneously detected at the two different 
wavelengths (Figure 4.5).   
 
4.4.3.6 Choice of Solvent for EFV 
 
The solvent of a sample may affect the quality of the eluting peaks, especially with respect to 
peak shape. EFV was dissolved in MeOH, ACN and MP to produce the same concentrations. 
The same amount of EFV was loaded into the column, and the peak heights were compared. 
The sample dissolved in MP gave sharper/higher peaks (Fig 4.6), hence, MP was chosen as 
the solvent for solutions of EFV. 
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 Figure 4.5. Chromatogram of EFV peaks dissolved in ACN (blue), MeOH (red) and MP (green). 
 
Figure 4.6. A chromatogram of a spiked plasma sample containing EFV (red: λ=247 nm) at a 
concentration of 1.5 µg/ml and IS (green: λ=275 nm) at a concentration of 4.0 µg/ml. 
EFV 
DIC 
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4.4.3.7 Mobile Phase (MP) Preparation and Selection 
 
The composition of the MP is very critical to separation of compounds as it affects the 
functionality of the chromatographic system. Changes in MP composition are the most 
effective and convenient; hence during optimisation of the separation, this is usually the first 
step to be undertaken.  The changes that can be made to the MP include pH, solvent polarity, 
and flow rate, amongst others. An isocratic mode was used, and the initial MP composition 
consisted of acetonitrile: 0.01 M formic acid (56:44% v/v). The MP was filtered under 
reduced pressure through a 0.45 µm Durapore (PVDF) filter (Millipore, Bedford, MA, USA), 
and degassed using an Eyela Aspirator A-25 (Tokyo Rikakikai Co. Ltd, Tokyo, Japan) prior 
to use. 
 
In reversed phase chromatography, sample retention increases with an increase in 
hydrophobicity of compounds, therefore, increasing ionisation of ionisable compounds will 
reduce their retention times. Since EFV is a weak base, a decrease in pH results in ionisation 
of EFV rendering this compound less hydrophobic. Initially, the concentration of formic acid 
was varied to assess separation parameters, and the 0.1 M concentration yielded the lowest 
tailing factor and the highest value of column efficiency. 
 
An increase in MeCN content resulted in a decrease in resolution and a reduction in capacity 
factor and retention time. At a MP composition of 50:50 MeCN/0.1 M FA, the tailing factor 
was relatively low. Addition of methanol (MeOH) and reduction of volume of formic acid 
resulted in reduction of retention time of EFV to 7.7 min, therefore, the run time was less 
than 10 minutes. 
 
The flow rate of 0.30 ml/min gave a capacity factor > 5. This flow rate was the most suitable 
and also cost-effective because less MP is used during analysis. The temperature of the 
column can affect the retention and separation of compounds, hence, effect of column 
temperature on the separation and elution of EFV and IS was investigated. The peaks were 
sharper when the column temperature was at 40 °C 
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4.4.3.8 Sample Volume (Injection volume) Optimisation 
 
 
The injection volume should be adequate such that the peak area of the smallest concentration 
is easily measured. In this case, the sample volume had to be adequate to allow re-injection of 
sample if required, without the need for re-extraction. Therefore, the injection volume was 
varied to find the smallest volume possible to result in an acceptable peak (Table 4.5). A 10 
µl injection volume was considered adequate. 
 
Table 4.5. Effect of injection volume on peak area 
Injection volume 
(µl) 
Efavirenz peak 
area 
10 12037 
15 17172 
20 22168 
 
 
The following chromatographic conditions were finally chosen for the analysis of EFV 
(Table 4.6) 
 
Table 4.6. Final chromatographic conditions for the determination of EFV 
Column temperature 40 ± 2 °C 
Flow rate 0.3 ml/min 
Mobile phase ACN: 0.1 M FA: MeOH 
(52:43:5 v/v) 
Injection volume 10 µl 
IS DICNa 
 
 
4.4.3.9 Plasma Sample Preparation 
 
 Plasma contains various endogenous substances which can interfere with the quantitative 
analysis of EFV, therefore, a suitable method of extraction of EFV from plasma was 
developed. The objective was to develop a rapid method which would be cost-effective, 
accurate, precise and have the necessary sensitivity to quantitatively determine EFV in the 
plasma from a clinical study involving human subjects. 
 
4.4.3.9.1 Liquid-liquid Extraction 
 
The first extraction procedure investigated involved liquid-liquid extraction where the sample 
(compound to be analysed) is partitioned between two immiscible phases, one phase being 
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aqueous, and the other an organic solvent. Polar compounds prefer the aqueous phase, whilst 
the non-polar, hydrophobic compounds preferentially partition into the organic phase. 
Hydrophobic analytes may be recovered from the organic solvent by evaporation, while 
analytes in the aqueous phase may be directly injected onto the column.  
 
Ethyl acetate (EtAc) was investigated as an extraction solvent, and the initial method which 
utilized FLU as internal standard was as follows: 
• 200 µl EtAc containing 1.0µg/ml FLU was added to an aliquot of 100 µl of plasma in 
an Epperndorf® safe lock tube, 1.5 ml capacity (Epperndorf Ag, Hamburg, Germany).  
• The mixture was vortexed on a Lab Dancer for 50 s and centrifuged at 10 000 g for 10 
min in an Epperndorf centrifuge 5415 (Epperndorf Geräteban Netheler + Hinz 
GmBH, Hamburg, Germany).  
• The resultant supernatant (about 180 µl) was removed and placed in a micro-insert 
(Separations Pty Ltd,) and the EtAc was evaporated to dryness using a stream of 
nitrogen in an N-EVAP® Analytical Evaporator (Organomation Associates Inc., 
Massachusets, USA).  
• The dried sample residue was re-constituted with 100 µl of MP. The solution was 
vortexed for 1 min and 10 µl was injected directly onto the column. 
 
The chromatogram of the blank plasma extract did not show any interference on the EFV and 
IS peaks. However, recovery of both EFV and FLU was low.  In an attempt to improve 
recovery, several extractions, using various volumes of EtAc, were attempted but, this did not 
improve the recovery. Since the EtAc method yielded poor extraction efficiency, another 
extraction procedure was investigated. 
    
4.4.3.9.2 Sample Preparation by Protein Precipitation 
 
An extraction procedure based on the method used by Kappelhoff et al [213] was 
investigated and subsequently adapted with several modifications. Various steps of the 
precipitation method were manipulated to yield high recovery, with good accuracy and 
precision. These were the precipitating solvent, dilution, and vortex times. Extraction 
efficiency of EFV and FLU was assessed after dilution with MP or MeCN, and also without 
dilution. The supernatant following precipitation with MP which was undiluted gave higher 
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and sharper peaks. Overall, as the mixing time increased, the %RSD improved, and the 
values were lowest after vortexing for 50 s. Variability of the peak areas of EFV was 
relatively high, with RSD values ranging from 9.05 to 23.30%. However, mixing of the 
supernatant by vortexing for 10 s before injection reduced the variability.  
 
During the development of this extraction procedure, plasma components in some of the 
plasma batches interfered with the elution of the IS, FLU (Figure 4.7). This necessitated the 
identification of an alternative IS. FLU was subsequently replaced with diclofenac sodium 
(DICNa) as IS. and this proved to be successful (Figure 4.8).  
 
The following extraction procedure was subsequently used for the analysis of plasma samples 
from study subjects. 
 
• Plasma samples (100 µl) were transferred into 1.5 ml Epperndorf® tubes.   
• An aliquot (200 µl) of DICNa in MP (4 µg/ml) was added.   
• Mixture was vortexed  for 50 s and centrifuged at10 000 g for 10 min 
• The supernatant (100 µl) was transferred into a 150 µl micro- insert vial and vortexed 
for 10 s. 
• Ten microlitres injected  onto the column  
 
  
 
73 
 
 
 
Figure 4.7. A blank plasma extract (green) and spiked plasma sample containing EFV and FLU as IS (red 
- λ=247 nm).    
 
 
 Figure 4.8. A blank plasma extract (red) and a spiked plasma sample containing EFV and DICNa as IS 
(green: λ=275 nm).  
 
 
FLU 
EFV 
EFV 
DIC 
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4.4.3.10 Validation of HPLC-UV Method 
 
Method validation establishes the performance of the analytical procedure. Parameters that 
can affect the reliability and reproducibility of the data generated by the method are assessed 
and results documented [225]. These are: selectivity, accuracy, recovery, precision, 
sensitivity, linearity and reproducibility. In addition, the stability of stock solutions, un-
extracted and extracted samples, also need to be assessed. A full validation according to FDA 
Guidance on Validation of Bioanalytical Methods [225] was performed. 
 
4.4.3.10.1 Preparation of Standards and Quality control (QC) samples 
 
Stock solutions of EFV and DICNa in mobile phase were prepared by weighing out 
appropriate amounts of the analyte and IS on a Mettler Toledo AG 135 balance (Mettler 
Toledo, Zurich, Switzerland), and dissolving them in MP to yield concentrations of 1mg/ml. 
For DICNa, an appropriate amount of the stock solution was measured and diluted to yield a 
working solution of 4 µg/ml. An appropriate aliquot of the EFV stock solution was 
transferred to a volumetric flask, and plasma was added by weight on a Mettler Toledo AG 
135 balance (Mettler Toledo, Zurich, Switzerland) to produce a concentration of 10 µg/ml. 
The specific gravity of plasma, 1.025 g/ml, was used [226] to convert the weight to volume. 
Plasma weight was used since it is considered to be more accurate and avoids errors due to 
frothing and the formation of air bubbles which make it difficult to make up to volume in a 
volumetric flask. The plasma stock solution was gently shaken for 1 hr on a shaker (The 
Chemical Rubber Co., Cleveland, Ohio, USA). Calibration standard samples were prepared 
from a different stock solution to that of the QC samples. Concentrations of the QC plasma 
samples were 0.30, 1.5 and 7.5 µg/ml for the low, medium and high samples, respectively. 
 
4.4.3.10.2 Selectivity 
 
Selectivity is the capability of a method to differentiate and measure the analyte in the 
presence of components of the matrix. In the case of plasma, the components include various 
endogenous substances, drug metabolites and also exogenous xenobiotics.   Plasma from six 
different sources was evaluated for interference with the analyte (EFV), and the internal 
standard, DICNa. Blank plasma samples were extracted and compared with spiked plasma 
extracts containing EFV at the LLOQ. 
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4.4.3.10.3 Accuracy 
 
The accuracy of a method is a measure of how close the measured mean value is to the true 
value. Three sets of QC samples at low, medium and high concentrations were prepared by 
accurately weighing an appropriate amount of EFV plasma stock solution, and diluting with 
blank plasma. These were extracted and analysed in the same manner as calibration 
standards. Using the peak area ratio of EFV/IS, concentrations of the samples were back 
calculated, using regression analysis of the calibration plot. The calculated concentration was 
used to determine the accuracy of the method. Specifications for accuracy of the QC samples 
in this method were set at 85-115%. Intra-day and inter-day accuracy was evaluated over 
three days. 
 
4.4.3.10.4 Recovery 
 
Recovery of a method is a measure of extraction efficiency to determine how much of the 
added analyte can be extracted from the matrix. It is obtained by comparing the detector 
response of the extracted analyte to the detector response of a pure standard solution. Three 
QC plasma samples containing EFV were prepared at low, medium and high concentrations. 
Five replicates were prepared at each concentration. The average peak area ratios of standards 
in MP were compared to those of plasma extracts. 
 
4.4.3.10.5 Precision 
 
The degree of scatter between a series of measurements obtained from multiple sampling of a 
single homogenous sample is referred to as precision. It is a measure of variability of the 
method, and can be divided into: repeatability, intermediate precision and reproducibility. 
Variability of the method was assessed using low, medium and high QC samples. Replicates 
of each QC samples were extracted five times, and the supernatant injected for analysis. The 
%RSD values for each concentration were calculated, and the acceptance criteria were set at 
%RSD values of less than 15%. 
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4.4.3.10.6 Determination of Lower Limit of Quantitation (LLOQ) 
 
The LLOQ is the lowest amount of the analyte in a sample that can be quantitatively 
determined with acceptable accuracy and precision [227]. Five separate plasma samples at 
the LLOQ were extracted, and the variability and accuracy of the extraction method were 
assessed.  
 
4.4.3.10.7 Linearity 
 
Linearity is the measure of the relationship between the concentration of the sample and the 
corresponding detector response. A calibration curve was prepared from seven calibrators, 
including one at the LLOQ. Each calibration standard was extracted three times, and an 
average of the three extracts was used to construct the plot. The concentration range of the 
calibration curve was 0.2 to 10 µg/ml. The acceptance criteria for the calibration plot was that 
variation of more than six calibration standards should  be better than  15% RSD, and that of 
the LLOQ should be better than  20% RSD. 
 
4.4.3.10.8 Stability 
 
Stability of stock solution of EFV and DICNa was assessed after storage in the refrigerator at 
2-8 °C for 1 week, and on the bench top (22 ± 2°C) for 4 hr. The stability of the stock 
solutions should be assessed for the anticipated storage period [228], which, for the 
refrigerator, was one week, and for the bench top, four hours. The peak areas of the stored 
samples were compared to freshly prepared samples, with acceptance criteria set to be within 
5-7% RSD. 
 
Short-term stability is evaluated to assess the extent of degradation of the analyte during 
preparation or extraction of study samples prior to analysis. It is also referred to as bench-top 
or process stability [228]. Two sets of stability samples were used, set one was removed from 
the chest freezer defrosted in a water-bath at ambient temperature, and kept on the bench for 
six hours, and the second set was removed from the freezer at the end of the six hours, and 
defrosted in a water-bath. After defrosting the second set, both sets were analysed and the 
calculated concentration of EFV compared between both sets, as well as freshly prepared 
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samples. The acceptance criteria for the difference between the two sets of samples were set 
to be within 15% of each other, and within 15% of nominal values. 
 
The long-term stability of samples was assessed to determine the time period of stability from 
sample collection to sample analysis. Long term stability was assessed over a period of two 
months. Samples were stored in a deep freezer at -10 °C and analysed after 7, 30 and 60 days, 
and compared to freshly prepared samples. The acceptance criteria for the difference between 
the two sets of samples were set to be within 15% of the nominal concentration. 
 
The FDA guidance recommends that a sample must be exposed to at least three freeze thaw 
cycles to ascertain stability [225]. The reasons for freeze-thaw stability include failed 
analytical runs and the use of incorrect dilutions when preparing samples. Freshly prepared 
samples were stored in a chest freezer (-10 °C) for 24 hr, then defrosted in a water-bath at 
ambient temperature. Once thawed, the samples were re-frozen for 12 hr, again defrosted and 
this procedure was repeated once more, thus samples were exposed to three freeze thaw 
cycles and then analysed. This was done in triplicate for the low, medium and high QC 
samples. The concentration of EFV in the freeze-thaw samples was compared to freshly 
prepared samples, and the concentrations of the freeze-thawed samples should be within 85% 
to 115% of the nominal concentration. 
 
It was anticipated that during analysis of QC samples, calibration samples and study samples 
would be prepared and analysed in a serial manner, which could result in these samples 
staying in the autosampler for a long period. Therefore, there was a need to perform stability 
studies on processed samples. This is referred to as on-instrument stability. Triplicates of QC 
samples were evaluated for stability on the instrument for 24 hr. Extracted samples were 
analysed immediately after preparation, and kept on the instrument carousel for 24 hr before 
re-analysis. Actual concentrations of the samples were calculated from the regression 
equation, and compared to nominal concentrations; the target difference was set at within 
15% of the nominal concentration. 
 
Re-injection or re-analysis samples were injected and left in the instrument for 24 hr, and re-
injected. On re-injection, the concentrations of samples were compared to freshly prepared 
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samples, and the back calculated concentrations. The difference target was set at within 15% 
of the nominal concentration. 
 
4.4.3.11 Results and Discussion 
 
4.4.3.11.1 Selectivity 
 
Figure 4.9 depicts chromatograms showing a blank plasma extract (A) and the response from 
a spiked plasma sample containing EFV (λ=247 nm) at the LLOQ (B), and the IS (λ=275) nm 
and (C) plasma samples of a subject collected two hours following the oral administration of 
a 600 mg EFV tablet.  There were no interfering endogenous compounds in any of the 
different batches of human plasma obtained from six different sources.  
 
4.4.3.11.2 Accuracy 
 
Intra-day (Table 4.7) and inter-day (Table 4.8) accuracy were within the set criteria, and 
found to be   between 12.3 and 17.7% at the LLOQ, and between -5.8 and 9.1% for the QC 
samples. 
 
Table 4.7. Inter-day Accuracy. 
QC Day Mean (n=5) 
Nominal 
concentration 
(µg/ml) 
Mean (n=5) 
calculated 
standard 
concentration 
(µg/ml) 
Accuracy (%) RSD (%) 
Low 1 0.2956 0.3225 109.1 3.7 
2 0.3118 0.2991 95.9 4.7 
3 0.3171 0.3449 108.8 4.2 
Medium 1 1.4888 1.4881 99.9 0.8 
2 1.5627 1.4749 94.5 1.7 
3 1.5711 1.5253 94.4 1.2 
High 1 7.4261 7.4138 99.8 2.6 
2 7.8119 7.5101 96.2 2.2 
3 7.9151 8.0910 102.2 3.4 
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Figure 4.9. A blank plasma extract (red - λ=247 nm and green - λ=275 nm)   and B = spiked plasma 
sample containing EFV (red: λ=247 nm) at the LLOQ and IS (green: λ=275 nm) and (C) plasma of a 
volunteer two hours after the oral administration of a 600 mg EFV tablet to a human subject. 
A 
B 
EFV  
 
DIC 
C 
EFV  
 
DIC  
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Table 4.8. Intra-day Accuracy of extracted plasma samples. 
 LOW QC Medium QC HIGH QC 
Replicates Nominal 
concentration 
(µg/ml) 
Calculated 
standard 
concentration 
(µg/ml) 
Accuracy 
(%) 
Nominal 
concentration 
(µg/ml) 
Calculated 
standard 
concentration 
(µg/ml) 
Accuracy 
(%) 
Nominal 
concentration 
(µg/ml) 
Calculated 
standard 
concentration 
(µg/ml) 
Accuracy 
(%) 
1 0.2956 0.3254 110.1 1.4748 1.4724 99.8 7.4369 7.1163 95.7 
2 0.2940 0.3270 111.2 1.4847 1.4734 99.2 7.3710 7.5261 102.1 
3 0.2958 0.3368 113.9 1.4946 1.4854 99.4 7.3977 7.4939 101.3 
4 0.2962 0.3169 107.0 1.5028 1.5207 101.2 7.4758 7.5409 100.9 
5 0.2965 0.3065 103.4 1.4874 1.4886 100.1 7.4493 7.3916 99.2 
Mean 0.2956 0.3225 109.1 1.4888 1.4881 99.9 7.4261 7.4138 99.8 
RSD (%) 0.3 3.5 3.7 0.7 1.3 0.8 0.56 2.4 2.6 
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4.4.3.11.3 Recovery 
 
Extraction efficiencies of EFV from plasma were 94.1, 92.7 and 94.1% for the low, mid and 
high QC samples, respectively. The % relative standard deviation (RSD) values ranged from 
1.4 to 2.1. Chromatograms of standards of EFV at mid QC and IS in mobile phase, and of a 
plasma sample spiked with EFV at mid QC and DIC is shown in Figure 4.10. 
 
Figure 4.10. EFV at mid QC and IS in mobile phase solution (green) and plasma samples spiked with 
EFV at mid QC and IS (red) monitored at λ=247nm. 
 
4.4.3.11.4 Precision 
 
Intra-day and inter-day precision are shown in Tables 4.9 and 4.10, respectively. Precision of 
EFV determinations were better than 7% RSD across the entire QC concentration range. 
 
EFV 
DIC 
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Table 4.9. Intra-day Precision. 
QC Mean (n=5) calculated standard 
concentration ± standard deviation 
(µg/ml) 
Nominal 
standard 
concentration 
(µg/ml) 
RSD (%) 
Low 0.3298 ± 0.0076 0.2958 2.3 
Medium 1.5429 ± 0.0449 1.4946 2.9 
High 7.6153 ± 0.1612 7.3987 2.1 
 
Table 4.10. Inter-day Precision. 
QC Day Mean (n=5) 
Nominal 
concentration 
(µg/ml) 
Mean (n=5) calculated standard 
concentration  (µg/ml) 
 
RSD (%) 
Low 1 0.2958 0.3298 ± 0.0076 2.3 
2 0.3133 0.3060  ± 0.0135 4.4 
3 0.3172 0.3416 ±   0.0321 6.8 
Medium 1 1.4946 1.5429 ± 0.0449 2.9 
2 1.5619 1.5314 ±  0.0605 3.9 
3 1.5787 1.6145 ± 0.0226 1.4 
High 1 7.3987 7.6153 ± 0.1612 2.1 
2 7.8371 7.9353 ±  0.1750 2.2 
3 7.9368 8.4532 ± 0.1488 1.8 
 
4.4.3.11.5 Lower Limit of Quantification (LLOQ) 
 
The LLOQ was found to be 0.2 µg/ml, and the average accuracy was 115.5% with % RSD of 
2.1%, and detector response more than five times the blank. 
 
4.4.3.11.6 Linearity 
 
An un-weighted regression analysis was used to measure linearity, and the linearity 
parameters are shown in Table 4.11. The %RSD value of the slopes was 2.3. 
 
Table 4.11. Calibration linearity.  
DAY Slope Y-intercept Correlation coefficient r2 
Day 1 0.2107 0.0126 0.9999 
Day 2 0.2205 0.0088 0.9994 
Day 3 0.2144 0.0180 0.9999 
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4.4.3.11.7 Stability  
 
The stock solutions were found to be stable with RSD values less than 5% at both 
temperatures during the relevant periods of investigations.  
 
For the short-term stability, the difference between the two sets of samples were within 15% 
of each other, and within 15% of nominal values (Table 4.12), thus EFV was found to be 
stable when stored on the bench-top for six hours. 
 
Table 4.12. Short-term stability of unprocessed samples. 
SET QC Mean (n=3) 
calculated standard 
concentration (µg/ml) 
Mean % of Nominal 
concentration 
RSD (%) 
ONE Low 0.3100 91.4 3.5 
Medium 1.5542 100.4 5.0 
High 7.7705 97.3 4.4 
TWO Low 0.3100 89.5 3.1 
Medium 1.5542 95.7 3.8 
High 7.7705 96.6 7.8 
 
Generally the results of the long-term stability studies depicted in Table 4.13 indicate that 
plasma samples of EFV remained stable for up to 60 days. However, the mean % nominal 
concentration of the low QC samples was found to be out of specification (Table 4.17). This 
was due to one of the replicate samples which produced an unexpectedly high result outside 
of the low QC concentration range. The respective sample chromatogram was revisited and 
inspected, and it was noticed that the peak area of the IS appeared to be unusually high. This 
was thus considered to be an outlier and in view of the fact that the longer term stability 
samples at Days 30 and 60 were all shown to be stable, stability of the low QC samples was 
not re-investigated.  
 
Table 4.13. Long term stability of EFV in plasma. 
 
 
QC* 
Day 7 Day 30 Day 60 
Nominal 
conc**. 
(µg/ml) 
Mean % 
nominal 
conc. 
RSD 
(%) 
 
Nominal 
conc. 
(µg/ml) 
Mean % 
nominal 
conc. 
RSD 
(%) 
 
Nominal 
conc. 
(µg/ml) 
Mean % 
nominal 
conc. 
RSD 
(%) 
 
Low 0.3111 116.8 6.7 0.3082 93.4 7.4 0.3133 109.3 7.2 
Med 1.5745 99.9 1.5 1.5390 84.5 1.1 1.5612 98.3 7.3 
High 7.8853 100.6 12.6 7.6994 95.5 8.9 7.8553 99.4 4.4 
Notes: 
* n = 3, **conc. - concentration  
EFV was stable under all short-term conditions studied as shown in Table 4.14. 
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Table 4.14. Short-term stability of the samples. 
Stability 
sample 
Sets  QC Mean (n=3) nominal 
concentration (µg/ml) 
% of Nominal concentration 
at end of run 
RSD 
(%) 
Freeze thaw SET 
ONE 
Low 0.3095 90.2 4.7 
Medium 1.5466 98.7 11.3 
High 7.7434 97.2 4.8 
SET 
TWO 
Low 0.3095 98.1 3.1 
Medium 1.5466 98.8 5.0 
High 7.7434 107.9 5.7 
On-instrument Low 0.3095 98.7 4.9 
Medium 1.5466 100.9 4.9 
High 7.7434 101.0 5.8 
Re-injection Low 0.3095 94.8 2.2 
Medium 1.5466 102.1 6.1 
High 7.7434 107.2 1.7 
 
4.4.3.12 Conclusions 
 
 
A cost-effective HPLC-UV method was developed which is simple, rapid, precise, accurate 
and repeatable, and thus applicable for the quantitative analysis of EFV in human plasma. 
Separation between EFV and IS was achieved with a C18 column, and the run time was less 
than 9 min. The mobile phase optimisation and detection by dual wavelengths resulted in 
well resolved peaks, and permitted the use of lower concentrations of the IS.  EFV was found 
to be stable in the mobile phase for one week. A simple protein precipitation method using 
readily-available solvents yielded excellent recoveries for EFV, with increased sensitivity.  
The assay performance data show that the method meets the requirements of a suitable 
bioanalytical method which can be applied for the analysis of samples for pharmacokinetic 
studies.  
 
Previous methods utilized various organic modifiers and/or ion pairing reagents at relatively 
high pH (> 10 and greater), or even complicated and time consuming gradient elution. The 
mobile phase used in this study, consisted of a simple mixture of a low concentration of 
formic acid (0.1 M) solution, together with acetonitrile and a small amount of methanol (5%) 
at a pH of 2.2. This system is cost-effective and in addition provides protection of the silica 
column stationary phase from high pH damage thereby ensuring that the column life is not 
shortened. 
 
  
 
85 
 
CHAPTER 5 
IN VIVO INTERACTIONS BETWEEN EFAVIRENZ AND AFRICAN 
POTATO (Hypoxis hemerocallidea) 
 
5 Introduction 
 
Clinical studies aimed at assessment of drug interactions are pivotal to the characterisation of 
new drug molecules, as well as evaluating safety of medications used concomitantly in 
clinical practice. Clinical drug interaction studies are now rationally designed because of 
recent scientific developments in the areas of pharmacokinetics and pharmacodynamics. Prior 
to designing a clinical drug interaction study, researchers have to consider a number of 
factors, such as the physico-chemical properties of the substrate and the interacting drug, 
duration of use of the substrate and the interacting drug, metabolic pathways, and in vitro 
data. This is important because the substrate drug and the interacting drug may share a 
common metabolic pathway, and may be found to interact in vitro but this does not 
necessarily imply that a clinically-significant interaction will occur. A clinically-significant 
interaction is one which leads to a change in the therapeutic and/or toxicity of a drug such 
that the dose of the drug has to be adjusted, and/or frequency of administration or a medical 
intervention will be necessary [229]. 
 
In recent years, better understanding of the role and mechanisms of CYP450 enzymes has 
resulted in the development of methods for the determination of effects of drugs on the 
enzymes in vitro. However, the data from in vitro studies are usually used qualitatively. An 
evaluation of the data submitted to the U.S.A. Food and Drug Administration revealed that 
there are limitations caused by unpredictability of in vivo drug interactions from in vitro data 
[230]. The uncertainties in predicting in vivo drug interactions from in vitro data are a result 
of it not being possible to determine the concentration available to the enzyme in the liver 
[64]. Some proposals to use surrogate in vivo concentrations that could be used to extrapolate 
in vitro results have been suggested. However, there is still a need to confirm positive in vitro 
interaction results using in vivo studies. The use of in vitro induction data has also been 
discussed during the recent review of the FDA guidance on in vivo drug 
metabolism/interactions studies, and so far, there are no consistent criteria for determining 
whether a clinical drug-drug interaction study should be conducted [231]. For inhibition 
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studies, it has been proposed that in vivo studies should be conducted if in vitro data show an 
[I]/Ki > 0.1, where [I] is the mean maximum plasma concentration (Cmax) value of the total 
drug (bound and unbound) at the steady state of the highest clinically-used dose, and Ki is the 
inhibition constant [232]. This, however, cannot be applied to TMs/CAMs since the clinical 
doses for most of these medicines have not yet been determined, and most of the TMs/CAMs 
do not exist as single compounds. Further limitations of predicting in vivo TM-drug 
interactions from in vitro data include variability of composition of the TMs/CAMs products, 
and lack of knowledge of hepatic concentrations, bioavailability, metabolism and extent of 
plasma protein binding of the product/constituents. 
 
As mentioned in Chapter 1, drug interactions may occur between orthodox medicines and 
TM/CAMs. An in vitro drug interaction study using recombinant P450 enzymes on effects of 
AP, hypoxoside and rooperol, showed that these products are inhibitors of CYP3A4, A5 and 
19 [88]. Because of the use of AP by patients on HAART, it is necessary to asses the effect of 
AP on EFV which is the backbone of HAART. EFV is metabolised by CYP3A4 and 
CYP2B6. Therefore there is a possibility of a drug interaction between EFV and AP. AP may 
reduce metabolism of EFV, resulting in high plasma concentrations of EFV. The high plasma 
concentrations of EFV could lead to increased risk of adverse events which could also lead to 
reduced adherence to treatment and ultimately treatment failure. Therefore, the objective of 
this project was to design a clinical study and evaluate the effect of African Potato (AP) on the 
pharmacokinetics of EFV in human volunteers.  
 
5.1 Clinical Trial Design 
 
The design of a clinical trial depends on the objective/s of the study, which should be 
determined at the planning stage [233]. Clinical studies can be classified as parallel or 
crossover. A crossover trial is when patients receive two or more treatments, and a parallel 
design is when each patient receives only one treatment. During planning, the design of the 
study must establish various factors and requirements such as objectives, factors (in an 
efficacy trial the drugs are factors to be evaluated), types of responses, and sample size, 
amongst others.  
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5.1.1 Parallel Design 
 
For a parallel study design, an equal number of patients are given treatment A, and another 
group is given treatment B. The results of the two groups are compared, and the number of 
treatments may be more than two. It is important to have an equal number of patients in both 
groups so that the standard deviation is minimised, hence the statistical power of the study is 
at its maximum. Randomisation is important so that it becomes a matter of chance which 
subjects receive a given treatment. In this case, it is assumed that the average effect of a given 
drug will be the same, regardless of which randomly selected group of patients happen to 
receive it [233]. This type of study is suitable for clinical trials where carry-over effects 
cannot be controlled or eliminated. 
 
5.1.2 Cross-over Designs 
 
In a cross-over study design, each subject is exposed to two treatments under investigation on 
different occasions. In this design, each patient acts as his or her own control, and can be used 
to evaluate within subject variability.  It allows for direct comparison of treatments, and is 
more relevant in the presence of large inter-individual variation.  
 
Treatments are administered on two occasions, and these are often called legs, periods or 
visits, and the order of treatment may be randomised to reduce period effects. A period effect 
is where a difference in response is due to the occasion on which the treatment is given, 
independent of the effect due to the treatment. This is considered as a statistical interaction or 
“differential carry-over” which may occur in the cross-over design. This carryover effect 
occurs when the response of the second period is dependent on the response of the first 
period, and this dependency differs, depending on the sequence of treatment. In this case a 
sufficiently long washout period should be employed to avoid the carryover effect.  The 
possibility of period effects increases if the order is not balanced. Intra-subject variability is 
usually smaller in these designs, hence, it is more precise than parallel designs. One 
disadvantage of the cross-over design is that it may not be suitable when carry-over effects 
and other interaction effects are anticipated, hence, a parallel design is preferable. The other 
disadvantage of a cross-over design is that it may take longer time to complete.  
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5.2 Drug Interaction Study Designs 
 
Drug interaction studies are usually conducted during phase 1 clinical trial, i.e., during the 
development stage of a new drug, and can also be conducted after market authorisation is 
granted by assessing retrospective data obtained during clinical use. The studies may be 
open-labelled, unless pharmacodynamic end-points are part of the assessment. Open-labelled 
studies are studies where both the subjects and researchers know which treatment is being 
administered. Clinical drug interaction studies are usually of a randomised, cross-over or one 
sequence cross-over or parallel design, with appropriate washout periods. The following 
study designs to investigate drug-interactions are used in the pharmaceutical industry [234]:  
• single dose substrate drug and single dose CYP450 enzyme probe administered in 
combination, and each compound given alone in a three-way cross-over study 
• single dose CYP450 enzyme probe followed by multiple dose substrate drug co-
administered with single dose CYP450 enzyme probe, or single dose substrate drug 
followed by multiple dose interacting drug co-administered with single dose substrate 
drug  in a sequential two-way cross-over 
• multiple dose CYP450 enzyme probe and multiple dose substrate drug in one three-
way cross-over or two two-way cross-over trial.   
 
5.2.1 Study Population and Sample Size 
 
Generally, clinical drug interaction studies are performed using healthy volunteers drawn 
from the general population, and this is based on the assumption that results from healthy 
volunteers should predict findings in the patient population [235]. Patients can be used if 
there are undue risks on healthy volunteers. When a drug interaction involves enzymes which 
exhibit polymorphism, then genotyping of the volunteers to identify polymorphs is important 
to assist interpretation of the results because a drug interaction may only occur in slow 
metabolisers. The number of volunteers should be adequate to assess differences, thus the 
power of the study should be adequate.  
 
5.2.2 Washout Period 
 
The washout period is the time between two doses of the same drug during a clinical study, 
and should be adequate to allow complete elimination of the drug, and is based on the half-
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life of the drug. The recommended washout period should be based on more than five (5) 
half-lives of the drug [236]. 
 
5.3 Analysis of Pharmacokinetic Data 
 
5.3.1 Pharmacokinetic Analysis 
 
Drug interactions in which the pharmacokinetics of the substrate drug is affected are assessed 
using pharmacokinetic data of the substrate drug. Clinical significance of an interaction 
depends on the dose/concentration and concentration/response relationships for both desirable 
and undesirable drug effects in the general population or in specific populations. Therefore, 
knowledge of the relationship between dose, blood levels and response may guide the use and 
interpretation of particular pharmacokinetic parameters [235]. Measures of systemic absorption 
are used to asses the effect on the pharmacokinetics of the substrate drug. If the clinical outcome 
is related to the peak concentration, then maximum concentration (Cmax) may be more appropriate 
than area under the curve (AUC). Other parameters, e.g., clearance (Cl), volume of distribution 
(Vd), half-life (t1/2) and time to reach maximum concentration (Tmax), are usually reported, but 
their results alone cannot be used to assess the occurrence of drug interactions. If studies are 
conducted at steady-state, then an additional measure, such as trough concentration (Cmin) is 
reported to demonstrate that the dosing strategies were sufficient to attain near steady-state 
conditions before and during the study.  
The arithmetic means AUC from the ln-transformed data of the time-concentration profile of the 
substrate drug are compared to assess effect of interacting drug on bioavailability of the substrate 
drug. The AUC may be determined up to the last sampling time of the study (AUCt), or truncated 
at a particular time point and/or the AUC extrapolated to the time infinity (AUC∞). The use of a 
truncated AUC has been proposed where some limitations, which include limited assay 
sensitivity and long plasma half-lives of some drugs, exist [237-241].  Nevertheless, caution has 
been placed on the use of truncated AUC for drugs with long half-lives [242], and that AUC can 
only be truncated provided that absorption has been completed, and must be truncated at 72 hr.   
 
5.3.2 Statistical Analysis 
 
Statistical methods used in a drug interaction study must be predetermined at the planning 
stage, and must be stated “a priori” in the protocol. The choice of a statistical method 
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depends on, amongst others, whether the analysis is qualitative or quantitative, and whether 
one is looking for relationships or differences. There are various different statistical methods 
for the comparison of two groups, or three or more groups, including comparison of 
pharmacokinetic parameters from the two periods. Measurement of bioequivalence can be 
used to assess the presence or absence of an interaction. Two types of statistical methods, 
namely, parametric and non-parametric methods, may be used to assess difference or 
similarity of pharmacokinetic parameters in drug interaction studies.  
 
Parametric methods involve manipulation of data that can be assumed to derive from normal 
distributions [243]. An assumption has to be made that the data is normally distributed. 
Assumptions made before applying the parametric methods are called parametric 
assumptions. These assumptions are necessary to ensure that reliable and informed 
hypothesis testing and other procedures are carried out.  The assumptions and their 
definitions are shown in Table 5.1. 
 
Table 5.1. Definitions of parametric assumptions. 
Assumption Definition 
Additivity Effects of the factors are additive 
Normality Data and errors are  normally distributed  
Homoscedasticity Errors  e.g. standard deviations, of the data even when they come from different 
populations are the same 
Independence Errors of data from two or more distributions are independent of random variables. In 
difference tests and similar single-statistic tests, the differences are assumed to come from a 
single population difference  
  
These assumptions can be tested for violations and where violations, have been made, there 
are remedies designed by statisticians to ensure reliability of the data.  The parametric 
methods commonly used are t-tests and analysis of variance (ANOVA). The t-test is used to 
compare two means of two treatments only, thus can be used for drug interaction studies 
including comparison of two independent samples, e.g., means from a parallel study. 
ANOVA is conceivably the most robust statistical tool, and is designed to analyse data from 
studies whose objective is to compare two or more means. ANOVA can be applied to data 
from cross-over studies, provided that an assumption that, carry-over effects are absent. This 
is a critical assumption for correct interpretation of the results.  
 
In instances where parametric assumptions are violated, non-parametric tests are employed. 
These methods assume that period or sequence (carry-over) effects are absent, and no 
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adjustments are made for these effects. Data for use in the non-parametric tests have to be 
ranked or ordered, and must have a continuous distribution. The two non-parametric tests 
which can be used to assess equivalence are the Wilcoxon signed rank test, and the Mann-
Whitney U-test. These are alternatives to the t-test from parametric tests, the latter being the 
alternative to the independent t-test because it compares means from two independent groups. 
The Friedman test is another non-parametric test which is applied to data in the form of a 
two-way ANOVA design. In this test the two groups are ranked within each person or 
subject, disregarding differences between subjects. Other tests which have been used in drug 
interaction studies are Chi-squared test which is an alternative to one-way ANOVA [244], 
and Fischer’s test which is an alternative of unpaired t-test. Non-parametric tests have been 
shown to be consistently less powerful than parametric tests [245], and the FDA requires 
justification of their use in bioequivalence assessment [236].     
 
In drug interaction studies, the inter-changeability concept of bioequivalence can be applied 
because administration of one drug alone or in combination with another may or may not result in 
dose adjustment. Therefore, drug-drug interactions may be handled as an equivalence problem 
[246], using confidence intervals of the ratios of the means of relevant pharmacokinetic 
parameters. It has been proposed that when analysing drug interaction study data using the 
bioequivalence limits where the null hypothesis “no relevant interaction present” cannot be 
rejected, a clinically relevant interaction may only be reported if the power of the study is 
sufficient to avoid false positive signal [247]. According to the FDA guidance on conducting 
drug interaction studies in vivo, a no drug interaction conclusion is reached if the 90% confidence 
intervals of the geometric means of the AUC and Cmax fall exactly within 80 -125% limit [235]. 
However, the European Agency for the Evaluation of Medical Products [229] in its similar 
guidance, allows for narrowing or widening of these limits, depending on the therapeutic 
consequences of the drug interaction. 
  
In some cases, specific “no effect” boundaries or clinical equivalence intervals may be used 
instead of the bioequivalence model [235]. A survey conducted by the FDA on the quality and 
quantity of drug-drug interaction studies submitted to the agency between 1995 and 1996 showed 
that 30% of submissions included the more relevant equivalent approach with 90% confidence 
intervals for key pharmacokinetic parameters [248].   
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5.4 Methods and Procedures 
 
5.4.1 Ethical and Institutional Review 
 
The study protocol (See annexure I) was approved by the Rhodes University Ethical 
Standards Committee (RUESC) [249] before commencement.  
 
The study was conducted in accordance with the recommendations of the guidelines as set 
out in the Declaration of Helsinki (1964) and its subsequent amendments [250], according to 
ICH Good Clinical Practice (GCP) guidelines [251], standard operating procedures (SOPs). 
 
5.4.2 Study Population 
 
An advert approved by the RUESC was posted around the university campus and various 
places in Grahamstown. Interested respondents were invited for a talk about the study in 
which the reasons for the study and study performance were explained. All participants were 
taken through the volunteer information brochure, and attendance was recorded. The 
respondents who were still interested in participating in the study were given 24 hr to read the 
informed consent forms and the volunteer information brochure. Signed informed consent 
forms were filed in the study folder and a copy was given to each volunteer. 
 
Ten healthy male subjects who were non-smokers and HIV negative were enrolled into the 
study after giving informed consent. The demographics of the ten volunteers are shown in 
Table 5.2. The eligibility criteria (Table 5.3) included the ages between 18 and 55 years, and 
a body mass index (BMI) between 19 and 30 kg/m2. Pre-study medical screening was 
performed within a month of initiating the study and volunteers who passed the physical, 
medical and laboratory screening tests according to the stated inclusion and exclusion 
criteria, were enrolled. Laboratory tests included tests for liver function, hepatitis B and C, 
HIV as well as blood biochemistry, urinalysis and drugs of abuse. The latter included tests for 
amphetamines, barbiturates, benzodiazepines, cocaine, methamphetamine, morphine, 
phencyclidine, THC, and TCA and volunteers were required to abstain from alcohol 
consumption prior to the study.  
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Table 5.2. Demographic data of volunteers. 
 
Age 
(yrs) Race 
Weight 
(Kg) Height (m) BMI 
Subject 1 22 Black 58.2 1.675 20.74 
Subject 2 23 Black 79.4 1.750 25.93 
Subject 3 22 Black 77.2 1.880 21.84 
Subject 4 22 White 67.2 1.860 19.42 
Subject 5 23 Black 67.2 1.67 24.10 
Subject 6 27 Black 66.0 1.83 19.82 
Subject 7 25 Black 72.2 1.80 22.28 
Subject 8 19 Black 84.0 1.82 25.50 
Subject 9 23 Black 64.2 1.81 19.71 
Subject 10 24 Black 87.4 1.77 27.90 
Mean 22.91   71.8 1.78 22.55 
Min 19   58.2 1.67 19.42 
Max 27   87.4 1.88 27.90 
 
Prescription and over-the-counter medicines were restricted from 1 week before each phase, until the 
last blood sample had been taken at the end of the study.  Consumption of alcohol was forbidden from 
4 days before the study, and caffeine and grapefruit juice were restricted from 48 hr before the study.  
In addition, volunteers were prohibited from strenuous exercise from 24 hr before the study.  
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Table 5.3. Inclusion and selection criteria. 
Criteria 
  
Inclusion 
criteria 
1.  Mentally competent subjects who are available for the entire study period and willing to adhere to the protocol requirements and able to 
give informed consent by signing the informed consent form. 
 2.  Males between ages 18 and 55 years of age. 
 3.  Volunteers with a BMI of between 19 and 30. 
 4.  Non-smoking volunteers who have not smoked for at least two months. 
 5.  Normal in terms of medical history at the pre-study screening medical, or in the case of an abnormality, if the medical practitioner 
considers the abnormality to be clinically non-significant. 
 6.  Normal in terms of physical examination at the pre-study screening medical, or in the case of an abnormality, if the medical practitioner 
considers the abnormality to be clinically non-significant. 
 7.  Normal in terms of laboratory test values for the pre-study screening medical within the laboratory’s stated normal range, or in the case of 
an abnormality, if the medical practitioner considers the abnormality to be clinically significant. 
 8.  Mentally competent subjects who are available for the entire study period and willing to adhere to the protocol requirements and able to 
give informed consent by signing the informed consent form. 
Exclusion 
criteria 
1.  Any history of hypersensitivity or idiosyncratic reaction to EFV or AP. 
 2.  Any history of cardiovascular abnormality or disease. 
 3.  Any history of liver dysfunction. 
 4.  Any history of anaemia or cytopenia. 
 5.  Any history of renal dysfunction. 
 6.  Any history of adrenal or pituitary insufficiency. 
 7.  Any history of chronic asthma, bronchitis or other bronchospastic conditions. 
 8.  Any history of epilepsy or other convulsive disorders. 
 9.  Any history of psychiatric disorders including depression or mania. 
 10.  Any history or other condition which the study physician regards as clinically significant to the study (including fainting upon blood 
sampling). 
 11.  Any history of drug or alcohol abuse or other use of tobacco within two months of the study start date. 
 12.  Treatment with any drug known to have a well-defined potential for toxicity to one of the major organs, particularly renal and hepatic 
toxicity, within three months of the study start date. 
 13.  Treatment with any drug which could modify renal excretion of drugs (e.g. probenecid) within one month of the study start date. 
 14.  The intake of a restricted or abnormal diet for longer than a week within 4 weeks of the study start date. 
 15.  Maintenance therapy with any drug or regular use of chronic medication. 
 16.  A major illness considered to be clinically significant by the study physician within 3 months of the study start date. 
 17.  Participation in another study or the donation of one pint or more of blood within 1 month of the study start date. 
 18.  A positive test for Hepatitis B surface antigen, Hepatitis C or HIV. 
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Criteria 
  
Exclusion 
criteria 
19.  Treatment with any prescription drug within one week of the study start date, unless the drug is considered to be clinically insignificant by 
the study physician. 
 20.  Treatment with any Over The Counter (OTC) drug within one week of the study start date, unless the drug is considered to be clinically 
insignificant by the study physician. 
 21.  The consumption of alcohol or other enzyme inducing agents within 96 hours of the start date (all barbiturates, corticosteroids, 
phenylhydantoins etc.). 
 22.  Any vomiting or diarrhoea within 24 hours of dosing. 
 23.  A positive urine test for any drug of abuse tested for at the pre-study screening medical or at check-in. 
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5.4.3 Study Design 
 
A single dose, two phase sequential study was conducted in healthy male volunteers under 
fasting conditions. The study was divided into two phases, phase 1 which started on day 1 
and phase 2 which started on day 29, each phase lasting for three days. The washout period 
between the administrations of the EFV doses was 28 days. The night before the study (Day 
0) volunteers were checked into the clinic and tested for drugs of abuse and alcohol 
consumption, as well as being questioned to ensure that they complied with the study 
restrictions (Table 5.4). Volunteers fasted for 10 hr before they were administered a 600 mg 
EFV tablet followed with a 240 ml glass of water. A mouth and hand check were conducted 
to confirm that the dose had been ingested and this was done by a different person from the 
one who had administered the dose. Subjects were seated for the first 4 hr after drug 
administration, and were not permitted to lie down or sleep until after 4 hr post-dose, unless 
this was necessary due to an adverse event. Standard meals were provided until 24 hr post-
dose, and the times at which meals were commenced and ended were recorded as well as 
approximate amounts consumed. Ten millilitre blood samples were collected into 
Vacutainers®, containing potassium EDTA as the anticoagulant, at the following time 
intervals; before dosing (0) and at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 12.0, 18.0, 
24.0, 36.0 and 48 hr post-dose. Blood samples were stored in an ice-bath immediately after 
withdrawal and until centrifugation commenced, which was within 30 min of collection. The 
blood samples were centrifuged at 2800 g for 10 min at 4ºC. Duplicate aliquots of harvested 
plasma were stored in polypropylene tubes at -80 ± 10ºC until transfer to the analytical 
laboratory. The tubes were labelled with study number, phase number, subject number, 
sample number and sampling time. 
 
From Day 16 until Day 30 of the study, the volunteers were administered a freshly prepared 
traditional AP decoction at a dose of 15 mg/kg/day of hypoxoside at the same time daily for 
14 consecutive days. The AP decoction was prepared and assayed for hypoxoside content 
prior to administration. After receiving 12 consecutive daily doses of the AP decoction, phase 
2 was initiated on day 28 when each of the volunteers received a 600 mg dose of EFV in the 
same manner as they did at the beginning of the study. Blood samples were collected at the 
same time intervals as previously described in phase 1. Dropouts were not replaced. 
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Table 5.4. Study Restrictions. 
Restricted Item Duration of Restriction Examples of Restriction Comments 
Prescription medicines From 1 week before the start of the 
study, until the end of Phase 2 of the 
study 
• All medicines obtained on prescription 
• Antibiotics, vaccinations 
• Anti-inflammatories 
• Antiasthmatics 
• Antiacne medicines 
This includes all long-term medication. 
Over-the-Counter (OTC) 
medicines 
From 1 week before the start of the 
study, until the end of Phase 2 of the 
study. 
• Anti-flu medicines, sports supplements, 
paracetamol 
• Vitamins, minerals 
This includes all medication that can be bought 
without a prescription. 
Caffeine From 2 days (48 hours) before the 
start of each phase and during each 
phase until the last blood sample for 
that phase has been taken.  
No caffeine containing beverages for 
a total of 10 days for each phase. 
• Drinks: coffee, tea, coke, most colas, 
green tea, Milo etc. 
• Foods: chocolate, Tonics, Bioplus 
This includes all chocolate containing foods e.g. 
chocolate cake, chocolate ice cream, choc chip 
biscuits. 
 
Rooibos tea and herbal teas containing guarana 
are allowed. 
Alcohol For 4 days (96 hours) before the start 
of each phase and during each phase 
until the last blood sample for that 
phase has been taken. 
No alcohol for a total of 12 days for 
each phase. 
• All alcoholic drinks and alcohol 
containing foods. 
It is very important that this requirement is 
taken seriously and observed, as alcohol can 
significantly affect the liver. Failure to comply 
with this requirement can seriously affect the 
study. 
Strenuous Physical 
Exercise 
From 24 hours before the start of 
each phase and during each phase 
until the last blood sample for that 
phase has been taken. 
No strenuous exercise for a total of 9 
days for each phase. 
• Rugby 
• Squash 
• Rowing 
• Gym 
• Tennis etc. 
Light exercise such as walking is permitted. 
Food and Fluids For the duration of the clinic stay for 
each phase as well as restrictions 
detailed above 
• All foods and fluids Food and fluid intake will be standardised while 
you are in the clinic to minimise inter-individual 
variation, and will be provided for you. 
Grapefruit From 2 days (48 hours) before the 
start of each phase and during each 
phase until the last blood sample for 
that phase has been taken. 
• Grapefruit  
• Grapefruit juice 
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5.4.4 Analysis of Plasma Samples 
 
Plasma samples were analysed according to the validated HPLC-UV method described in 
Chapter 4. All plasma samples were analysed within 40 days of collection, and samples for 
each volunteer covering both phases were analysed in one analytical batch. An analytical 
batch consisted of individual subject’s samples (both phases),  together with  seven (7) 
calibration standards, and  two sets of quality control samples at three different 
concentrations (0.3, 1.5 and 7.5 µg/ml). The QC samples were analysed at the beginning and 
at the end of each run. The peaks from the chromatograms were integrated and peak areas of 
EFV and diclofenac sodium (DICNa), the internal standard (IS), were used to calculate peak 
area ratios. 
 
Calibration plots were constructed for each batch, and the acceptance criteria for the curve 
was that six of the calibration standards should be <15% of the nominal concentration, and 
that of the standard at the lower limit of quantitation (LLOQ) was <-20%. Upon acceptance 
of a calibration plot and QC samples, an un-weighted linear regression plot was generated. 
Concentration of EFV in plasma of subjects was determined from the linear regression 
equation of the calibration plot.  
 
5.4.5 Preparation of African Potato Decoction 
 
The AP corms used to prepare the AP decoctions were bought from a registered traditional 
healer based in Grahamstown. An AP decoction was freshly prepared each day according to 
the traditional manner. The roots on the corms were removed prior to washing with tap water. 
The washed corms were grated and weighed on a Mettler PM 4600 balance (Mettler 
Instruments AG, Zurich, Switzerland). About 200 g of the grated corm was added to 2.5 L of 
water, and brought to boil for about 45 min. The decoction was allowed to cool at ambient 
temperature. Fifteen decoctions were prepared daily in this manner and analysed accordingly. 
 
5.4.6 Analysis of AP Decoction 
 
The quality of AP corms can be quite variable, hence standardisation of each decoction 
preparation was necessary. The AP decoction was analysed using an HPLC-UV method (Nair 
  
 
99 
 
2006). Two samples of the prepared decoction was analysed, and the concentration of 
hypoxoside in the decoction was determined.  
 
5.4.7 Dosing of AP Decoction 
 
The dose of AP decoction was standardised according to the hypoxoside content, which was 
used as the QC marker. Each volunteer received the equivalent of 15 mg/kg/day of 
hypoxoside in the form of the decoction. The choice of the hypoxoside dose was based on   
published hypoxoside safety data.  The toxicity of hypoxoside was previously assessed in 
patients with lung cancer at doses ranging from 1200 to 3200 mg daily, and the compound 
was found to be safe throughout the dosage range [193]. More recently, a single dose toxicity 
study performed in mice and assessed over a period of 48 hr indicated that the lethal dose was 
found to be 1948 ± 57 mg/kg [181]. A further study was subsequently reported where similar 
results were found following a single dose to mice and followed for 14 days [170]. Even 
though these studies are considered to provide inadequate information of the mitigation of 
risk for human participants in clinical studies, they do provide an indication of AP 
toxicity/safety. Therefore, the 15 mg/kg/day dose of hypoxoside was considered safe to use in 
healthy, human volunteers.     
 
5.4.8 Data Analysis 
 
5.4.8.1 Pharmacokinetic Analysis 
  
The pharmacokinetic parameters of EFV before and after co-administration with AP were 
determined using a non-compartmental model [252]. Exposure measures such as area under 
the curve (AUC) of the plasma concentration-time profiles from 0 hr to 48 hr (AUC0-48), and 
peak plasma EVF concentrations (Cmax), were used to assess the effect of AP on the 
pharmacokinetics of EFV. Other parameters that were monitored included the elimination 
half-life (t1/2), time taken to reach peak plasma concentration (tmax), and the elimination rate 
constant (kel). The AUC0-48 and Cmax were calculated, and the trapezoidal rule was used to 
estimate AUC0-48.  
 
5.4.8.2 Statistical Analysis 
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ANOVA was conducted on Cmax and AUC0-48, using log-transformed data, and the geometric 
mean ratios were calculated. The two one-sided t-test [253] was used to determine the 
respective 90% CIs. An interaction is concluded if the 90% CIs for Cmax and AUC0-48 are 
found to be outside the limits of 80 -125% [235]. ANOVA analysis was conducted using 
SAS® software (SAS Institute Inc., Cary, North Carolina, USA).  
 
If a pre-dose concentration (carry-over) of EFV is detected in Phase 2, the subject’s data are 
included in the statistical analysis, if it represents less than 5% of the Cmax value. However, if 
this is greater than 5% of the Cmax value, then the subject must be excluded from the study 
[236]. 
 
5.5 Results  
 
All volunteers completed the study and there were no deviations from the study restrictions. 
Three volunteers experienced minor adverse events of dizziness, loss of concentration and 
sleepiness within 4 hr of dosing with EFV. These events subsided without any medical 
intervention within 2 hr of reporting. All adverse events were recorded in the case report 
forms. 
 
5.5.1 AP decoction Preparations and Analyses 
 
The concentrations of hypoxoside in the 15 AP decoctions ranged from 8.03 and 27.02 
mg/ml, see Table 5.5.  
 
5.5.2 Plasma EFV Analysis 
 
All samples were analysed using the previously described validated HPLC-UV method 
(Chapter 4), and none of the samples were excluded from the pharmacokinetic analysis. A 
bioanalytical report is given in Annexure II. Mean plasma EFV concentrations were 
calculated and plotted to generate plasma EFV profiles (Figure 5.1). The profiles are virtually 
super-imposable during the early stages of the absorption phase, as well as later during the 
elimination phase, but differences were apparent around the Cmax.  
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Table 5.5. Linearity of hypoxoside calibration curve and concentrations of AP decoction. 
DAY Y –
intercept  
Gradient of calibration 
curve 
Correlation 
coefficient 
Concentration of AP decoction 
(µg/ml) 
1 -0.1507 0.0444 0.9981 10.16 
2 -0.14 0.481 0.9955 8.03 
3 -0.2497 0.0515 0.9979 16.60 
4 -0.1749 0.0440 0.9939 18.21 
5 -0.0592 0.0350 0.9839 12.92 
6 -0.0925 0.0423 0.9996 13.26 
7 -0.173 0.0387 0.9985 19.26 
8 -0.1229 0.0411 0.9992 14.97 
9 -0.1116 0.0433 0.9986 15.81 
10 0.0139 0.0352 0.9954 13.92 
11 -0.139 0.0339 0.9962 17.92 
12 -0.0292 0.0301 0.9937 27.02 
13 0.1043 0.0383 0.9892 15.45 
14 -0.0153 0.0363 0.9968 15.31 
15 0.1275 0.0333 0.9986 21.41 
 
 
 
 
Figure 5.1. Mean and SD of plasma concentration vs time of EFV alone and EFV co-administered with 
AP. 
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5.5.3 Pharmacokinetic and Statistical Parameters 
 
The mean Tmax of EFV following single dose administration of a 600 mg EFV tablet alone 
was found to be similar to the published values of approximately within 5 hours. The mean 
Tmax after co-administration with AP was approximately the same, occurring at 2.9 hours. 
Cmax and AUC0-48 values before and after AP administration was also fairly similar, see Table 
5.6.  
 
Table 5.6. Summary of statistics of pharmacokinetic parameters and statistical analysis of EFV alone and 
EFV co-administered with AP. 
Pharmacokinetic 
Parameter 
EFV alone (n=10) EFV with AP 
(n=10) 
Ratios of geometric means (90% 
CI) 
AUC0-48 (µg.h/ml)    
mean 49.65 48.60 102.82 (89.04-118.80) 
CV% 25.63 29.07  
Cmax (µg/ml)    
mean 2.41 2.53 97.30  (78.81- 120.14) 
CV% 16.52 26.52  
t1/2 (h)    
mean 52.29 48.02 N/A* 
CV% 43.29 36.30  
Tmax (h)    
mean 3.10 2.90 N/A 
CV% 46.75 37.95  
k    
mean 0.015 0.016 N/A 
CV% 36.15 34.55  
*N/A = Not Applicable 
 
5.6 Discussion 
 
The Cmax parameter, is a discontinuous variable which is known to have high variability due 
to the uncertainty of precisely determining it, compared to the AUC, which is a continuous 
variable. Furthermore, Cmax is confounded by AUC, hence, the 90% CI set for Cmax may have 
been too narrow.  The point estimate of the ratio of the means of Cmax was 97.30, which is 
very close to unity, and with a CV% of 25.3, an increase in the sample size is unlikely to 
improve the results, since the power of the study was greater than 90%, using only 10 
subjects. Although the 90% CIs for Cmax did not fall within the 80-125% interval, the 
acceptance limits for this parameter are generally considered to be less important than the 
AUC, as previously discussed, except where the clinical outcome of the drug treatment is 
related to peak concentration as an indicator of toxicity. The clinical outcome of EFV is 
related to exposure of the drug, and not the Cmax, therefore, in this case, the use of AUC alone 
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as a measure of drug interaction should be adequate. It has been suggested that when setting 
pharmacokinetic margins for clinical significance of a drug interaction, the pharmacodynamic 
and efficacy data of the substrate drug should be also considered [247]. Safety of EFV was 
monitored during this study, and there were no adverse events reported which were linked to 
the administration of EFV. Therefore, the strict application of the of 80-125% interval to the 
Cmax in determining an interaction is probably inappropriate. The EMEA recommends the use 
of AUC, Cl and bioavailability (F) for the determination of an interaction, and recommend 
that Cmax may be used as a parameter for assessing drug interactions where the safety issue of 
the drug is dependent on its pharmacological action [229].  In the case of EFV, there is 
conflicting information on the correlation of its safety, and with its plasma concentrations 
[254-256].  Use of both point estimates as well as the CIs to form a basis of a drug interaction 
is recommended by the EMEA. Hence, the findings from this study suggest that interactions 
as a result of the co-administration of AP and EFV are unlikely.  
 
In vitro studies have shown that hypoxoside inhibits CYP3A4 enzymes, and also induces P-
gp [88]. The situation is different in vivo since hypoxoside is rapidly metabolised to rooperol 
following oral administration in humans [186], and is not absorbed per se. Thus, only 
rooperol, the hypoxoside metabolite, enters the systemic circulation where it is subsequently 
metabolised to form highly water soluble glucuronides and sulphates. Hence, any effect on 
the CYP3A4 enzymes following AP administration is unlikely to be due to hypoxoside. On 
the other hand, the effective metabolism of rooperol may result in low concentrations of this 
metabolite in the blood after oral consumption of AP, which may be too low to significantly 
affect the activity of the CYP3A4 enzyme system.  
 
Recent papers have suggested that EFV is mainly metabolised by CYP2B6, and to a lesser 
extent CYP3A4 [121]. Whereas hypoxoside and rooperol have been shown to affect CYP3A4 
in vitro, and since the pharmacokinetics of EFV were not altered following co-administration 
of AP, components of AP probably do not affect CYP2B6 enzymes. Some other constituents 
of AP such as stigmasterol, however, were also found to inhibit CYP3A4 in vitro, but activity 
of stigmasterol in vivo did not alter the pharmacokinetics of EFV in this study.  
 
Even though hypoxoside is not absorbed into the blood, it could still induce P-gp in the 
stomach and small intestine because it is only metabolised in the colon. Therefore, absorption 
of therapeutic agents which are substrates of P-gp, could be affected. Notwithstanding, such 
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an interaction is not expected to influence the plasma concentration of EFV, since EFV is not 
a substrate of P-gp [112]. 
 
5.7 Conclusions 
 
The traditionally prepared AP decoction did not significantly change the AUC of EFV after 
single dose of EFV, but the Cmax was outside the bioequivalence limit. The absence of 
adverse events related to EFV and the results from the pharmacokinetic analysis of EFV, 
indicated that the short-term administration of a traditionally prepared AP decoction is 
unlikely to affect the pharmacokinetics of EFV. There is, however a need to investigate the effect 
of AP on other ARVs, particularly those ARV’s which are P-gp substrates, or whose major metabolic 
pathway is via CYP3A4 isozymes, particularly protease inhibitors.   
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CONCLUDING REMARKS 
 
The use of TMs/CAMs brings challenges to healthcare professionals and researchers. The 
increase in the use of these medicines necessitates the need for further research in this area, 
since many of these TMs/CAMs have not been well studied. As such products become more 
and more commercially available; there is a need to provide evidence-based information to 
the public so that they can make informed choices. The use of TMs/CAMs does not only 
occur in parts of the world where there is poor access to orthodox medicines; it also occurs in 
countries where there is easy access to good primary and secondary healthcare. In all these 
cases, patients may use TMs/CAMs alone or in combination with orthodox medicines. The 
possibility of resultant pharmacokinetic and/or pharmacodynamic drug-TM interactions is 
thus extremely important to investigate. Therefore, the in vitro methods which have been 
applied to orthodox medicines can be readily applied to investigate the effects of TMs/CAMs 
on enzymatic and drug transporter mechanisms. One of the challenges with TM/CAM 
products is that they generally exist as complex mixtures of multi-components; hence, prior 
to conducting an in vitro study, it is important to identify a suitable analytical marker that can 
be used to quantitatively determine the effects of the TM/CAM on CYP enzymes and 
transporters. Another challenge with TMs/CAMs is that they are loosely regulated, hence, 
when using commercially-available unregulated products, one must be aware that the label 
claim may not be accurate, hence, it is important to standardise the dose when conducting a 
study.  
 
Whereas data from in vitro studies of drug-TM interactions may in some instances suggest 
that interactions have occurred, confirmation of such interactions are essential, and should 
thus be followed up by conducting appropriate in vivo studies. This study, in fact, was 
influenced by previously reported in vitro data where AP was shown to interact with 
CYP3A4 and also induced P-gp.  Guidelines developed for drug interactions of orthodox 
medicines may be applied to drug interactions involving the use of TMs/CAMs, since the 
principles of interactions are the same. In the past few years, there has been an increase in 
clinical studies evaluating drug-TM interactions, but only a relatively few of these medicines 
have been studied for possible interactions with concurrent therapy. The present study 
investigated the effects of concomitant administration of AP with the antiretroviral agent 
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EFV since this NNRTI is the backbone of HAART, and AP is commonly used concurrently 
with ARVs by people living with HIV/AIDS in South Africa.  
 
A bioanalytical method for the quantitative determination off EFV in plasma was developed, 
validated and applied to the study samples. The method developed has significant advantages 
over previously reported HPLC methods, being rapid and cost-effective, as well as having the 
requisite accuracy, precision and sensitivity to quantitatively determine EFV in human 
plasma. 
 
Changes in pharmacokinetic parameters of EFV were assessed following the administration 
of EFV alone, and after co-administration of EFV and traditionally prepared AP decoction to 
healthy human subjects. The 90% CI of the AUC and Cmax were 89.04 -118.80 and 78.81 – 
120.14% respectively, and the geometric mean ratios were 102.82 and 97.30 respectively. 
 
AP is consumed in various preparations, and also in pharmaceutical dosage forms including 
traditionally-prepared decoctions. Since this study evaluated the effect of a traditionally-
prepared AP decoction, these results should not be extrapolated to other AP preparations or 
pharmaceutical dosage forms, since those may contain other components which may, on their 
own, have effects on metabolism and efflux of EFV. Furthermore, administration of AP in 
any form needs to be standardised, and this was carried out on the freshly-prepared AP 
decoctions using hypoxoside as a QC marker.  
 
Finally, future investigations should consider conducting studies on other ARVs which are 
metabolised mainly by CYP3A4, such as the protease inhibitors, and also perhaps, in patients 
on an antiretroviral treatment regimen.  
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ANNEXURES  
1. Research Protocol 
2. Raw data of the pharmacokinetic parameters and concentrations of plasma 
standards, QC samples and subjects samples 
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3. Study Summary 
 
Title As Single-Dose, Two-Phase, SEQUENTIAL Design, Drug-Interaction Study 
of the effect of Hypoxis hemerocallidea (African Potato) on the 
Pharmacokinetics of Efavirenz in Healthy Male Volunteers under fasting 
conditions. 
  
Objective To assess the effect of African Potato (AP) on the pharmacokinetics of 
Efavirenz (EFV) by comparing the single-dose pharmacokinetics of EFV 
before administration of African Potato and after 12 days of a daily 
standardised administration of AP. EFV will be administered in each phase a 
single dose under fasting conditions. 
  
Products Reference Product 
 
 
 
Co-Administered Product 
Stocrin® 600mg tablets 
(EFV 600mg) 
MSD, South Africa 
 
African Potato extract (15mg/kg/day 
Hypoxoside) 
Standardised AP preparation 
  
Clinical Facility The research study will be conducted in the Biopharmaceutics Research 
Institute’s clinic situated on the Rhodes University campus. The clinic will be 
staffed by the Principal Investigator, co-investigator and a registered physician 
in attendance. Professional nurses will be responsible for phlebotomy and 
subject monitoring throughout the study. The study physician will be on-site 
prior to and for the first four hours after administration of the first dose in each 
phase and thereafter will be contactable by telephone.  
  
Study Design The study will be a single-dose, two-phase, SEQUENTIAL design conducted 
in normal healthy non-smoking male subjects. A single oral dose of EFV 
600mg will be administered in the fasted state before and after the repeated 
administration of a standardised African Potato preparation at a dose of 
15mg/kg/day of Hypoxoside. Not all subjects will necessarily be expected to 
begin dosing on the same day or at the same time. 
  
Number of 
Subjects 
Twelve (12) subjects will be enrolled into the study. Dropouts will not be 
replaced. Statistical analysis will be conducted on all subjects who complete 
the study. 
  
Blinding The study will be an open-label study and will not be blinded in any way. 
  
Subject 
characteristics 
Healthy non-smoking male volunteers aged between 18 and 55 years of age 
with a body mass index (BMI) between 19 and 30 will be recruited. 
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Pre-Study 
Medical 
Screening 
Subjects will be selected according to the stated inclusion and exclusion 
criteria and after providing their written informed consent to participate in the 
study. Subjects must be healthy according to the pre-study screening medical 
which will include a thorough physical examination, vital signs, medical 
history, routine laboratory tests for haematology, blood chemistry and 
urinalysis, and must test negative for Hepatitis B-antigen, Hepatitis C, Human 
Immune deficiency Virus (HIV) and selected drugs of abuse. 
  
Post-Study Tests Subjects will undergo a medical screening consisting of haematology, abridged 
blood chemistry, and urinalysis within 48hours following completion or 
termination of the study. Subjects will also be re-tested for HIV infection six 
months after the end study. 
  
Confinement Subjects will check into the clinic at least 13 hours before the scheduled dosing 
time on the evening proceeding each study day for each phase. Subjects will be 
allowed to leave the clinic after the 24 hour sample but will return for each of 
the remaining post-dose samples.  
  
Dosing On Day-1 of the study ( start of Phase 1), all subjects will receive a single oral 
dose of EFV (1 X 600mg tablet) after which blood sampling will continue for 
2 days (48hours). From Day-16 subjects will take a daily dose of AP 
(15mg/kg/day of Hypoxoside) until Day-31 i.e. daily dose for 15 days. On 
Day-29 (after 13 days of administration of AP) all subjects will receive a 
single dose of EFV (1 X 600mg tablet) (i.e. at the start of Phase 2 on Day-29) 
after which blood sampling will continue for 48hours. Each dose will be taken 
with 240ml tap water at room temperature. 
  
Sampling Blood samples will be withdrawn and collected into Vacutainer® tubes 
containing K-EDTA prior to each dosing with EFV (0.0 hr) then at 0.5, 1.0, 
1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 12.0, 18,  24, 36, 48 hr after dosing. A 
total of 17 samples will be collected from each subject for each phase.  
Blood samples will be stored in an ice-bath immediately after being taken until 
centrifugation commences. Centrifugation will commence within 30minutes of 
sample withdrawal. Duplicate aliquots of harvested plasma will be stored in 
polypropylene tubes at -80±10°C until end of phase 2. Once phase two has 
been completed, samples will be transferred immediately to the analytical 
facility. 
The total volume of blood withdrawn from each subject, including pre- and 
post study blood screening, will not exceed 460ml.  
  
Fasting The intake of food and fluid will be standardised from check-in for each phase 
until the 24hour post-dose sample has been taken. Subjects will fast for at least 
10hours prior to dosing with EFV and standard meals or snacks will be served 
at 4, 8, 12 and 24 hours after dosing. The intake of fluids will be restricted for 
1 hour before dosing to 240ml 2 hours post-dose. Water will be allowed ad. 
libitium 4 hours post-dose. Apart from study restrictions, subjects will be 
allowed to continue with their normal routine between Phases 1 and 2. 
  
Washout Period 28 days 
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Sample Analysis EFV concentrations will be determined in plasma samples using an appropriate 
and validated HPLC-UV assay. 
  
Pharmacokinetic 
Standards 
Pharmacokinetic parameters of interest for statistical analysis will be Cmax, 
AUC0-T, AUC 0-∞ and kel. A statistically significant effect of AP on EFV 
pharmacokinetics will be demonstrated if: 
1. Cmax  The mean Cmax ratio of EFV ( Cmax(after)/ Cmax(before)) lies outside 
80-125% calculated using Ln-transformed data. 
2. AUC0-T  The mean AUC0-T ratio of EFV (AUC0-T(after)/ AUC0-T(before)) 
lies outside 80-125% calculated using Ln-transformed data. 
3. AUC0-∞  The mean AUC0-∞ ratio of EFV (AUC0-∞(after)/ AUC0-∞(before)) 
lies outside 80-125% calculated using Ln-transformed data. 
4. kel   The mean kel ratio of EFV (kel (after)/ kel (before)) lies outside 80-125% 
calculated using un-transformed data 
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4. BACKGROUND INFORMATION 
4.1. EFAVIRENZ 
4.1.1. Molecular Structure 
The molecular structure of EFV is depicted below. 
N
O
H
O
Cl
F3C
 
Efavirenz 
4.1.2. Mode of Action and Uses 
EFV is a non-nucleoside reverse transcriptase inhibitor (NNRTI) effective 
against the human immunodeficiency virus type-1 (HIV-1). This activity is 
predominantly by non-competitive inhibition of the HIV-1 reverse 
transcriptase. HIV type 2 reverse transcriptase and human cellular DNA 
polymerase α, β, γ and δ are not inhibited by EFV1. 
 
4.1.3. Pharmacokinetic Parameters 
The absorption of EFV from the gastro-intestinal tract is relatively slow and 
maximum concentrations are attained about 2-5hours after administration in 
the fasted state1,2,3. Co-administration of EFV with food has been shown to 
significantly increase both Cmax and AUC1. Cmax and AUC data suggests that 
there is diminished absorption at higher doses over the range of 100 to 
1600mg. In addition, these parameters appear to be highly variable1,3. 
 
Efavirenz is metabolised predominantly by the cytochrome P450 system (CYP 
3A4 and CYP2B6) by hydroxylation and subsequent glucuronidation to 
inactive metabolites. Elimination is primarily by urinary excretion of 
metabolites and to a lesser extent by elimination of unchanged drug in the 
faeces. EFV has been shown to induce P450 enzymes which results in the 
induction of its own metabolism. This is evident by lower than expected 
accumulation and a shorter half-life following multiple dose administration1. 
 
The terminal half-life of EFV has been reported to be between 52 and 76 hours 
after a single dose and between 40 and 55 hours after multiple doses. Plasma 
protein binding is high and has been reported as 99.5-99.75%, predominantly 
to albumin. 
                                                 
1
 Package Insert, Stocrin MSD, RSA, 2006 
2
 Veldkamp AL, Harris M, Montaner JSG et al., The Journal of Infectious Diseases, 184 (2001)37-42 
3
 Vilani P, Regazzi MB, Castelli F et. al., Br. J. Clin. Pharmacol., 48 (1999) 712-715 
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4.1.4. Adverse Effects 
The majority of adverse events reported for EFV are following multiple drug 
therapies after varying periods of time. However, there is little reported on adverse 
events following single doses if EFV alone and no severe or serious adverse 
effects are expected following a single dose of this compound1. 
 
During therapy, the more serious adverse events, which present with skin 
rashes and psychiatric symptoms, generally occur after weeks to years of 
treatment. Grade 4 rashes (e.g. erythema multiforme and Steven-Johnson 
syndrome) have been reported. In the early stages of treatment, skin rashes are 
common and can occur after several days of treatment. After long-term 
treatment e.g. >1 year, psychiatric symptoms such as severe depression, 
suicidal ideation, non-fatal suicide attempts, aggressive behaviour, paranoid 
reaction and manic reactions have been observed. However, a history of 
psychiatric disorder and concurrent treatment with psychiatric medication are 
associated with these symptoms1. 
 
More common but less serious adverse events generally present with nervous 
system symptoms of dizziness, insomnia, impaired concentration, 
somnolescence, abnormal dreams and hallucinations. These symptoms can 
begin on the first or second day of therapy, however symptoms generally 
resolve after 2-4 weeks of continued therapy1. 
 
4.1.5. Contraindications 
EFV must not be administered to individuals who have an allergy to this 
compound or any of the tablet ingredients. EFV must be administered with 
caution to individuals who have a past history of psychiatric disorder and 
when medications for other ailments are given concurrently1. However, in this 
study, volunteers taking any medications will be excluded from the study. 
 
 
 
 
5. STUDY DRUGS 
5.1. Description 
 
 Reference Product Co-Administered Product 
Generic Name Efavirenz African Potato  
Hypoxis hemerocallidea 
Commercial Name Stocrin® 600mg Tablets African Potato Extract 
Dosage Form Immediate Release Tablets Liquid Decoction 
Strength Equivalent to 600mg 
Efavirenz 
Equivalent to 15mg/kg/day 
Hypoxoside 
Manufacturer Merck Sharpe and Dohme 
(MSD) South Africa 
Faculty of Pharmacy 
Rhodes University 
Dosage 1 X 600mg tablet each phase Equivalent to 15mg/kg 
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Hypoxoside from Day-17 to 
Day-31 
5.2. Supply and Storage 
Sufficient reference and co-administered products will be provided for the 
study. The quantity as well as any batch number where appropriate, will be 
recorded in the appropriate register. Dispensing and administration of 
reference and co-administered products will also be recorded. 
 
A decoction of African Potato will be freshly prepared in the traditional 
manner and administered to subjects on a daily basis for 15 days. This is done 
by boiling African Potato in water and based on its hypoxoside content; each 
subject will receive an aqueous dose corresponding to 15mg/kg body weight. 
 
Unused products will be stored for two years after the submission of the final 
report after which they will be disposed appropriately. 
 
 
 
 
6. Objectives 
 
The use of traditional medicine and Natural Health Products (NHPs) is widespread among 
people living with HIV/AIDS4. Many HIV/AIDS patients take a wide range of NHPs in 
addition to their conventional therapeutic products for HIV/AIDS as well as for related 
problems including dermatological, nausea, depression, insomnia and weakness. In 
Africa, herbal medicines are at times used as primary treatment of HIV/AIDS. The 
African Potato (Hypoxis hemerocallidea) is a common traditional medicine used in Africa 
by HIV/AIDS patients as an alleged immune booster and for various other conditions. 
 
Preliminary in vitro studies have identified the potential for Hypoxis hemerocallidea to 
cause early inhibition of certain ARV metabolic mechanisms followed by induction of the 
same mechanisms after prolonged therapy4. Initially this can increase the risk of serious 
adverse events due to increased exposure to the ARV, followed later by other adverse 
drug events such as drug resistance due to increased exposure. Inhibition/induction of the 
cytochrome P450 enzyme CYP3A4 by African Potato has been implicated in this effect. 
 
Phase 1 trials have been conducted that show that Hypoxoside is not toxic and no side 
effects have been reported at high doses 4,5,6. 
 
                                                 
4
 Albrecht C.F., Kruger B.P, Smit B.J, Freestone M, Gouws L, Miller R, van Jaarsveld P.P, The 
pharmacokinetic behaviour of hypoxoside taken orally by patients with lung cancer in phase I trial, 
SAMJ, 85 (1995) 861-865 
5
 Albrecht C.F., Kruger B.P, Smit B.J, Freestone M, Gouws L, et. al, A phase I trial  of hypoxoside as 
an oral prodrug for cancer therapy-absence of toxicity, SAMJ, 85 (1995) 865-870 
6
 Laporta O, Perez-Fons L, Mallavia R, Caturla N, Micol V. Isolation, characterisation and antioxidant 
capacity assessment of the bioactive compounds derived from hypoxis rooperi corm extract (African 
Potato). Food Chemistry. 101 (2007) 1425-1437. 
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Efavirenz is an ARV used widely in combination first-line therapy and is metabolised 
significantly by CYP2B6. The objective of this in vivo study is therefore to determine 
whether African Potato influences the pharmacokinetics of Efavirenz. 
 
7. STUDY DESIGN 
 
This drug-interaction study is designed to determine the pharmacokinetics of Efavirenz 
before and after co-administration with African Potato and subsequently determine the 
influence of African Potato on the pharmacokinetics of this ARV agent. 
 
The study will be a single-dose, two-phase, sequential design in healthy male non-
smoking volunteers which will be conducted over a period of 31 days. On Day-1 of the 
study (start of Phase 1), all subjects will receive a single oral dose of EFV (1 X 600mg 
tablet) after which blood sampling will continue for two days (48 hours). From Day-17 
subjects will take a daily dose of African Potato (15mg/kg/day of Hypoxoside) until Day-
31 i.e. daily for 15 days until the end of the study. On Day-29 (after 12 days of 
administration of African Potato) all subjects will receive a single oral dose of EFV (1 X 
600mg tablet) (i.e. at the start of the Phase 2 on Day-29) after which blood sampling will 
continue for two days (48 hours). Each dose will be taken with 240ml of tap water at 
room temperature. Plasma will be harvested and assayed. Pharmacokinetics of EFV will 
be evaluated following each dose. 
 
The washout period between EFV doses will be 28 days. Not all subjects will necessarily 
be expected to start on the same day. Data from all subjects who complete both phases 
will be included in the statistical analysis and the final report. 
 
8. STANDARDS FOR BIOEQUIVALENCE, PHARMACOKINETICS 
AND STATISTICS 
 
8.1. Standards for Pharmacokinetic Evaluation 
Pharmacokinetic parameters for EFV before and after administration of African Potato 
will be determined. Statistically significant effect of African Potato on EFV 
pharmacokinetics will be demonstrated if: 
 
1. Cmax  The mean Cmax ratio of EFV ( Cmax(after)/ Cmax(before)) lies outside 80-125% 
calculated using Ln-transformed data. 
2. AUC0-T  The mean AUC0-T ratio of EFV (AUC0-T(after)/ AUC0-T(before)) lies outside 80-
125% calculated using Ln-transformed data. 
3. AUC0-∞  The mean AUC0-∞ ratio of EFV (AUC0-∞(after)/ AUC0-∞(before)) lies outside 80-
125% calculated using Ln-transformed data. 
4. kel   The mean kel ratio of EFV (kel (after)/ kel (before)) lies outside 80-125% calculated 
using un-transformed data. 
 
  
 
120 
 
8.2. Pharmacokinetics and Statistics 
Pharmacokinetic and statistical parameters will be determined using the SAS statistical 
package. 
 
8.2.1. Pharmacokinetic Analysis 
EFV plasma concentration vs. time profiles will be constructed and the following 
pharmacokinetic parameters derived there from: 
 
 
 
1. Cmax The maximum concentration of EFV in a subject’s plasma. 
2. Clast The last measurable concentration. 
3. Tmax The sample time at which the Cmax was attained. If this occurs at more than 
one time pint, it is identified as the first time point with this value (hour). 
4. Tlast The time of the last quantifiable concentration (hour). 
5. Tlin The time point where log linear elimination begins (hour). 
6. AUC0-T The cumulative area under the plasma concentration vs. time curve from the 
time zero to the last post-dose sample at the last measurable concentration, 
determined using trapezoidal rule. 
7. AUC0-∞   The area under the extrapolated plasma concentration vs. time curve from 
time zero to infinity, calculated as the sum of the AUC0-T and Clast /kel. 
8. AUC0-T/0-∞ The percent ratio of AUC0-T to AUC0-∞  as a measure of the extent to which 
elimination of the drug was followed. 
9. kel The apparent first-order terminal elimination rate constant calculated by linear 
regression of the terminal linear portion of a semi-logarithmic plot of plasma 
concentrations. Time using at least the last three measurable concentrations. 
10. T1/2el Mean elimination half-life (hour). 
 
 
 
 Kel, T1/2el, AUC0-∞, AUC0-T/0-∞ and Tlin will not be calculated for concentration vs. 
time profiles that do not exhibit a terminal log-linear phase. 
 
8.2.2. Statistical Analysis 
Descriptive statistical parameters of the mean, standard deviation (SD) and coefficient of 
variation (CV%), will be calculated for the demographic variables of age, height, weight and 
Body Mass Index (BMI). These statistical parameters will also be calculated for plasma 
concentrations at each individual time point as well as for the pharmacokinetic parameters 
listed in Section 8.2.1. In addition to the descriptive statistics described above, ANOVA 
analysis will be conducted for additional information. These analyses will be conducted on 
Cmax, AUC0-T, and AUC0-∞ using ln-transformed data and on Tmax and kel using untransformed 
data. If a pharmacokinetic parameter of a subject cannot be determined for one period, the 
subject will be excluded from that particular statistical comparison. 
 
If a pre-dose concentration of EFV is detected in Phase 2, the subject’s data can be included 
in the statistical analysis, without adjustment, if it represents less than 5% of the Cmax value. 
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If this is greater than 5% of the Cmax value, the subject will be dropped from the evaluations 
of pharmacokinetic changes. 
 
 
9. STUDY POPULATION AND MEDICAL ASSESSMENT 
 
9.1. Number of Subjects 
As an initial investigation the effect of African Potato on the pharmacokinetics of EFV, 
12 subjects will be enrolled. Dropouts will not be replaced. All subjects who complete the 
study will be included in the statistical analysis as detailed in Section 8.2.2. 
 
9.2. Inclusion Criteria 
Only subjects meeting the following criteria may be included in the study: 
 
1.  Mentally competent subjects who are available for the entire study period and willing to 
adhere to the protocol requirements and able to give informed consent by signing the 
informed consent form. 
2.  Males between ages 18 and 55 years of age. 
3.  Volunteers with a BMI of between 19 and 30. 
4.  Non-smoking volunteers who have not smoked for at least two months. 
5.  Normal in terms of medical history at the pre-study screening medical, or in the case of 
an abnormality, if the medical practitioner considers the abnormality to be clinically 
significant. 
6.  Normal in terms of physical examination at the pre-study screening medical, or in the 
case of an abnormality, if the medical practitioner considers the abnormality to be 
clinically significant. 
7.  Normal in terms of laboratory test values for the pre-study screening medical within the 
laboratory’s stated normal range, or in the case of an abnormality, if the medical 
practitioner considers the abnormality to be clinically significant. 
 
 
9.3. Exclusion Criteria 
 
1.  Any history of hypersensitivity or idiosyncratic reaction to EFV or AP. 
2.  Any history of cardiovascular abnormality or disease. 
3.  Any history of liver dysfunction. 
4.  Any history of anaemia or cytopenia. 
5.  Any history of renal dysfunction. 
6.  Any history of adrenal or pituitary insufficiency. 
7.  Any history of chronic asthma, bronchitis or other bronchospastic conditions. 
8.  Any history of epilepsy or other convulsive disorders. 
9.  Any history of psychiatric disorders including depression or mania. 
10.  Any history or other condition which the study physician regards as clinically significant 
to the study (including fainting upon blood sampling). 
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11.  Any history of drug or alcohol abuse or other use of tobacco within two months of the 
study start date. 
12.  Treatment with any drug known to have a well-defined potential for toxicity to one of the 
major organs, particularly renal and hepatic toxicity, within three months of the study 
start date. 
13.  Treatment with any drug which could modify renal excretion of drugs (e.g. probenecid) 
within one month of the study start date. 
14.  The intake of a restricted or abnormal diet for longer than a week within 4 weeks of the 
study start date. 
15.  Maintenance therapy with any drug or regular use of chronic medication. 
16.  A major illness considered to be clinically significant by the study physician within 3 
months of the study start date. 
17.  Participation in another study or the donation of one pint or more of blood within 1 
month of the study start date. 
18.  A positive test for Hepatitis B surface antigen, Hepatitis C or HIV. 
19.  Treatment with any prescription drug within one week of the study start date, unless the 
drug is considered to be clinically insignificant by the study physician. 
20.  Treatment with any Over The Counter (OTC) drug within one week of the study start 
date, unless the drug is considered to be clinically insignificant by the study physician. 
21.  The consumption of alcohol or other enzyme inducing agents within 96 hours of the start 
date (all barbiturates, corticosteroids, phenylhydantoins etc.). 
22.  Any vomiting or diarrhoea within 24 hours of dosing. 
23.  A positive urine test for any drug of abuse tested for at the pre-study screening medical 
or at check-in. 
 
 
9.4. Concomitant Medication and Subject Restrictions 
 
1. Medication No prescription medication or OTC medication (cold preparations, 
vitamins, complementary medicines or natural products used for therapeutic 
benefits, antacids) will be allowed for at least one week prior to the study. 
Any medication taken between the screening medical and dosing will be 
assessed for its effect on the study and subjects may be excluded if 
necessary. 
 
With exception of study drugs no concomitant medication may be taken by 
subjects during the study. 
 
2. Alcohol No alcohol may be taken by subjects from 96 hours prior to dosing until the 
last sample of each phase has been taken and after Phase 2 until the post-
study clinical investigations have been completed.  
 
3. Caffeine No caffeine containing beverages and foods (e.g. tea, coffee, cola drinks, 
and chocolate) may be taken by subjects from 48hours before dosing until 
the last sample of each phase has been taken. 
 
4. Exercise No strenuous physical activity may be undertaken by subjects from 24 
hours before each phase until the last sample of Phase 1 has been taken and 
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until the post study clinical investigations after phase two have been 
completed. 
 
5. Smoking Subjects must not have smoked for at least 2 months prior to the study and 
will refrain from smoking until the end of the second phase after the last 
sample has been withdrawn. 
 
6. Grapefruit No grapefruit juice may be consumed within 48 hours before each phase 
and until the end of each phase. 
 
Subjects will be informed of the above restrictions and each subject will be specifically 
questioned on these points prior to drug administration. Any deviations from the above 
restrictions which are made known to the investigators either voluntarily or on 
questioning will be recorded on the appropriate Case Report Form (CRF). A decision as 
to whether the affected subject continues with the study will be taken by the Principal 
Investigator in consultation with the Co-Investigator. 
 
9.5. Criteria for removal from the Study 
 
 Any subject may withdraw voluntarily due to any reason. 
In addition, any subject may be withdrawn from the study at any time due to: 
 
1.  Illness or injury during the study if regarded as clinically significant by the study 
physician. 
2.  Any adverse event or signs of toxicity if regarded as clinically significant by the study 
physician. 
3.  Failure of the subject to comply with or be uncooperative towards any study 
requirements if regarded as clinically significant by the study physician. 
4.  If it is determined that the subject did not follow pre-study directions regarding 
alcohol, drug use, fasting etc. the study physician or the Principal Investigator can 
remove the subject from the study. 
 
 
A post-study medical will be conducted on any subject who withdraws from the study and 
any follow-up procedures where necessary. Reasons for a subject’s withdrawal will be 
documented in the subject’s CRF and in the final study report. Blood concentration data of a 
subject who withdraws due to drug adverse reaction will be presented in the final report. 
However, this data will not be presented for a subject who withdraws voluntarily or is 
removed from the study due reasons other than an adverse event. 
 
10. STUDY PROCEDURE 
 
10.1. Pre- and Post-Study Medical Screening 
Pre- and post-study evaluations will be conducted as listed in the table below. 
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Pre-study screening will be conducted not more than 30 days prior to the start of Phase 1. 
Post study screening will be conducted within 48 hours of the final sample of Phase 2 or 
termination of the study. 
 
Screening Test Pre-Study Post-Study 
Medical History Yes1 Yes8 
Physical Examination Yes2 No 
Haematology Yes3 Yes3 
Blood Chemistry Yes4 Yes9 
Urinalysis Yes5 Yes5 
Serology Yes6 Yes10,12 
Drugs-of-Abuse Yes7 no 
Yesn – tests conducted as per footnote # “n”, No- Tests not conducted. 
 
 
1. Medical History: Demographic data ( date of birth, age, sex, origin), emotional (psychiatric), cns, ears-
eye-nose-throat, cardiovascular, respiratory, hepatic, gastrointestinal, renal, 
genitourinary, endocrine, metabolic, musculoskeletal, skin (dermatological), 
connective tissue and blood lymphatic illness, allergies, blood donation, alcohol 
consumption, smoking habits and sporting commitments. 
2. Physical: Demographic data (height, weight, BMI), vital signs (BP, pulse, oral temperature), 
skin, head-neck, thyroid, eyes, ears-nose-throat, chest, lungs, heart, 10 Lead ECG, 
neurological, musculoskeletal, abdomen, nutritional status, JACCOL (jaundice, 
anaemia, cyanosis, clubbing, oedema, lymphadenopathy). 
3. Haematology: Haemoglobin, total and differential red blood cell count, haematocrit, total and 
differential white cell count, platelet count and sedimentation rate. 
4. Blood Chemistry: Sodium, potassium, chloride, urea, urate, creatinine, cholesterol, random glucose, total 
protein, albumin, total and conjugated bilirubin, alkaline phosphates, GGT (glutamyl 
transpeptidase), ALT (alanine transaminase) and AST (aspartate transaminase) 
5. Urinalysis: Appearance, microscopic examination if positive of sediment, glucose, ketones, blood 
protein, nitrite, specific gravity, pH, leucocyte esterase, bilirubin and urobilinogen. 
6. Serology: Hepatitis: B S-antigen and C, HIV 
7. Drugs-of-Abuse: Urine samples from each subject will be tested for methaqualone by the contracted 
registered pathology laboratory at the time of the pre-study screening medical. Urine 
samples from each subject will be tested for amphetamines, barbiturates, 
benzodiazepines, cocaine, methamphetamine, morphine, phencyclidine, THC, TCA, 
and ethyl alcohol at each check-in using test kits. 
8. Medical History: Since start of Phase1. 
9. Blood Chemistry: Urea, urate, alkaline phosphatise, GGT (glutamyl transpeptidase), ALT (alanine 
transaminase) and AST (aspartate transaminase), total and conjugated bilirubin. 
10. Blood Analysis: Baseline full blood counts (FBCs) will be determined immediately prior to the first 
African Potato dose, weekly thereafter during the full period of African Potato dosing. 
11. Histology: Peripheral blood smears for microscopy. 
12. Serology: HIV 6 months after end of study 
 
If any study related abnormalities are observed at the post-study medical, appropriate 
follow-up action will be taken and re-examination and re-testing conducted until the 
abnormality returns to normal or until the Principal Investigator considers the abnormality 
as clinically significant. Clinically significant abnormal laboratory values will be reported 
as an adverse event. 
 
10.2. Rationale for HIV Screening 
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HIV screening will be conducted prior to the study and volunteers who are HIV-positive 
will be excluded from participation. This is necessary to prevent persons being exposed to 
single doses of EFV, which could result in HIV resistance to EFV and significantly 
compromise the individual’s future treatment. However, the possibility exists that 
subjects enrolled into the study may have been infected with HIV at the time of screening, 
but were in the “window period” and not detected as HIV-positive. In addition, subjects 
could become infected during the study. In these cases subjects infected with HIV would 
inadvertently exposed to the EFV. Appropriate modification of anti-HIV treatment would 
then be necessary. The duration of the window period varies from subject to subject and 
on the type and sensitivity of the HIV test conducted, and may be from ten days to six 
months. For the ELISA HIV screening tests which will be used for this study, it is 
generally accepted that this period is a maximum of six months. Screening at the end of 
the maximum window period post-study will ensure that any subject who was infected 
with HIV at the time of the study will be detected, although it should be noted that an 
HIV-positive result at this time does not necessarily mean the subject was infected during 
the study. All subjects who take EFV during the course of the study will therefore be 
screened for HIV six months post-study. The participant will undergo the standard pre- 
and post-counselling for this test. Furthermore, the participant will be advised to notify 
their own medical practitioner that they have received two single doses of EFV as this 
may affect their future antiretroviral therapy. 
 
10.3. Clinic Check-in and Confinement 
 
Subjects will undergo a brief medical examination at the check-in, inclusion and 
exclusion criteria check, study restriction check, and urine screening for the specified 
drugs of abuse. 
 
Subjects accepted into the study will remain in the clinic from check-in until the 24 hour 
post-dose blood sample has been taken. Subjects will then be allowed to leave the clinic 
provided that there are no significant symptoms or adverse events present. Thereafter, 
they will return for each of the remaining samples. Dosing with EFV for each phase will 
be 28 days apart. 
 
10.4. Preparation for Dosing and Dosing instructions 
 
The study will be a single-dose, two-phase, sequential design in healthy male non-
smoking volunteers which will be conducted over a period of 31 days. On Day-1 of the 
study (start of Phase 1), all subjects will receive a single oral dose of EFV (1 X 600mg 
tablet) after which blood sampling will continue for two days (48 hours). From Day-17 
subjects will take a daily dose of African Potato (15mg/kg/day of Hypoxoside) until Day-
31 i.e. daily for 15 days until the end of the study. On Day-29 (after 12 days of 
administration of African Potato) all subjects will receive a single oral dose of EFV (1 X 
600 mg tablet)( i.e. at the start of the Phase 2 on Day-29) after which blood sampling will 
continue for two days (48 hours). Each dose will be taken with 240 ml of tap water at 
room temperature. 
 
Prior to each subject’s scheduled dosing time an indwelling cannula will be inserted into 
an arm vein and a pre-dose blood sample taken. Vital signs (blood pressure and pulse) 
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will be monitored. At the scheduled dosing time for each phase, subjects will receive one 
oral dose of EFV. Each dose will be taken with 240ml of tap water at room temperature. 
A mouth and hand check will be conducted to confirm that the dose has been ingested. 
 
10.5. Posture and Physical Activity 
 
Subjects will be seated for the first 4 hours after drug administration and will not be 
permitted to lie down or sleep until after 4 hours post-dose, unless this is necessary due to 
an adverse event. Subjects will be required to adhere to restrictions on physical activity 
after leaving the clinic following 24 hours post-dose sample until after the last sample has 
been taken. 
 
10.6. Blood Sampling, Processing and Storage 
 
Blood samples collected during the first 12 hours after dosing will be collected into 10ml 
syringes via an intravenous cannula then transferred directly into 10ml Vacutainer® tubes 
containing K-EDTA. Subsequent samples will be collected by repeat venipuncture. 
Samples (10ml) will be withdrawn at the time of cannulation (pre-dose, 0.0) then at the 
following time points: 
 
0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 12, 18, 24, 36 and 48 hours after dosing. 
 
A total of 17 samples will be collected from each subject for each phase. 
 
The clinic clock time of the blood samples will be recorded and reported for each subject. 
Any deviation from the sampling time schedule will be recorded and reported for each 
subject. The total amount of blood collected from each subject over the entire period, 
including blood samples withdrawn for pre- and post screening test, will not be greater 
than 460ml. 
 
Blood samples will be stored in an ice-bath immediately after being taken and until 
centrifugation commences. Centrifugation at 2800rpm for 10 minutes at 4ºC will 
commence within 30 minutes of sampling time. Duplicate aliquots of harvested plasma 
will be stored in polypropylene tubes at -80 ± 10 ºC until transfer to the analytical facility. 
The tubes will be labelled with study number, phase number, subject number, sample 
number and sampling time. 
10.7. Fasting, Refreshments and Meals 
 
 
1. Food and fluid intake will be standardised from the time subjects check-in at the clinic 
until the 24 hour post-dose. 
2. Water will be allowed ad libitium until 07.00 am on the morning of dosing i.e. no water at 
least 1 hour before dosing. Thereafter, water will be restricted until 2 hours post dose 
where 240ml where 240ml will be given at the time of dosing and 240ml 2 hours after 
dosing. 
3. The following standard xanthine free meals, snacks and refreshments (caffeine free cola) 
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will be provided:- 
 
 4 hours post-dose lunch Chicken, vegetables, salad, fruit 
salad, soda 
8 hours post-dose snack Cake and soda 
12 hours post dose dinner Pizza, salad, fruit, and soda 
 24 hours post dose breakfast Toast, juice, fruit, egg 
 
4. Water will be permitted ad libitium 4 hours post-dose. 
 
10.8. Subject Monitoring 
 
1.  The study physician will remain at the clinic from before the commencement of the 
dosing until 4 hours after the first dose has been administered, and be contactable by 
phone for the duration of the study. 
2.  Blood pressure and pulse will be checked just prior to dosing then after sampling at 4 
and 8 hours post-dose. Additional readings will be taken if necessary. 
3.  Subjects will be asked open-ended questions about their health at the time of removal 
of each blood sample. 
4.  Clinic nursing staff will ensure that subjects adhere to the restrictions regarding 
posture, movement and the consumption of food and beverages while at the clinic. 
 
11. ETHICAL AND REGULATORY REQUIREMENTS 
 
11.1. Ethical and Institutional Review 
Approval by the Rhodes University Ethical Standards Committee (RUESC) will be 
obtained before the study commences. A letter of approval and a list of committee 
members and their qualifications will be provided to the funding body. The original 
signed letter of the ethical approval will be retained. 
 
The study will be conducted in accordance with the recommendations of the guidelines as 
set out in the Declaration of Helsinki (1964) and its amendments of Tokyo (1975), Venice 
(1983), Hong Kong (1989), Somerset West (1996) and Edinburgh (2000), according to 
ICH Good Clinical Practice (GCP) guidelines, BRI standard operating procedures (SOPs) 
and in compliance with South African regulatory authority requirements. 
 
11.2. Written Informed Consent 
 
Preceding the study, the nature, purpose and the risk of participating in the study will be 
explained to all volunteers. If volunteers desire, they will be given time to consider the 
information and any questions that they might have will be answered. The nature of the 
insurance cover will also be explained. They will also be informed that they may 
withdraw from the study at any time without penalty to themselves (other than a reduced 
remuneration) but that they must be committed to completing the study prior to their 
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enrolment. Subjects will receive written, detailed instructions concerning the study 
performance and restrictions. 
 
11.3. Case Report Forms 
 
All CRFs will be Quality Assured and all major events such as final acceptance of a 
subject adverse event and final release from the study will be signed by the Principal 
Investigator and a copy included in the final report if requested. 
 
 
11.4. Quality Assurance 
 
Designated personnel are responsible for maintaining quality assurance and quality 
control systems with written Standard Operating Procedures (SOPs) to ensure that the 
study is conducted and that data are generated, documented and reported in compliance 
with the study protocol, GCP and applicable regulatory requirements. 
 
 
11.5. Record Retention 
 
All source documents, study reports and other study documentation will be archived and 
retained for a period of 10 years after the completion of the study or for a longer period if 
required. 
 
11.6. Insurance 
 
The BRI will undertake to provide adequate insurance cover on behalf of the Sponsor. 
Insurance is in accordance with ABPI guidelines and documentation of the policy will be 
made available for scrutiny by the funder and volunteers at their request. A copy of the 
insurance certificate will be provided to the South African Medical control Council as 
part of application to the MCC to conduct a clinical study. The funder will not be liable in 
the event of negligence on the part of study subjects, investigators, employees and 
personnel of the BRI. The BRI will be responsible for adequate insurance cover for these 
events. Insurance compensation is only payable in cases where a physical disability arises 
as a direct result of participation in the study. Compensation is determined by the nature 
and severity of the physical disability as assessed by qualified medical practitioners and 
according to a standardised scale. A maximum of R1 000 000.00 can be paid to any one 
subject. Medical expenses up to R50 000.00 which result directly from participation in 
the study are covered by insurance. 
 
11.7. Termination of the Study 
 
The Faculty of Pharmacy reserves the right to terminate the study in the interests of 
subject welfare following consultation with the Principal Investigator. The Principal 
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Investigator may terminate the study at any time for scientific or corporate reasons. If the 
study is prematurely terminated or suspended for any reason the Principal Investigator 
will promptly inform the subjects, take appropriate steps as deemed necessary under the 
circumstances to assure the subjects and where applicable follow up with therapy and 
inform the regulatory authorities. 
 
11.8. Monitoring of the Study 
 
An external monitor will not be required for this study. 
 
11.9. Adherence to Protocol 
 
Excluding an emergency situation in which proper treatment is required for the 
protection, safety and well-being of the study subjects, the study will be conducted as 
described in the approved protocol and performed according to ICH and GCP guidelines. 
Any deviation from the protocol will be recorded and explained. 
 
Should amendments to the protocol be required, the amendments will be documented and 
signed by the Principal Investigator. If a protocol amendment has an impact on the safety 
of subjects, such as a change in dosing regimen or additional blood draws, the amendment 
will be resubmitted to the Institutional Review Board for approval. 
 
11.10. Blinding 
 
The study will be open-label study and will not be blinded in any way. 
 
11.11. Drug Accountability 
 
See Section 5.2. 
 
11.12. Adverse Events/Adverse Drug Reactions 
 
Subjects will be questioned on their health status at check-ins for each study period, 
during the study period and before leaving the clinic at the end of each phase. During the 
study, open-ended questions will be asked. If any adverse events are reported, the study 
physician will monitor the adverse event, initiate appropriate treatment if require and 
decide whether or not to withdraw the subject from the study. Signs and symptoms of any 
adverse events (AEs) which occur during the study will be fully documented in the 
appropriate CRF. 
 
Adverse events (which include illnesses, subjective and objective signs and symptoms 
that have appeared or worsened during the course of the study and significant shifts in 
laboratory values or vital signs) will be assessed by the study physician during and after 
each phase of the study to determine whether or not they are related to the investigational 
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products (an Adverse Drug Reaction or ADR), to the study procedure or other. The 
outcome of this assessment will be recoded in the appropriate CRF. 
 
AEs classified as serious will be reported to the Principal Investigator and the Rhodes 
University Ethical Standards Committee. 
 
ADRs classified as serious and unexpected will be subject to expedited reporting as 
detailed in the ICH E2A and E2B guidelines on Clinical Safety Data Management and 
Data Elements for Transmission of Individual Case Report Forms respectively. The 
Principal Investigator will inform the sponsor, within the time specified in the protocol, of 
any serious or unexpected adverse events occurring during the study. A serious adverse 
event initial report form and any relevant follow-up information will be sent to the 
Sponsor, who in turn should forward the relevant information to the appropriate ethics 
committee and regulatory authority. A serious adverse event will be reported within 24 
hours, whilst unexpected AEs will be reported without undue delay. 
 
Samples obtained from a subject who withdraws due to an adverse event will be assayed 
for EFV. The withdrawn volunteer’s plasma level data will be provided in the final report 
but will not be included in the statistical analysis. If the volunteer is withdrawn due to 
pharmacokinetic reasons i.e. non or mal-absorption of the drug for reasons such as 
vomiting, diarrhoea or a drug dosing problem, or, if the volunteer withdraws voluntarily 
for personal reasons, plasma level data are not required and samples collected there from 
all not be analysed. 
 
 
12. SAMPLE ANALYSIS AND STORAGE 
 
12.1. Analytical Facility 
Study samples will be analysed at the analytical facility detailed in Section2. 
12.2. Sample storage 
 
Study samples will be stored at -80 ±10ºC immediately after harvesting. These samples 
will be transferred to the analytical facility at the Faculty of Pharmacy, Rhodes University 
in dry ice and maintained at a temperature of -10±2ºC until analysis. 
12.3. Analytical Method 
 
Analysis of the samples will be undertaken in the laboratories of the Faculty of Pharmacy. 
12.4. Quality Control Samples 
 
Quality control samples will be prepared and analysed according to the relevant SOP of 
the analytical site. 
12.5. Aberrant Values and Retested Samples 
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Unacceptable values attributable to analytical or pharmacokinetic reasons will be re-
assayed. Final concentrations will be chosen according to the analytical site’s procedures. 
All cases of re-assay will be reported in the final report. 
13. REPORTS 
 
A full report on the clinical, analytical and statistical sections of the study will be 
prepared. 
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ANNEXURE II 
 
 
 
RAW DATA OF PHARMACOKINETIC PARAMETERS AND COCENTRATIONS OF 
STUDY PLASMA STANDARDS, QC SAMPLES AND SUBJECT SAMPLES 
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Table 1. Summary of batches for EFV in human plasma 
 
Description Extraction Date Regression Status Comment 
Day 01 Subjects 1, 2, 3, 4 09- December-2007 Accepted  OK 
Day 02 Subjects 5,8,9 10- December-2007 Accepted  OK 
Day 03 Subjects 6,7 12- December-2007 Accepted  OK 
 
 
Table 2. Calibration plot parameters for EFV in human Plasma 
 
Batch date Curve plot slope intercept Correlation coefficient (r2) 
09- December-2007 1 0.26 -0.022 0.999 
10- December-2007 2 0.221 -0.021 0.999 
12- December-2007 3 0.218 0.001 0.999 
 
 
Table 3. Inter-assay precision ad accuracy fro calibration standards for EFV in human plasma 
 
 
Batch date Analytical 
run 
number 
STD A STD B STD C STD D STD E STD F STD G 
09- December-2007 01 106.51 101.79 98.64 103.12 99.99 98.29 100.41 
10- December-2007 02 117.02 108.02 103.33 99.63 96.04 98.63 100.57 
12- December-2007 03 87.87 92.39 95.60 95.35 105.96 100.98 99.47 
Mean  106.98 100.73 99.19 99.37 100.66 99.30 100.15 
STD 19.36 7.87 3.89 3.89 4.99 1.46 0.60 
%RSD 18.09 7.81 3.92 3.92 4.96 1.48 0.59 
n 3 3 3 3 3 3 3 
 
 
 
 
Table 3. Inter-assay precision ad accuracy fro calibration standards for quality control 
samples for EFV in human plasma 
 
Batch date Plot 
Number 
QC A QC B QC C 
09- December-2007 
 
1 105.55 86.16 101.82 
113.49 87.16 93.54 
10- December-2007 
 
2 104.04 102.93 108.29 
107.72 103.10 107.84 
12- December-2007 3 102.57 101.43 102.54 
96.26 103.08 102.24 
MEAN  104.94 97.31 102.71 
STD  5.71 8.28 5.34 
%RSD  5.44 8.51 5.20 
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Table 5. Final concentrations for EFV in Human Plasma (µg/ml) of subjects samples 
 
Subject Period* 0 0.5 1 1.5 2 2.5 3 3.5 4 5 6 8 12 18 24 36 48 
01 1 0.00 0.00 0.62 0.89 0.98 1.71 1.38 1.57 2.76 3.05 2.39 1.86 1.07 1.04 1.00 0.67 0.67 
01 2 0.00 0.46 1.08 1.54 2.07 2.77 2.44 3.01 2.77 2.35 1.90 1.75 1.20 0.98 0.96 0.77 0.50 
02 1 0.00 0.08 1.36 2.27 2.61 1.96 1.77 1.91 1.76 1.26 0.91 0.81 0.81 0.68 0.62 0.58 0.49 
02 2 0.00 0.13 2.22 2.30 2.30 2.17 1.89 1.89 1.78 1.55 1.54 1.13 0.98 0.64 0.68 0.45 0.40 
03 1 0.00 0.56 1.42 2.01 2.19 2.28 2.25 2.29 2.19 1.88 1.52 1.42 1.22 0.88 0.88 0.81 0.69 
03 2 0.00 0.00 0.85 1.34 1.66 1.66 1.70 1.65 1.64 1.34 1.23 1.14 0.95 0.70 0.62 0.51 0.41 
04 1 0.00 0.32 1.02 1.69 2.40 2.55 2.39 2.45 2.36 2.09 2.09 1.60 1.60 1.39 1.24 1.17 0.81 
04 2 0.00 0.05 1.06 1.35 1.36 1.60 1.54 1.47 1.43 1.46 1.23 0.98 0.88 0.93 0.84 0.75 0.67 
05 1 0.00 0.17 0.69 1.30 2.72 2.41 2.41 2.24 2.27 2.00 1.69 1.63 1.55 1.34 1.28 1.22 0.81 
05 2 0.00 0.24 1.33 2.71 2.90 2.81 2.38 2.45 2.47 2.18 1.78 1.43 1.26 1.12 0.93 0.85 0.72 
06 1 0.00 0.60 1.68 1.88 1.65 1.55 1.64 1.43 1.34 1.16 1.00 0.76 0.79 0.58 0.73 0.68 0.49 
06 2 0.00 0.00 0.15 0.28 0.43 1.07 1.38 1.74 2.89 3.14 1.99 1.66 1.18 0.88 0.83 0.72 0.57 
07 1 0.00 0.00 0.14 0.22 0.33 0.72 0.64 1.06 1.23 2.19 2.70 2.07 1.71 1.49 1.32 1.27 0.72 
07 2 0.00 0.34 1.11 1.79 1.99 2.05 2.11 2.13 2.19 1.89 1.85 1.65 1.57 1.32 1.31 1.78 0.85 
08 1 0.00 0.43 1.71 2.42 2.49 2.10 1.94 1.87 1.67 1.42 1.32 1.16 1.36 1.15 1.06 0.89 0.56 
08 2 0.00 0.33 1.07 1.42 1.52 2.76 3.26 3.03 2.96 1.89 2.23 1.43 1.34 0.99 1.05 0.73 0.48 
09 1 0.00 0.30 1.53 1.49 1.57 1.70 1.62 1.88 1.62 1.48 1.29 1.30 1.22 0.99 0.99 1.11 0.63 
09 2 0.00 0.38 1.02 1.72 2.74 2.97 3.34 3.00 2.76 2.65 2.70 2.33 1.87 1.35 1.25 1.00 0.76 
10 1 0.00 0.46 0.74 1.38 1.70 1.76 1.96 1.91 1.66 1.28 1.04 0.91 0.72 0.47 0.48 0.35 0.27 
10 2 0.00 0.19 1.26 1.89 1.65 1.81 1.65 1.61 1.57 1.11 0.94 0.75 0.55 0.35 0.48 0.37 0.30 
• *Period : 1 is for EFV administered alone and 2 for EFV co-administered with AP 
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Figure 1. Plasma concentration vs time profiles of 10 subjects after administration with a 
single dose of EFV 600 mg tablet alone and after co-administered with AP  
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Table 6 Pharmacokinetic parameters of EFV before and after co-administration with AP 
 
EFV administered alone 
Subject CMAX TMAX AUCT AUCI KEL LQCT THALF 
1 3.05 5 50.606 87.614 0.0169 48 40.94 
2 2.606 2 35.871 84.295 0.0102 48 67.64 
3 2.2884 3.5 49.813 134.92 0.0083 48 83.21 
4 2.5473 2.5 64.533 116.62 0.0165 48 41.97 
5 2.7205 2 63.872 120.24 0.0156 48 44.32 
6 1.8832 1.5 36.278 111.29 0.0072 48 95.76 
7 2.702 6 63.792 99.857 0.0222 48 31.18 
8 2.4923 2 51.872 77.95 0.0231 48 30 
9 1.8781 3.5 51.501 106.78 0.0132 48 52.59 
10 1.9631 3 28.32 42.376 0.0196 48 35.3 
MEAN 2.4131 3.1 49.646 98.195 0.0153 48 52.29 
STD 0.3986 1.45 12.722 26.359 0.0055 0 22.64 
C.V. 16.52 46.75 25.626 26.843 36.15 0 43.29 
        
EFV co-administered with AP 
Subject CMAX TMAX AUCT AUCI KEL LQCT THALF 
1 3.0143 3.5 51.874 75.187 0.0228 48 30.45 
2 2.3027 1.5 37.649 58.674 0.0185 48 37.49 
3 1.6967 3 35.278 58.012 0.0179 48 38.79 
4 1.5986 2.5 42.128 107.27 0.0103 48 67.43 
5 2.8988 2 54.373 108.29 0.0133 48 51.95 
6 3.1378 5 46.529 86.828 0.0145 48 47.91 
7 2.1915 4 71.054 168.05 0.011 48 63.25 
8 3.2629 3 52.216 72.042 0.0257 48 26.95 
9 3.3394 3 68.537 108.79 0.0192 48 36.04 
10 1.8945 1.5 26.384 63.436 0.0087 48 79.92 
MEAN 2.5337 2.9 48.602 90.657 0.0162 48 48.02 
STD 0.672 1.1 14.126 33.888 0.0056 0 17.43 
C.V. 26.522 37.95 29.065 37.38 34.55 0 36.3 
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